

CLINICAL RESEARCH IN INFECTIOUS DISEASES

SAFETY SUMMARY REPORT

Prepared for the Safety Monitoring Committee

for

DMID Protocol 20-0003:

**Phase I, Open-Label, Dose-Ranging Study of the Safety and
Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy
Adults**

02 JUNE 2020

Prepared and distributed by:
Statistical and Data Coordinating Center (SDCC)
Emmes
Rockville, Maryland

THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL

TABLE OF CONTENTS

1. SUMMARY 1

2. PURPOSE OF THE REPORT 1

3. REVIEW OF THE STUDY DESIGN..... 1

4. METHODS FOR SAFETY ASSESSMENTS 3

5. REVIEW OF THE SAFETY DATA 3

 5.1 Overview 3

 5.2 Study Status 3

 5.3 Halting Rules Surveillance 4

TABLE 1: Study Halting Rules 5

 5.4 Adverse Events 5

 5.5 Solicited Events and Symptoms..... 8

 5.6 Clinical Laboratory Results and Vital Signs..... 10

 5.7 Protocol Adherence..... 11

 5.8 Pregnancies 12

6. TABLES AND FIGURES..... 12

 TABLE 2A: Summary of Categorical Demographic and Baseline Characteristics by Vaccination Group - All Subjects 18-55 Years of Age 13

 TABLE 2B: Summary of Categorical Demographic and Baseline Characteristics by Vaccination Group - All Subjects 56-70 Years of Age 14

 TABLE 2C: Summary of Categorical Demographic and Baseline Characteristics by Vaccination Group - All Subjects ≥ 71 Years of Age 15

 TABLE 2D: Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects 18-55 Years of Age 16

 TABLE 2E: Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects 56-70 Years of Age 17

 TABLE 2F: Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects ≥ 71 Years of Age 18

 TABLE 2G: Study Status: Number of Subjects Completing Study Milestones 19

 TABLE 2H: Subject Disposition Vaccination Group - All Subjects 18-55 Years of Age 20

 TABLE 2I: Subject Disposition Vaccination Group - All Subjects 56-70 Years of Age 21

 TABLE 2J: Subject Disposition Vaccination Group - All Subjects ≥ 71 Years of Age 22

 TABLE 2K: Early Terminations or Discontinued Subjects 23

 TABLE 3A: Listing of Serious Adverse Events 24

 TABLE 3B: Listing of MAAEs and NOCMCs 25

 TABLE 4A(i): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, Relationship to Study Vaccination, and Vaccination Group – 25 mcg mRNA-1273, 18-55 Years of Age (N=15) 26

 TABLE 4A(ii): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15) 28

TABLE OF CONTENTS *(continued)*

TABLE 4A(iii): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15)	30
TABLE 4A(iv): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – All Subjects 18-55 years (N=45)	32
TABLE 4B(i): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10)	34
TABLE 4B(ii): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10)	36
TABLE 4B(iii): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – All Subjects 56-70 years (N=20)	38
TABLE 4C(i): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10)	40
TABLE 4C(ii): All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10)	42
FIGURE 1A: Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group - 18-55 Years of Age	46
FIGURE 1B: Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group – 56-70 Years of Age	47
FIGURE 1C: Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group – ≥ 71 Years of Age	48
TABLE 4D(i): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 years (N=15)	49
TABLE 4D(ii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15)	51
TABLE 4D(iii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15)	53
TABLE 4D(iv): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group –mRNA-1273 All Subjects 18-55 years (N=45).....	55
TABLE 4E(i): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10)	58
TABLE 4E(ii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10)	59

TABLE OF CONTENTS *(continued)*

TABLE 4E(iii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 56-70 years (N=20) 60

TABLE 4F(i): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10) 62

TABLE 4F(ii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10)..... 63

TABLE 4F(iii): Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – ≥71 years (N=20) 64

TABLE 4G(i): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 Years of Age (N=15) 65

TABLE 4G(ii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15) 67

TABLE 4G(iii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15) 69

TABLE 4G(iv): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 18-55 years (N=45)..... 72

TABLE 4H(i): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10) 76

TABLE 4H(ii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10) 77

TABLE 4H(iii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 56-70 years (N=20)..... 78

TABLE 4I(i): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10) 80

TABLE 4I(ii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10) 81

TABLE 4I(iii): Number and Percentage of Subjects Experiencing Unsolicited Adverse Events MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – ≥71 years (N=20)..... 82

FIGURE 2A(i): Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - 18-55 Years of Age..... 84

FIGURE 2A(ii): Maximum Severity of Solicited Events by Symptom and Vaccination Group – Local - 18-55 Years of Age..... 85

TABLE OF CONTENTS *(continued)*

Figure 2B(i): Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - 56-70 Years of Age 86

Figure 2B(ii): Maximum Severity of Solicited Events by Symptom and Vaccination Group - Local - 56-70 Years of Age 87

Figure 2C(i): Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - ≥ 71 Years of Age 88

Figure 2C(ii): Maximum Severity of Solicited Events by Symptom and Vaccination Group - Local - ≥ 71 Years of Age 89

TABLE 5A(i): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group - Any Symptom - 18-55 Years of Age 90

TABLE 5A(ii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Systemic Symptoms - 18-55 Years of Age 91

TABLE 5A(iii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Local Symptoms - 18-55 Years of Age 96

TABLE 5B(i): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Any Symptom - 56-70 Years of Age 100

TABLE 5B(ii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Systemic Symptoms - 56-70 Years of Age 101

TABLE 5B(iii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Local Symptoms - 56-70 Years of Age 106

TABLE 5C(i): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Any Symptom - ≥ 71 years of Age 110

TABLE 5C(ii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Systemic Symptoms - ≥ 71 years of Age 111

TABLE 5C(iii): Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Local Symptoms - ≥ 71 years of Age 113

FIGURE 3A(i): Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group - 18-55 Years of Age 115

FIGURE 3A(ii): Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group – 56-70 Years of Age 116

FIGURE 3A(iii): Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group - ≥ 71 Years of Age 117

TABLE 6A(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (18-55 years) 118

TABLE 6A(ii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 25 mcg mRNA-1273 (18-55 years) 121

TABLE 6A(iii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 25 mcg mRNA-1273 (18-55 years) 124

TABLE OF CONTENTS *(continued)*

TABLE 6B(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 127

TABLE 6B(ii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2 Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 130

TABLE 6B(iii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 133

TABLE 6C(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 136

TABLE 6C(ii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2 Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 139

TABLE 6C(iii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 142

TABLE 6D(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 145

TABLE 6D(ii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2 Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 148

TABLE 6D(iii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 151

TABLE 6E(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 154

TABLE 6E(ii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2 Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 157

TABLE 6E(iii): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 160

TABLE 6F(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (≥ 71 years)..... 163

TABLE 6G(i): Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (≥ 71 years)..... 166

TABLE 6H(i): Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of
Age: Dose Number = Dose 1 169

TABLE 6H(ii): Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years
of Age: Dose Number = Dose 2..... 172

TABLE 6H(iii): Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years
of Age: Dose Number = Any Dose..... 175

TABLE 6I(i): Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of
Age: Dose Number = Dose 1 178

TABLE 6I(ii): Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of
Age: Dose Number = Dose 2 181

TABLE 6I(iii): Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years
of Age: Dose Number = Any Dose..... 184

TABLE 6J(i): Summary of Systemic Solicited Events for All Vaccination Groups by Day ≥ 71 years of
Age: Dose Number = Dose 1 187

TABLE OF CONTENTS *(continued)*

FIGURE 4A: Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group 18-55 Years of Age..... 190

FIGURE 4B: Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group 56-70 Years of Age..... 191

FIGURE 4C: Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group ≥ 71 Years of Age..... 192

TABLE 7A(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (18-55 years)..... 193

TABLE 7A(ii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 25 mcg mRNA-1273 (18-55 years)..... 195

TABLE 7A(iii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 25 mcg mRNA-1273 (18-55 years)..... 197

TABLE 7B(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 199

TABLE 7B(ii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 201

TABLE 7B(iii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 100 mcg mRNA-1273 (18-55 years)..... 203

TABLE 7C(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 205

TABLE 7C(ii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 207

TABLE 7C(iii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 250 mcg mRNA-1273 (18-55 years)..... 209

TABLE 7D(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 211

TABLE 7D(ii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 213

TABLE 7D(iii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 25 mcg mRNA-1273 (56-70 years)..... 215

TABLE 7E(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 217

TABLE 7E(ii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 2 Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 219

TABLE 7E(iii): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Any Dose Vaccination Group – 100 mcg mRNA-1273 (56-70 years)..... 221

TABLE 7F(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 25 mcg mRNA-1273 (≥ 71 years)..... 223

TABLE 7G(i): Summary of Local Solicited Events by Days Post Treatment and Vaccination Group Dose Number = Dose 1 Vaccination Group – 100 mcg mRNA-1273 (≥ 71 years)..... 225

TABLE 7H(i): Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age: Dose Number = Dose 1 227

TABLE OF CONTENTS *(continued)*

TABLE 7H(ii): Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age: Dose Number = Dose 2	229
TABLE 7H(iii): Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age: Dose Number = Any Dose	231
TABLE 7I(i): Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age: Dose Number = Dose 1	233
TABLE 7I(ii): Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age: Dose Number = Dose 2	235
TABLE 7I(iii): Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age: Dose Number = Any Dose	237
TABLE 7J(i): Summary of Local Solicited Events for All Vaccination Groups by Day \geq 71 years of Age: Dose Number = Dose 1	239
TABLE 8A: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter	241
TABLE 8B: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – White Blood Cells	246
TABLE 8C: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Hemoglobin	252
TABLE 8D: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Platelets	257
TABLE 8E: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Prothrombin Time	262
TABLE 8F: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Partial Thromboplastin Time	267
TABLE 8G: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Any Chemistry Parameter	272
TABLE 8H: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Serum Creatinine	277
TABLE 8I: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Aspartate Aminotransferase	287
TABLE 8J: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Alkaline Phosphatase	292
TABLE 8K: Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group – Total Bilirubin	297
TABLE 8L: Laboratory Results by Parameter, Severity, and Study Day Serum Lipase	302
FIGURE 5A: Clinical Laboratory Results by Severity and Vaccination Group 18-55 Years of Age	307
FIGURE 5B: Clinical Laboratory Results by Severity and Vaccination Group 56-70 Years of Age	308
FIGURE 5C: Clinical Laboratory Results by Severity and Vaccination Group \geq 71 Years of Age	309
TABLE 9A: Distribution of Protocol Deviations by Category, Type, and Vaccination Group 18-55 Years of Age	310
TABLE 9B: Distribution of Protocol Deviations by Category, Type, and Vaccination Group 56-70 Years of Age	311

TABLE OF CONTENTS *(continued)*

TABLE 9C: Distribution of Protocol Deviations by Category, Type, and Vaccination Group \geq 71 Years of Age..... 312

Notes on this Report

The following notes are provided for clarification of the data included in this safety report:

- Study accrual and vaccinations remain ongoing at the time of this report.
- Data entry, querying, and monitoring are in progress at the time of the report. The data are neither clean nor complete.
- At the time of the data cutoff for this report, 25 May 2020, there were no SAEs reported. If any additional SAEs are reported between the time of this report preparation and the SMC meeting, the details of those events will be provided to the SMC separately.
- Appendices are presented in a separate file named 20-0003_SMC_Report_02JUN2020_appendices.pdf.

SAFETY SUMMARY REPORT

DMID Protocol 20-0003

Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults

1. SUMMARY

DMID Protocol 20-0003 is examining the safety and immunogenicity of a 2019-nCoV vaccine (mRNA-1273 manufactured by ModernaTX, Inc.), for the prevention of 2019-nCoV (SARS-CoV-2) infection. Males and non-pregnant females, 18-55, 56-70, and ≥ 71 years old, inclusive, who are in good health and meet all eligibility criteria will receive 2 doses (Days 1 and 29) of mRNA-1273 at 25 mcg, 100 mcg or 250 mcg.

As of the data cutoff date of May 25, 2020, a total of 85 subjects had been enrolled into this study, and vaccination records had been submitted for 85 of those subjects for the first dose of vaccine; 61 of these 85 subjects had received the second dose of vaccine. The safety data presented in this report focus on both solicited and unsolicited events experienced by subjects following vaccination and entered in the study database as of the data cutoff date for this report.

2. PURPOSE OF THE REPORT

This report provides an interim update on the study of 85 subjects enrolled and vaccinated as of May 25, 2020.

3. REVIEW OF THE STUDY DESIGN

This is a Phase 1, dose-ranging, open-label, sequential study comparing the immunogenicity and safety of 2019-nCoV mRNA-1273 vaccine in subjects receiving 2 doses (Days 1 and 29) at 25 mcg, 100 mcg and 250 mcg.

Potential subjects will be screened by medical history, physical exam, vital signs, and clinical laboratory tests including white blood cells (WBC), hemoglobin (Hgb), platelet count, total bilirubin, alanine aminotransferase (ALT), Aspartate aminotransferase (AST), serum lipase, Alkaline Phosphatase (ALP), Prothrombin time (PT), Partial thromboplastin time (PTT), and creatinine (Cr). Height and weight will be obtained to calculate BMI. Urine will be collected for drug screening. Potential female subjects of childbearing potential will have a serum pregnancy test. In addition, potential subjects will be screened for HIV 1 and 2 antibody, Hepatitis C antibody, and Hepatitis B surface antigen prior to study product administration.

For this report eighty-five subjects were enrolled into one of seven cohorts as shown below. Subjects will receive an IM injection of mRNA-1273 on Days 1 and 29 in the deltoid and will be followed through 1-year post 2nd vaccination (Day 394). The second dose of vaccine (0.5 mL) will

be administered preferably in the same arm used for the first dose. Follow up visits will occur 1, 2, and 4 weeks after each vaccination (Days 8, 15, 29, 36, 43, and 57), as well as 3 months, 6 months and 12 months after 2nd vaccination (Days 119, 209, and 394). Safety endpoints will be assessed at these visits as well as blood drawn for immunogenicity assays. Additional safety and reactogenicity data will be solicited via phone calls to subjects 1 and 2 days post each vaccination (Days 2, 3, 30, and 31).

To determine early safety signals for this Phase 1 study, vaccination will proceed in a staged fashion. Sentinel subject dosing will begin with four subjects in cohort 1 (25 mcg). The four sentinel subjects for cohort 2 (100 mcg) will be enrolled no earlier than one day after enrollment of the last of the four sentinel subjects in cohort 1. If no halting rules are met for these eight sentinel subjects after Day 5, then full enrollment will proceed first with the remaining subjects in cohort 1, followed by the remaining subjects in cohort 2, without interruption. If no halting rules have been met after all subjects in cohort 2 have completed Day 8, dosing of four sentinel subjects will begin in cohort 3. If no halting rules are met after Day 5, then full enrollment of cohort 3 will proceed.

If no halting rules have been met after all subjects in cohorts 1 and 2 have completed Day 8, dosing will begin for cohorts 4 (25 mcg; 56-70 years of age) and 5 (100 mcg; 56-70 years of age). If no halting rules have been met after all subjects in cohorts 4 and 5 have completed Day 8, dosing will begin for cohorts 7 (25 mcg; ≥71 years of age) and 8 (100 mcg; ≥71 years of age).

Vaccination Arms

Cohort	Sample Size	Age	First and Second Dose
1	15	18-55	25 mcg mRNA-1273
2	15	18-55	100 mcg mRNA-1273
3	15	18-55	250 mcg mRNA-1273
4	10	56-70	25 mcg mRNA-1273
5	10	56-70	100 mcg mRNA-1273
7	10	≥71	25 mcg mRNA-1273
8	10	≥71	100 mcg mRNA-1273

Note: Cohorts 6 and 9 have not been enrolled as of the time of this report and therefore are not included.

On vaccination days, all females of childbearing potential will have a urine pregnancy test done. All subjects will have vital signs measured and a physical examination pre-vaccination. Blood will be collected pre-vaccination for immunogenicity testing. On vaccination days, clinical safety laboratory tests will be collected pre-vaccination. Vaccine will then be administered by intramuscular injection.

Subjects will be observed for at least 60 minutes after the injection is given. Reactogenicity will be measured by the occurrence of solicited injection site and systemic AEs. Subjects will maintain a memory aid through 7 days post each vaccination recording temperature, solicited local and systemic symptoms. Unsolicited non-serious AEs will be collected from the time of first study vaccination through approximately 28 days after the last vaccination. From Day 57 through completion of study participation, only SAEs, MAAEs, and NOCMCs will be recorded as AEs in the study database. Clinical safety labs will be collected on Days 1, 8, 29 and 36.

Evaluation of immunogenicity will include quantitation of antibodies to the 2019-nCoV S protein at multiple timepoints following each study vaccination as measured by ELISA, pseudovirus and live virus neutralization assays. In addition, exploratory studies to characterize T and B cell responses as well as determination of major antigenic sites and amino acid residues on the 2019-nCoV S protein recognized by B cell clones are planned. Venous blood will also be collected at multiple time points following study vaccination for the secondary research use of serum, plasma and peripheral blood mononuclear cells (PBMCs).

4. METHODS FOR SAFETY ASSESSMENTS

A summary of the procedures for vaccination and follow-up of the study cohort is provided in the protocol.

Brief descriptions of the collection and protocol definitions of adverse events, serious adverse events, and the grading scales for solicited events, clinical laboratory results, and vital signs are excerpted from the protocol (Version 3.0, 30 March 2020) and included in Appendix A.

5. REVIEW OF THE SAFETY DATA

5.1 Overview

The safety data presented in this report focus on both solicited and unsolicited events experienced following product administration. Adverse events are reported to the staff at Kaiser Permanente Washington Health Research Institute, Emory Children's Center and Hope Clinic of the Emory Vaccine Center.

The report includes the available safety data from subjects who received study product with data entered into the study database as of the data cutoff date of May 25, 2020. The monitoring of the data collected to date remains ongoing. The data are not considered clean.

5.2 Study Status

Enrollment was initiated on 16 March 2020. As of the data cutoff date for this report, 85 subjects have been enrolled, 85 subjects had received the first dose of vaccine and 61 subjects had received 2 doses of vaccine. 193 potential subjects were screened to accrue this number, for an overall

screening failure rate of 56%. The most common reasons for screening failure were Screening laboratory evaluations are not within acceptable normal ranges (44%), Systolic BP is not within the allowable range of 85 to 150 mmHg, inclusive (9%), and Has any medical disease or condition that precludes study participation (6%).

Tables 2A-2F present demographic characteristics (sex, ethnicity, race, and age) of the subjects enrolled in the study who have received study product.

Of the 45 subjects enrolled into the 18-55 years of age cohorts, 38 (84%) reported their ethnicity as not Hispanic or Latino; 40 (89%) subjects reported their race as White, 2 (4%) subjects reported their race as Black, 1 (4%) subject reported their race as American Indian or Alaska Native, and 1 (4%) subject reported their race as Unknown. The mean age in the 18-55 years of age cohorts is 33.0 years and the range is 18 to 53 years; the mean BMI is 25.34 kg/m² and the range is 20.4 to 32.6 kg/m².

Of the 20 subjects enrolled into the 56-70 years of age cohorts, 20 (100%) reported their ethnicity as not Hispanic or Latino; 20 (100%) subjects reported their race as White. The mean age in the 56-70 years of age cohorts is 64.8 years and the range is 56 to 70 years; the mean BMI is 24.56 kg/m² and the range is 20.8 to 29.5 kg/m².

Of the 20 subjects enrolled into the ≥71 years of age cohorts, 19 (95%) reported their ethnicity as not Hispanic or Latino; 19 (95%) subjects reported their race as White, and 1 (5%) subject reported their race as Asian. The mean age in the ≥71 years of age cohorts is 72.7 years and the range is 71 to 75 years; the mean BMI is 25.39 kg/m² and the range is 20.1 to 28.7 kg/m².

Table 2G shows the percentage of subjects in each vaccination group that have completed the study milestones and **Tables 2H-2J** display subject disposition. A total of 193 subjects were screened, and 85 were enrolled and 85 received treatment. 85/85 (100%) subjects have completed the Day 8 visit and 77/85 (91%) have completed the Day 15 visit. As of the data cutoff, four subjects discontinued treatment on the study; three of those subjects discontinued due to an AE (Hives on Lower Extremities, Sore Throat, and Maculopapular Rash), the other subject discontinued treatment due to COVID-19 exposure.

For a listing of subjects who have discontinued treatment and subjects who have terminated early from the study, see **Table 2K**.

5.3 Halting Rules Surveillance

The status of the study Halting Rules is summarized in **Table 1**.

TABLE 1: Study Halting Rules

Halting Rule #	Halting Rule Description	Number of Subjects n (%)
1	Any subject experiences an SAE after administration of the vaccine that is considered related to vaccine.	0 (0)
2	Any subject experiences laryngospasm, bronchospasm or anaphylaxis within 24 hours after administration of vaccine that is considered related to vaccine.	0 (0)
3	Any subject experiences ulceration, abscess or necrosis at the injection site that is considered related to vaccine administration.	0 (0)
4	Two (2) or more subjects experience an allergic reaction such as generalized urticaria (defined as occurring at three or more body parts) within 72 hours after administration of vaccine that is considered related to vaccine.	0 (0)
5	Three (3) or more subjects experience a Grade 3 AE (systemic and/or clinical laboratory abnormality), in the same Preferred Terms based on the Medical Dictionary for Regulatory Activities (MedDRA) coding, that lasted at least 48 hours after administration of the vaccine and is considered related to the vaccine. Clinical laboratory abnormalities are not subject to the time window.	0 (0)
6	Additionally, any AE for which the investigator checks the box for "In the opinion of the site investigator, this event should be evaluated for possible contribution toward the halting criteria for the group, cohort, or study" will trigger an automatic email from the EDC, even if it does not meet any of the requirements in the table above.	0 (0)

NOTE: No halting criteria have been met as of May 25, 2020.

Details of reported serious adverse events, if any, are included in **Table 3A**.

5.4 Adverse Events

Details of reported serious adverse events, medically attended adverse events (MAAEs), and new onset chronic medical conditions, if any, are included in **Table 3A and 3B**. Three MAAEs have been reported in 2 subjects as of data cutoff. One subject (50%) in the 56-70 years of age cohorts that received the 100 mcg dose reported 2 MAAEs after receiving one dose of the investigational product, with one in the Infections and infestations MedDRA® System Organ Class (SOC), and one in the Skin and subcutaneous tissue disorders SOC. One subject (50%) in the 18-55 years of age cohorts that received the 250 mcg dose reported one MAAE after receiving one dose of the investigational product in the Respiratory, thoracic and mediastinal disorders SOC. All MAAEs were assessed to be not related to the study product.

Tables 4A-4I summarize all unsolicited adverse events reported for subjects as of the data cutoff date. **Tables 4A, 4B, and 4C** classify each event in terms of MedDRA® System Organ Class (SOC), severity, and relationship to vaccination. **Tables 4D-4I** classify the events by MedDRA® SOC, Preferred Term (PT), relationship to vaccination, and severity. **Figure 1A-C** is a graphical

representation of the number and severity of all unsolicited adverse events by System Organ Class. Appendix B is a listing of all unsolicited events grouped by cohort and dose number.

At the time of data cutoff, in the 18-55 years of age cohorts, 32 subjects (71%) had reported 82 unsolicited adverse events. Sixty four (78%) of the events were determined to be mild (Grade 1) severity, sixteen (20%), were determined to be moderate (Grade 2) severity, and two (2%) were determined to be severe (Grade 3) severity; 32 (39%) of the events were determined to be related to study product, and 50 (61%) were determined to be not related to study product. Two events were reported within the Cardiac Disorders SOC, both reported as mild Bradycardia. Two events were reported within the Eye Disorder SOC, including one incidence of mild eye irritation and one incidence of mild Scintillating scotoma. Ten events were reported within the Gastrointestinal SOC, including 1 incidence of mild abdominal discomfort, 1 incidence of moderate abdominal pain, 1 incidence of mild abdominal pain upper, 1 incidence of mild faeces discoloured, 1 incidence of mild flatulence, 1 incidence of mild lip disorder, and 4 incidences of vomiting (2 mild and 2 moderate). Eighteen events were reported within the General Disorders and Administration site SOC, including 1 incidence of mild fatigue, 1 incidence of moderate feeling jittery, 3 incidences of mild injection site bruising, 2 incidences of injection site erythema (1 mild and 1 moderate), 4 incidences of mild injection site pruritus, 1 incidence of mild Malaise and 5 incidences of mild vessel puncture site bruise. Nine events were reported within the Injury, Poisoning and Procedural Complications SOC, including 2 incidences of mild contusion, 4 incidences of muscle strain (3 mild and 1 moderate), 1 incidence of mild skin abrasion, 1 incidence of mild skin laceration, and one incidence of mild thermal burn. One event was reported within the Investigations SOC (mild heartrate increased). Six events were reported in the Metabolism and nutrition disorders, including 5 incidences of decreased appetite (3 mild and 2 moderate), and 1 moderate hypoglycaemia. Five events were reported in the Musculoskeletal and connective tissue disorders, including 1 incidence of mild arthralgia, 1 incidence of moderate muscle spasm, 1 incidence of moderate muscle strain, 1 incidence of mild muscular weakness, and 1 incidence of mild neck pain. Seven events were reported within the Nervous System Disorders SOC, including 2 incidences of dizziness (1 mild and 1 severe), 3 incidences of headache (1 mild and 2 moderate), 1 incidence of mild presyncope and 1 incidence of sever syncope. Two events were reported in the Psychiatric disorders SOC, including 1 incidence of mild anxiety and 1 incidence of mild insomnia. Three events were reported in the reproductive system and breast disorder SOC, including 1 incidence of mild breast pain, 1 incidence of mild vaginal haemorrhage and 1 incidence of mild vulvovaginal pruritus. Seven events were reported within the Respiratory, Thoracic and Mediastinal Disorder SOC, including 1 incidence of mild diaphragmatic spasm, 1 incidence of mild dyspnea exertional, 1 incidence of mild nasal congestion and 4 incidences of mild oropharyngeal pain. Six events were reported within the Skin and Subcutaneous tissue disorder SOC, including 1 incidence of mild dermatitis contact, 1 incidence of mild erythema, 1 incidence of moderate hyperhidrosis, 1 incidence of moderate night sweats, 1 incidence of mild petechiae and 1 incidence of mild urticaria. Four events were reported within the Vascular Disorders SOC, including 1 incidence of mild

hypertension, 1 incidence of mild hypotension, 1 incidence of mild systolic hypertension and 1 incidence of mild vasodilation.

At the time of data cutoff, in the 56-70 years of age cohorts, 14 subjects (70%) had reported 16 unsolicited adverse events. Ten (63%) of the events were determined to be mild (Grade 1) severity, five (31%), were determined to be moderate (Grade 2) severity, and one (6%) was determined to be severe (Grade 3) severity; 3 (19%) of the events were determined to be related to study product, and 13 (81%) were determined to be not related to study product. One event was reported within the ear and labyrinth disorder SOC, one incidence of mild vertigo, two events were reported within the General Disorders and Administration site SOC, including 1 incidence of mild injection site bruising and, 1 incidence of mild vaccination site bruising. One event was reported within the Infections and infestations SOC, including 1 incidence of mild paronychia. One event was reported within the Injury, Poisoning and Procedural Complications SOC, including 1 incidences of mild exposure via inhalation. Two events were reported in the Metabolism and nutrition disorders, including 1 incidence of moderate decreased appetite, and 1 severe hypoglycaemia. Two events were reported within the Nervous System Disorders SOC, including 1 incidence of mild headache and 1 incidence of mild sciatica. One event was reported in the Psychiatric disorders SOC, including 1 incidence of mild insomnia. Three events were reported within the Respiratory, Thoracic and Mediastinal Disorder SOC, including 1 incidence of moderate nasal congestion and 2 incidences of mild oropharyngeal pain. One event was reported within the Skin and Subcutaneous tissue disorder SOC, including 1 incidence of moderate rash maculo-papular. Two events were reported within the Vascular Disorders SOC, including 1 incidence of mild diastolic hypertension, and 1 incidence of mild systolic hypertension.

At the time of data cutoff, in the 71 years of age and over cohorts, 10 subjects (50%) had reported 16 unsolicited adverse events. 15 (94%) of the events were determined to be mild (Grade 1) severity and one (6%) was determined to be moderate (Grade 2) severity; 5 (31%) of the events were determined to be related to study product, and 11 (69%) were determined to be not related to study product. Five events were reported within the General Disorders and Administration site SOC, including 1 incidence of mild increased energy, 2 incidences of mild injection site bruising and, 2 incidences of mild vessel puncture site bruise. Four events were reported within the Injury, Poisoning and Procedural Complications SOC, including 1 incidences of mild arthropod bite, 2 incidences of mild skin abrasion and 1 incidence of mild sunburn. Two events were reported in the Musculoskeletal and connective tissue disorders, including 1 incidence of mild joint swelling, and 1 incidence of moderate musculoskeletal chest pain. One event was reported within the Nervous System Disorders SOC, including 1 incidence of mild dizziness. One event was reported in the Psychiatric disorders SOC, including 1 incidence of mild anxiety. Three events were reported within the Skin and Subcutaneous tissue disorder SOC, including 1 incidence of mild dermatitis, 1 incidence of mild night sweat and 1 incidence of pruritus.

Refer to **Appendix B** for a detailed listing of moderate and severe non-serious, unsolicited, adverse events.

5.5 Solicited Events and Symptoms

Solicited events data, collected in-clinic pre-vaccination, post-vaccination and via memory aid through 7 days after vaccination, are summarized by symptom in **Figure 2A(i, ii)-2C(i, ii)** and **Table 5A(i, ii, iii)-5C(i, ii, iii)**, which report the maximum severity experienced by each subject over the 7-day post-vaccination reporting period, separated by Dose 1 and Dose 2.

Tables 6A(i, ii, iii)-6J(i) and **7A(i, ii, iii)-7J(i)** summarize the number of subjects who experienced a mild, moderate, or severe event for each symptom and across all symptoms for each day post-vaccination, separated by Dose 1 and Dose 2. **Tables 6A-6C** summarize the solicited systemic symptoms, and **Tables 7A-7C** summarize the solicited local symptoms. The row entitled "Not Reported" represents values that were missing on forms submitted into the database. This row does not take into account missing values due to forms not yet being submitted.

Figures 3A(i, ii, iii) and 4A(i, ii, iii) summarize the solicited event data across all vaccination groups and display the maximum severity experienced by each subject post-vaccination and on each day for all systemic and all local symptoms, respectively.

The graphical summaries of solicited events included in this report convey the number of subjects who experienced a maximum severity of mild (yellow), moderate (orange), or severe (red) during the post-vaccination period.

Twenty-five (55.6%) subjects in the 18-55 age group reported experiencing a maximum mild/grade 1 solicited local event for at least one day, 14 (31.1%) subjects experienced a maximum moderate/grade 2 solicited local event for at least one day, and 2 (4.4%) subjects experienced a maximum severe/grade 3 event for at least one day. Post any vaccination, 7 (15.6%) subjects reported experiencing a maximum of mild erythema/redness. Six (13.3%) subjects reported experiencing a maximum of mild induration/swelling with 1 (2.2%) subject experiencing a maximum of moderate induration/swelling. Twenty-eight (62.2%) subjects reported experiencing a maximum of mild injection site pain with 13 (28.9%) experiencing a maximum of moderate injection site pain.

Nine (20%) subjects in the 18-55 age group reported experiencing a maximum mild/grade 1 solicited systemic event for at least one day, 14 (57.8%) subjects experienced a maximum moderate/grade 2 solicited systemic event for at least one day, and 3 (6.7%) subjects experienced a maximum severe/grade 3 event for at least one day. Post any vaccination, 5 (11.1%) subjects reported experiencing a maximum of mild arthralgia, and 7 (15.6%) subjects reporting a maximum of moderate arthralgia. 11 (24.4%) subjects reported experiencing a maximum of mild fatigue, 16 (35.6%) subjects reported experiencing a maximum of moderate fatigue, and 2 (4.4%) subjects

experiencing a maximum of severe fatigue. Ten (22.2%) subjects reported experiencing a maximum of mild fever, 3 (6.7%) subjects reported experiencing a maximum of moderate fever, and 1 (2.2%), subject experienced a maximum of severe fever. Thirteen (28.9%) subjects reported experiencing a maximum of mild feverishness, 9 (20%) subjects reported experiencing a maximum of moderate feverishness, and 3 (6.7%), subjects experienced a maximum of severe feverishness. Eighteen, (40%) subjects reported experiencing a maximum of mild headache, 10 (22.2%) subjects reported experiencing a maximum of moderate headache, and 1 (2.2%), subject experienced a maximum of severe headache. Ten (22.2%) subjects reported experiencing a maximum of mild myalgia, 14 (31.1%) subjects reported experiencing a maximum of moderate myalgia, and 1 (2.2%), subject experienced a maximum of severe myalgia. Seven (15.6%) subjects reported experiencing a maximum of mild nausea, 4 (8.9%) subjects reported experiencing a maximum of moderate nausea, and 1 (2.2%), subject experienced a maximum of severe nausea.

Fifteen (75%) subjects in the 56-70 age group reported experiencing a maximum mild/grade 1 solicited local event for at least one day, and 2 (10%) subjects experienced a maximum moderate/grade 2 solicited local event for at least one day. Post any vaccination, 4 (20%) subjects reported experiencing a maximum of mild erythema/redness, 6 (30%) subjects reported experiencing a maximum of mild induration/swelling. Fourteen (70%) subjects reported experiencing a maximum of mild injection site pain, and 1 (5%) subject experienced a maximum of moderate injection site pain.

Eight (40%) subjects in the 56-70 age group reported experiencing a maximum mild/grade 1 solicited systemic event for at least one day, 6 (30%) subjects experienced a maximum moderate/grade 2 solicited systemic event for at least one day, and 1 (5%) subject experienced a maximum severe/grade 3 event for at least one day. Post any vaccination, 2 (10%) subjects reported experiencing a maximum of mild arthralgia, and 4 (20%) subjects reporting a maximum of moderate arthralgia. 5 (25%) subjects reported experiencing a maximum of mild fatigue, and 5 (25%) subjects reported experiencing a maximum of moderate fatigue. One (5%) subject reported experiencing a maximum of mild fever. Two (10%) subjects reported experiencing a maximum of mild feverishness, and 3 (15%) subjects reported experiencing a maximum of moderate feverishness. Six (30%) subjects reported experiencing a maximum of mild headache, and 2 (10%) subjects reported experiencing a maximum of moderate headache. Seven (35%) subjects reported experiencing a maximum of mild myalgia, and 3 (15%) subjects reported experiencing a maximum of moderate myalgia. Two (10%) subjects reported experiencing a maximum of mild nausea, and 1 (5%) subject reported experiencing a maximum of moderate nausea.

Fourteen (70%) subjects in the 71+ age group reported experiencing a maximum mild/grade 1 solicited local event for at least one day. Post dose 1, 1 (5%) subject reported experiencing a maximum of mild erythema/redness, and 14 (70%) subjects reported experiencing a maximum of mild injection site pain.

Eight (40%) subjects in the 71+ age group reported experiencing a maximum mild/grade 1 solicited systemic event for at least one day. Post dose 1, 1 (5%) subject reported experiencing a maximum of mild arthralgia. 5 (25%) subjects reported experiencing a maximum of mild fatigue. 1 (5%) subject reported experiencing a maximum of mild feverishness. Three (15%) subjects reported experiencing a maximum of mild headache. Five (25%) subjects reported experiencing a maximum of mild myalgia.

A listing of systemic and local solicited events is provided in Appendix C1-C2. The listing is limited to subjects who experienced a symptom of moderate or greater severity on at least one occasion.

Appendix D is a listing of all severe systemic solicited events contributing to halting criteria along with their attributions.

5.6 Clinical Laboratory Results and Vital Signs

Tables 8A-8L summarize the results of the scheduled hematology and chemistry clinical laboratory parameters conducted at the protocol specified visits. **Figure 5A-C** displays abnormal results by laboratory parameter and severity and takes into account all values reported after vaccination (scheduled and supplemental).

Appendix E includes listings of clinical laboratory results for subjects who experience abnormal hematology and chemistry results at any time post-vaccination.

Thirty-six (80%) subjects in the 18-55 age group experienced a maximum mild/grade 1 abnormal hematology result post-vaccination, and 3 (7%) subjects experienced a maximum moderate/grade 2 abnormal hematology result post-vaccination. Thirty five (78%) subjects experienced a maximum mild abnormal hemoglobin result and 3 (7%) of subjects experienced a maximum moderate abnormal hemoglobin result. Seven (16%) subjects experienced mild leukopenia.

Seventeen (85%) subjects in the 56-70 age group experienced a maximum mild/grade 1 abnormal hematology result post-vaccination, 2 (10%) subjects experienced a maximum moderate/grade 2 abnormal hematology result post-vaccination, and 1 (5%) subject experienced a maximum severe/grade 3 abnormal hematology result post-vaccination. Seventeen (85%) subjects in the 56-70 age group experienced a maximum mild abnormal hemoglobin result, 2 (10%) subjects experienced a maximum moderate abnormal hemoglobin result, and 1 (5%) subject experienced a maximum severe abnormal hemoglobin result. One (5%) subject experienced a maximum mild leukopenia result.

Nineteen (95%) subjects in the 71+ age group experienced a maximum mild/grade 1 abnormal hematology result post-vaccination. Seventeen (85%) subjects experienced a maximum mild

abnormal hemoglobin result, 1 (5%) subject experienced a maximum mild leukopenia result, and 1 (5%) subject experienced a maximum mild abnormal platelet result.

Seven (16%) subjects in the 18-55 age group experienced a maximum mild/grade 1 abnormal chemistry result post-vaccination, and 2 (4%) subjects experienced a maximum moderate/grade 2 abnormal chemistry result post-vaccination. Three (7%) subjects experienced a maximum mild abnormal alanine aminotransferase result, 1 (2%) subject experienced a maximum mild abnormal aspartate aminotransferase result, 2 (4%) subjects experienced a maximum mild abnormal bilirubin result and 1 (2%) subject experienced a maximum moderate bilirubin result. One (2%) subject experienced a maximum mild and 1 (2%) subject experienced a maximum moderate abnormal serum lipase result.

One (55%) subject in the 56-70 age group experienced a maximum mild/grade 1 abnormal chemistry result post-vaccination. This subject experienced a maximum mild abnormal aspartate aminotransferase result.

Two (10%) subjects in the 71+ age group experienced a maximum mild/grade 1 abnormal chemistry result post-vaccination. Both subjects experienced a maximum mild abnormal serum lipase result.

Appendix F includes a listing of vital signs for subjects who experience abnormal vital signs at any time post-vaccination.

5.7 Protocol Adherence

Tables 9A-9C summarizes the protocol deviations for this study by category and type. A full listing of protocol deviations is provided in **Appendix G**.

Among the subjects in the 18-55 years of age cohorts, a total of 23 deviations were reported in 19 subjects. There were 11 deviations reported for too few aliquots obtained, 5 for required procedure done incorrectly, 2 for required procedure not conducted, and one deviation each was reported for breach of confidentiality, out of window visit, non-required lab tests performed, and safety labs collected out of window.

Among the subjects in the 56-70 years of age cohorts, a total of 2 deviations were reported in 2 subjects. One deviation each was reported for missed visit/visit not conducted and too few aliquots obtained.

There were no deviations reported in the ≥ 71 years of age cohorts.

There was one non subject specific protocol deviation reported. A freezer storing the investigational product (IP) was out of range on April 17, 2020. The IP was immediately moved

to a different freezer at the site. The study team was alerted of this and the site was instructed to continue use of the IP.

5.8 Pregnancies

A listing of pregnancies is provided in **Appendix H**. No pregnancies have been reported as of data cutoff.

6. TABLES AND FIGURES

**TABLE 2A:
Summary of Categorical Demographic and Baseline Characteristics
by Vaccination Group - All Subjects 18-55 Years of Age**

Demographic Category	Characteristic	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
		n	%	n	%	n	%	n	%
Sex	Male	9	60	7	47	6	40	22	49
	Female	6	40	8	53	9	60	23	51
Ethnicity	Not Hispanic or Latino	14	93	12	80	12	80	38	84
	Hispanic or Latino	1	7	3	20	2	13	6	13
	Not Reported	1	7	1	2
	Unknown
Race	American Indian or Alaska Native	.	.	1	7	.	.	1	2
	Asian	1	7	1	2
	Native Hawaiian or other Pacific Islander
	Black	.	.	2	13	.	.	2	4
	White	15	100	11	73	14	93	40	89
	Multi Racial
	Unknown	.	.	1	7	.	.	1	2

**TABLE 2B:
Summary of Categorical Demographic and Baseline Characteristics
by Vaccination Group - All Subjects 56-70 Years of Age**

Demographic Category	Characteristic	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		n	%	N	%	n	%
Sex	Male	3	30	5	50	8	40
	Female	7	70	5	50	12	60
Ethnicity	Not Hispanic or Latino	10	100	10	100	20	100
	Hispanic or Latino
	Not Reported
	Unknown
Race	American Indian or Alaska Native
	Asian
	Native Hawaiian or other Pacific Islander
	Black
	White	10	100	10	100	20	100
	Multi Racial
	Unknown

**TABLE 2C:
Summary of Categorical Demographic and Baseline Characteristics
by Vaccination Group - All Subjects ≥71 Years of Age**

Demographic Category	Characteristic	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		n	%	N	%	n	%
Sex	Male	8	80	3	30	11	55
	Female	2	20	7	70	9	45
Ethnicity	Not Hispanic or Latino	9	90	10	100	19	95
	Hispanic or Latino	1	10	.	.	1	5
	Not Reported
Race	Unknown
	American Indian or Alaska Native
	Asian	1	10	.	.	1	5
	Native Hawaiian or other Pacific Islander
	Black
	White	9	90	10	100	19	95
	Multi Racial
	Unknown

**TABLE 2D:
Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects 18-55 Years of Age**

Variable	Statistic	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
		n	n	n	n	n	n	n	n
Age (Years)	Mean	36.7	31.3	31.0	33.0	33.0	33.0	33.0	33.0
	Standard Deviation	7.9	8.7	8.0	8.5	8.5	8.5	8.5	8.5
	Median	35.9	31.6	30.3	31.9	31.9	31.9	31.9	31.9
	Minimum	25	20	18	18	18	18	18	18
	Maximum	53	53	50	53	53	53	53	53
Height (cm)	Mean	175.70	171.33	167.93	171.65	171.65	171.65	171.65	171.65
	Standard Deviation	9.18	7.32	11.25	9.72	9.72	9.72	9.72	9.72
	Median	174.50	170.00	165.10	172.60	172.60	172.60	172.60	172.60
	Minimum	158.7	160.7	152.7	152.7	152.7	152.7	152.7	152.7
	Maximum	194.1	188.0	185.7	194.1	194.1	194.1	194.1	194.1
Weight (kg)	Mean	76.44	78.67	70.10	75.07	75.07	75.07	75.07	75.07
	Standard Deviation	14.86	10.69	13.70	13.41	13.41	13.41	13.41	13.41
	Median	72.20	78.50	74.10	75.60	75.60	75.60	75.60	75.60
	Minimum	56.2	54.2	52.1	52.1	52.1	52.1	52.1	52.1
	Maximum	107.9	98.7	95.9	107.9	107.9	107.9	107.9	107.9
BMI (kg/m²)	Mean	24.62	26.73	24.68	25.34	25.34	25.34	25.34	25.34
	Standard Deviation	3.45	2.60	3.09	3.16	3.16	3.16	3.16	3.16
	Median	24.50	27.40	23.70	25.40	25.40	25.40	25.40	25.40
	Minimum	21.1	20.4	20.4	20.4	20.4	20.4	20.4	20.4
	Maximum	32.6	31.5	29.4	32.6	32.6	32.6	32.6	32.6

**TABLE 2E:
Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects 56-70 Years of Age**

Variable	Statistic	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		n	n	n	n		
Age (Years)	Mean	65.8	63.8	64.8	64.8		
	Standard Deviation	4.5	4.3	4.4	4.4		
	Median	67.0	64.5	65.5	65.5		
	Minimum	56	56	56	56		
	Maximum	70	69	70	70		
Height (cm)	Mean	169.64	170.19	169.92	169.92		
	Standard Deviation	11.59	11.43	11.21	11.21		
	Median	167.60	169.35	167.65	167.65		
	Minimum	149.0	152.4	149.0	149.0		
	Maximum	186.0	195.6	195.6	195.6		
Weight (kg)	Mean	73.47	69.40	71.44	71.44		
	Standard Deviation	12.77	13.62	13.02	13.02		
	Median	70.45	65.60	68.25	68.25		
	Minimum	52.0	50.5	50.5	50.5		
	Maximum	89.8	95.2	95.2	95.2		
BMI (kg/m²)	Mean	25.38	23.73	24.56	24.56		
	Standard Deviation	2.53	2.26	2.48	2.48		
	Median	24.85	23.80	24.50	24.50		
	Minimum	22.4	20.8	20.8	20.8		
	Maximum	29.5	27.4	29.5	29.5		

**TABLE 2F:
Summary of Continuous Demographic and Baseline Characteristics by Vaccination Group - All Subjects ≥71 Years of Age**

Variable	Statistic	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		n	n	n	n		
Age (Years)	Mean	72.8	72.6	72.6	72.7		
	Standard Deviation	1.2	1.1	1.2	1.2		
	Median	72.6	72.6	72.6	72.6		
	Minimum	71	71	71	71		
	Maximum	75	75	75	75		
Height (cm)	Mean	171.03	166.57	166.80	168.80		
	Standard Deviation	8.21	8.43	8.42	8.42		
	Median	172.45	167.25	170.30	170.30		
	Minimum	153.9	152.5	152.5	152.5		
	Maximum	180.1	181.7	181.7	181.7		
Weight (kg)	Mean	72.95	72.16	72.56	72.56		
	Standard Deviation	13.81	10.89	12.11	12.11		
	Median	78.30	69.80	76.05	76.05		
	Minimum	47.4	57.9	47.4	47.4		
	Maximum	87.6	91.2	91.2	91.2		
BMI (kg/m²)	Mean	24.76	26.02	25.39	25.39		
	Standard Deviation	3.53	3.52	3.49	3.49		
	Median	25.80	26.70	26.00	26.00		
	Minimum	19.9	20.1	19.9	19.9		
	Maximum	29.2	29.7	29.7	29.7		

**TABLE 2G:
Study Status: Number of Subjects Completing Study Milestones**

	Day 1	Day 2	Day 3	Day 8	Day 15	Day 29	Day 30	Day 31
	Vaccination 1	Phone Follow-up	Phone Follow-up	Clinic Visit Follow-Up	Clinic Visit Follow-Up	Vaccination 2	Phone Follow-up	Phone Follow-up
25 mcg mRNA-1273 (18-55 years)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	13/15 (87%)	13/15 (87%)
100 mcg mRNA-1273 (18-55 years)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)
250 mcg mRNA-1273 (18-55 years)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	15/15 (100%)	14/15 (93%)	14/15 (93%)
25 mcg mRNA-1273 (56-70 years)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
100 mcg mRNA-1273 (56-70 years)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	9/10 (90%)	9/10 (90%)
25 mcg mRNA-1273 (≥71 years)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
100 mcg mRNA-1273 (≥71 years)	10/10 (100%)	10/10 (100%)	10/10 (100%)	10/10 (100%)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
All Subjects	85/85 (100%)	85/85 (100%)	85/85 (100%)	85/85 (100%)	77/85 (91%)	65/85 (76%)	61/85 (72%)	61/85 (72%)

Note: Percentages reflective of ongoing status of the trial.

	Day 36	Day 43	Day 57	Day 119	Day 209	Day 394
	Clinic Visit Follow-Up	Clinic Visit Follow-Up	Clinic Visit Follow-Up	Clinic Visit Follow-Up	Clinic Visit Follow-Up	Final Study Visit
25 mcg mRNA-1273 (18-55 years)	15/15 (100%)	15/15 (100%)	15/15 (100%)	0/15 (0%)	0/15 (0%)	0/15 (0%)
100 mcg mRNA-1273 (18-55 years)	15/15 (100%)	15/15 (100%)	14/15 (93%)	0/15 (0%)	0/15 (0%)	0/15 (0%)
250 mcg mRNA-1273 (18-55 years)	15/15 (100%)	4/15 (27%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)
25 mcg mRNA-1273 (56-70 years)	2/10 (20%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
100 mcg mRNA-1273 (56-70 years)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
25 mcg mRNA-1273 (≥71 years)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
100 mcg mRNA-1273 (≥71 years)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
All Subjects	47/85 (55%)	34/85 (40%)	29/85 (34%)	0/85 (0%)	0/85 (0%)	0/85 (0%)

Note: Percentages reflective of ongoing status of the trial.

**TABLE 2H:
Subject Disposition Vaccination Group - All Subjects 18-55 Years of Age**

Subject Disposition	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
	n	%	n	%	N	%	n	%
Screened
Enrolled	15	100	15	100	15	100	45	100
Received the first vaccination	15	100	15	100	15	100	45	100
Discontinued treatment ^a	2	13	.	.	1	7	3	7
Received the second vaccination	13	87	15	100	14	93	42	93
Discontinued treatment ^a	2	13	.	.	1	7	3	7
Study ongoing	15	100	15	100	15	100	45	100
Early termination ^a
Completed study

^aRefer to Table 2K for reasons subjects discontinued or terminated early.

TABLE 2I:
Subject Disposition Vaccination Group - All Subjects 56-70 Years of Age

Subject Disposition	25 meg mRNA-1273 (N=10)		100 meg mRNA-1273 (N=10)		All Subjects (N=20)	
	n	%	n	%	n	%
Screened
Enrolled	10	100	10	100	20	100
Received the first vaccination	10	100	10	100	20	100
Discontinued treatment ^a	.	.	1	10	1	5
Received the second vaccination	10	100	9	90	19	95
Discontinued treatment ^a	.	.	1	10	1	5
Study ongoing	10	100	10	100	20	100
Early termination ^a
Completed study

^aRefer to Table 2K for reasons subjects discontinued or terminated early.

TABLE 2J:
Subject Disposition Vaccination Group - All Subjects ≥ 71 Years of Age

Subject Disposition	25 meg mRNA-1273 (N=10)		100 meg mRNA-1273 (N=10)		All Subjects (N=20)	
	n	%	n	%	n	%
Screened
Enrolled	10	100	10	100	20	100
Received the first vaccination	10	100	10	100	20	100
Discontinued treatment ^a
Received the second vaccination
Discontinued treatment ^a
Study ongoing	10	100	10	100	20	100
Early termination ^a
Completed study

^aRefer to Table 2K for reasons subjects discontinued or terminated early.

**TABLE 2K:
 Early Terminations or Discontinued Subjects**

Subject ID	Vaccination Group	Enrollment Date	Treatment Discontinuation		Early Termination			
			Reason for Treatment Discontinuation	Number of Vaccinations Received	Subject Terminated Early	Termination Date	Reason for Early Termination	Length of Time on Study (days)
██████████	25 mcg mRNA-1273 (18-55 years)	03/24/20	Became ineligible after enrollment, specify and enter eligibility criterion #: Subject has been exposed(in PPE) to someone with SARS-CoV-2 infection.	1	No	-	-	-
██████████	25 mcg mRNA-1273 (18-55 years)	03/24/20	Adverse event, other than serious adverse event, specify AE # 2 (HIVES ON LOWER EXTREMITIES)	1	No	-	-	-
██████████	250 mcg mRNA-1273 (18-55 years)	04/08/20	Adverse event, other than serious adverse event, specify AE # 2 (SORE THROAT)	1	No	-	-	-
██████████	100 mcg mRNA-1273 (56-70 years)	04/23/20	Adverse event, other than serious adverse event, specify AE # 2 (MACULOPAPULAR RASH)	1	No	-	-	-

**TABLE 3A:
Listing of Serious Adverse Events**

No serious adverse events have been reported.

**TABLE 3B:
Listing of MAAEs and NOCMCs**

Subject ID	Vaccination Group	Event Description	Number of Doses Received at Time of Event	Date of Product Administration ^a	Duration of Event	Date of Onset	MedDRA [®] System Organ Class	MAAEs	NOCMCs	Relationship ^b	Outcome
██████████	100 mcg mRNA-1273 (56-70 years)	Paronychia	01	23APR2020	2 (13)	25APR2020	Infections and infestations	Yes	No	Not related	Recovered /resolved
██████████	100 mcg mRNA-1273 (56-70 years)	Maculopapular Rash	01	23APR2020	9 (Ongoing)	02MAY2020	Skin and subcutaneous tissue disorders	Yes	No	Not related	Recovering /resolving
██████████	250 mcg mRNA-1273 (18-55 years)	Sore Throat	01	08APR2020	24 (3)	02MAY2020	Respiratory, thoracic and mediastinal disorders	Yes	No	Not related	Recovered /resolved

^aDate of most recent dose/product administration.

^bRelated, Not Related.

**TABLE 4A(i):
All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity,
Relationship to Study Vaccination, and Vaccination Group – 25 mcg mRNA-1273,
18-55 Years of Age (N=15)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	20	4	-
	Moderate	1	1	-
	Severe	-	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	2	-	-
	Moderate	1	1	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	6	-	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	6	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	-	1	-

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

TABLE 4A(i):
All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, Relationship to Study Vaccination, and Vaccination Group – 25 mcg mRNA-1273, 18-55 Years of Age (N=15) (continued)

	Moderate	-	-	-
	Severe	-	-	-
Nervous System Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	2	1	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	2	2	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4A(ii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	14	8	-
	Moderate	1	2	-
	Severe	-	-	-
Cardiac Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	2	-	-
	Moderate	-	1	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	3	3	-
	Moderate	-	1	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	2	-	-
	Moderate	1	-	-
	Severe	-	-	-
Investigations	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	2	-
	Moderate	-	-	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	1	-	-

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

TABLE 4A-ii:
All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, Relationship to Study Vaccination, and Vaccination Group – 100 mcg mRNA-1273, 18-55 Years of Age (N=15) (continued)

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
	Moderate	-	-	-
	Severe	-	-	-
Nervous System Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	2	1	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4A(iii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	10	8	-
	Moderate	4	7	-
	Severe	-	2	-
Cardiac Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	1	2	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	1	2	-
	Moderate	-	2	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	1	-
	Moderate	1	2	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	1	-	-
	Moderate	1	1	-
	Severe	-	-	-

**TABLE 4A(iii):
All Adverse Events Cross-Classified by MedDRA® System Organ Class, Severity, Relationship to Study
Vaccination, and Vaccination Group – 250 mcg mRNA-1273,
18-55 Years of Age (N=15) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	1	-	-
	Moderate	2	-	-
	Severe	-	2	-
Psychiatric Disorders	Mild	1	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	1	1	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	-	-
	Moderate	-	2	-
	Severe	-	-	-
Vascular Disorders	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4A(iv):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects 18-55 years (N=45)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	44	20	-
	Moderate	6	10	-
	Severe	-	2	-
Cardiac Disorders	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	2	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	5	2	-
	Moderate	1	2	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	10	5	-
	Moderate	-	3	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	8	-	-
	Moderate	1	-	-
	Severe	-	-	-
Investigations	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	3	-
	Moderate	1	2	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	2	1	-
	Moderate	1	1	-
	Severe	-	-	-

**TABLE 4A(iv):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects 18-55 years (N=45) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	3	-	-
	Moderate	2	-	-
	Severe	-	2	-
Psychiatric Disorders	Mild	1	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	2	1	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	5	2	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	2	2	-
	Moderate	-	2	-
	Severe	-	-	-
Vascular Disorders	Mild	3	1	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(i):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	6	1	-
	Moderate	1	1	-
	Severe	-	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	1	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(i):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(ii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	2	1	-
	Moderate	3	-	-
	Severe	1	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	1	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(ii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	1	-	-
	Moderate	1	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Vascular Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(iii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects 56-70 years (N=20)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	8	2	-
	Moderate	4	1	-
	Severe	1	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	1	-
	Severe	1	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4B(iii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects 56-70 years (N=20) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	2	-	-
	Moderate	1	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	-	-
	Moderate	1	-	-
	Severe	-	-	-
Vascular Disorders	Mild	2	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4C(i):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	6	5	-
	Moderate	1	-	-
	Severe	-	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	1	1	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	4	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	1	-	-
	Moderate	1	-	-
	Severe	-	-	-

**TABLE 4C(i):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	-	2	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4C(ii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	4	-	-
	Moderate	-	-	-
	Severe	-	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	3	-	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4C(ii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Nervous System Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	1	-	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

**TABLE 4C(iii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects ≥71 years (N=20)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Mild	10	5	-
	Moderate	1	-	-
	Severe	-	-	-
Cardiac Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Ear And Labyrinth Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Eye Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Gastrointestinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
General Disorders And Administration Site Conditions	Mild	4	1	-
	Moderate	-	-	-
	Severe	-	-	-
Infections And Infestations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Injury, Poisoning And Procedural Complications	Mild	4	-	-
	Moderate	-	-	-
	Severe	-	-	-
Investigations	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Metabolism And Nutrition Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Musculoskeletal And Connective Tissue Disorders	Mild	1	-	-
	Moderate	1	-	-

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

**TABLE 4C(iii):
All Adverse Events Cross-Classified by
MedDRA® System Organ Class, Severity, and Relationship to Study Treatment, and
Vaccination Group – All Subjects ≥71 years (N=20) (continued)**

MedDRA System Organ Class	Severity	Relationship to Vaccination		
		Not Related (n)	Related (n)	Not Yet Determined (n)
	Severe	-	-	-
Nervous System Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Psychiatric Disorders	Mild	-	1	-
	Moderate	-	-	-
	Severe	-	-	-
Reproductive System And Breast Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Respiratory, Thoracic And Mediastinal Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-
Skin And Subcutaneous Tissue Disorders	Mild	1	2	-
	Moderate	-	-	-
	Severe	-	-	-
Vascular Disorders	Mild	-	-	-
	Moderate	-	-	-
	Severe	-	-	-

FIGURE 1A:
Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group - 18-55 Years of Age




FIGURE 1B:
Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group – 56-70 Years of Age





FIGURE 1C:
Number and Severity of All Adverse Events by MedDRA System Organ Class and Vaccination Group – ≥ 71 Years of Age



**TABLE 4D(i):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 years (N=15)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	26	24	2	-	21	5	-
Gastrointestinal disorders	Any PT	4	2	2	-	3	1	-
	Flatulence	1	1	-	-	1	-	-
	Vomiting	3	1	2	-	2	1	-
General disorders and administration site conditions	Any PT	6	6	-	-	6	-	-
	Fatigue	1	1	-	-	1	-	-
	Injection site irritation	1	1	-	-	1	-	-
	Vessel puncture site bruise	4	4	-	-	4	-	-
Injury, poisoning and procedural complications	Any PT	6	6	-	-	6	-	-
	Contusion	2	2	-	-	2	-	-
	Muscle strain	2	2	-	-	2	-	-
	Skin abrasion	1	1	-	-	1	-	-
	Skin laceration	1	1	-	-	1	-	-
Musculoskeletal and connective tissue disorders	Muscular weakness	1	1	-	-	-	1	-
Nervous system disorders	Presyncope	1	1	-	-	1	-	-
Respiratory, thoracic and mediastinal disorders	Any PT	3	3	-	-	2	1	-
	Dyspnoea exertional	1	1	-	-	1	-	-
	Oropharyngeal pain	2	2	-	-	1	1	-
Skin and subcutaneous tissue disorders	Any PT	4	4	-	-	2	2	-
	Dermatitis contact	1	1	-	-	1	-	-

**TABLE 4D(i):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 years (N=15) (continued)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
	Erythema	1	1	-	-	1	-	-
	Petechiae	1	1	-	-	-	1	-
	Urticaria	1	1	-	-	-	1	-
Vascular disorders	Systolic hypertension	1	1	-	-	1	-	-

**TABLE 4D(ii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, Severity, Relationship,
and Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity				Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)	
Any SOC	Any PT	25	22	3	-	15	10	-	
Cardiac disorders	Bradycardia	1	1	-	-	1	-	-	
Eye disorders	Eye irritation	1	1	-	-	-	1	-	
Gastrointestinal disorders	Any PT	3	2	1	-	2	1	-	
	Abdominal discomfort	1	1	-	-	1	-	-	
	Abdominal pain	1	-	1	-	-	1	-	
	Faeces discoloured	1	1	-	-	1	-	-	
General disorders and administration site conditions	Any PT	7	6	1	-	3	4	-	
	Feeling jittery	1	-	1	-	-	1	-	
	Injection site bruising	3	3	-	-	3	-	-	
	Injection site pruritus	3	3	-	-	-	3	-	
Injury, poisoning and procedural complications	Any PT	3	2	1	-	3	-	-	
	Muscle strain	2	1	1	-	2	-	-	
	Thermal burn	1	1	-	-	1	-	-	
Investigations	Heart rate increased	1	1	-	-	1	-	-	
Metabolism and nutrition disorders	Decreased appetite	2	2	-	-	-	2	-	
Musculoskeletal and connective tissue disorders	Neck pain	1	1	-	-	1	-	-	
Nervous system disorders	Dizziness	1	1	-	-	1	-	-	
Reproductive system and breast disorders	Breast pain	1	1	-	-	1	-	-	

**TABLE 4D(ii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15) (continued)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Respiratory, thoracic and mediastinal disorders	Any PT	3	3	-	-	2	1	-
	Diaphragmatic spasm	1	1	-	-	-	1	-
	Nasal congestion	1	1	-	-	1	-	-
	Oropharyngeal pain	1	1	-	-	1	-	-
Vascular disorders	Vasodilatation	1	1	-	-	-	1	-

**TABLE 4D(iii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, Severity, Relationship, Relationship to Study Vaccination, and Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity				Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)	
Any SOC	Any PT	31	18	11	2	14	17	-	
Cardiac disorders	Bradycardia	1	1	-	-	1	-	-	
Eye disorders	Scintillating scotoma	1	1	-	-	-	1	-	
Gastrointestinal disorders	Any PT	3	3	-	-	1	2	-	
	Abdominal pain upper	1	1	-	-	-	1	-	
	Lip disorder	1	1	-	-	1	-	-	
	Vomiting	1	1	-	-	-	1	-	
General disorders and administration site conditions	Any PT	5	3	2	-	1	4	-	
	Injection site erythema	2	1	1	-	-	2	-	
	Injection site pruritus	1	1	-	-	-	1	-	
	Malaise	1	-	1	-	-	1	-	
	Vessel puncture site bruise	1	1	-	-	1	-	-	
Metabolism and nutrition disorders	Any PT	4	1	3	-	1	3	-	
	Decreased appetite	3	1	2	-	-	3	-	
	Hypoglycaemia	1	-	1	-	1	-	-	
Musculoskeletal and connective tissue disorders	Any PT	3	1	2	-	2	1	-	
	Arthralgia	1	1	-	-	1	-	-	
	Muscle spasms	1	-	1	-	-	1	-	
	Muscle strain	1	-	1	-	1	-	-	
Nervous system disorders	Any PT	5	1	2	2	3	2	-	
	Dizziness	1	-	-	1	-	1	-	

**TABLE 4D(iii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15) (continued)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
	Headache	3	1	2	-	3	-	-
	Syncope	1	-	-	1	-	1	-
Psychiatric disorders	Any PT	2	2	-	-	1	1	-
	Anxiety	1	1	-	-	-	1	-
	Insomnia	1	1	-	-	1	-	-
Reproductive system and breast disorders	Any PT	2	2	-	-	1	1	-
	Vaginal haemorrhage	1	1	-	-	-	1	-
	Vulvovaginal pruritus	1	1	-	-	1	-	-
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1	1	-	-	1	-	-
Skin and subcutaneous tissue disorders	Any PT	2	-	2	-	-	2	-
	Hyperhidrosis	1	-	1	-	-	1	-
	Night sweats	1	-	1	-	-	1	-
Vascular disorders	Any PT	2	2	-	-	2	-	-
	Hypertension	1	1	-	-	1	-	-
	Hypotension	1	1	-	-	1	-	-

**TABLE 4D(iv):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, Severity, Relationship, and Vaccination Group –mRNA-1273 All Subjects 18-55 years (N=45)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	82	64	16	2	50	32	-
Cardiac disorders	Bradycardia	2	2	-	-	2	-	-
Eye disorders	Any PT	2	2	-	-	-	2	-
	Eye irritation	1	1	-	-	-	1	-
	Scintillating scotoma	1	1	-	-	-	1	-
Gastrointestinal disorders	Any PT	10	7	3	-	6	4	-
	Abdominal discomfort	1	1	-	-	1	-	-
	Abdominal pain	1	-	1	-	-	1	-
	Abdominal pain upper	1	1	-	-	-	1	-
	Faeces discoloured	1	1	-	-	1	-	-
	Flatulence	1	1	-	-	1	-	-
	Lip disorder	1	1	-	-	1	-	-
	Vomiting	4	2	2	-	2	2	-
General disorders and administration site conditions	Any PT	18	15	3	-	10	8	-
	Fatigue	1	1	-	-	1	-	-
	Feeling jittery	1	-	1	-	-	1	-
	Injection site bruising	3	3	-	-	3	-	-
	Injection site erythema	2	1	1	-	-	2	-
	Injection site irritation	1	1	-	-	1	-	-
	Injection site pruritus	4	4	-	-	-	4	-
	Malaise	1	-	1	-	-	1	-

**TABLE 4D(iv):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – mRNA-1273 All Subjects 18-55 years (N=45) (continued)**

	Vessel puncture site bruise	5	5	-	-	-	5	-	-	-
Injury, poisoning and procedural complications	Any PT	9	8	1	-	-	9	-	-	-
	Contusion	2	2	-	-	-	2	-	-	-
	Muscle strain	4	3	1	-	-	4	-	-	-
	Skin abrasion	1	1	-	-	-	1	-	-	-
Investigations	Skin laceration	1	1	-	-	-	1	-	-	-
	Thermal burn	1	1	-	-	-	1	-	-	-
	Heart rate increased	1	1	-	-	-	1	-	-	-
	Any PT	6	3	3	-	-	1	5	-	-
Metabolism and nutrition disorders	Decreased appetite	5	3	2	-	-	-	5	-	-
	Hypoglycaemia	1	-	1	-	-	1	-	-	-
	Any PT	5	3	2	-	-	3	2	-	-
Musculoskeletal and connective tissue disorders	Arthralgia	1	1	-	-	-	1	-	-	-
	Muscle spasms	1	-	1	-	-	-	1	-	-
	Muscle strain	1	-	1	-	-	1	-	-	-
	Muscular weakness	1	1	-	-	-	-	1	-	-
	Neck pain	1	1	-	-	-	1	-	-	-
	Any PT	7	3	2	2	-	5	2	-	-
Nervous system disorders	Dizziness	2	1	-	1	-	1	1	-	-
	Headache	3	1	2	-	-	3	-	-	-
	Presyncope	1	1	-	-	-	1	-	-	-
	Syncope	1	-	-	1	-	-	1	-	-
	Any PT	2	2	-	-	-	1	1	-	-
Psychiatric disorders	Anxiety	1	1	-	-	-	-	1	-	-
	Insomnia	1	1	-	-	-	1	-	-	-

**TABLE 4D(iv):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – mRNA-1273 All Subjects 18-55 years (N=45) (continued)**

Reproductive system and breast disorders	Any PT	3	3	-	-	2	1	-
	Breast pain	1	1	-	-	1	-	-
	Vaginal haemorrhage	1	1	-	-	-	1	-
	Vulvovaginal pruritus	1	1	-	-	1	-	-
Respiratory, thoracic and mediastinal disorders	Any PT	7	7	-	-	5	2	-
	Diaphragmatic spasm	1	1	-	-	-	1	-
	Dyspnoea exertional	1	1	-	-	1	-	-
	Nasal congestion	1	1	-	-	1	-	-
Skin and subcutaneous tissue disorders	Oropharyngeal pain	4	4	-	-	3	1	-
	Any PT	6	4	2	-	2	4	-
	Dermatitis contact	1	1	-	-	1	-	-
	Erythema	1	1	-	-	1	-	-
Vascular disorders	Hyperhidrosis	1	-	1	-	-	1	-
	Night sweats	1	-	1	-	-	1	-
	Petechiae	1	1	-	-	-	1	-
	Urticaria	1	1	-	-	-	1	-
Vascular disorders	Any PT	4	4	-	-	3	1	-
	Hypertension	1	1	-	-	1	-	-
	Hypotension	1	1	-	-	1	-	-
	Systolic hypertension	1	1	-	-	1	-	-
Vascular disorders	Vasodilatation	1	1	-	-	-	1	-

**TABLE 4E(i):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	9	7	2	-	7	2	-
General disorders and administration site conditions	Any PT	2	2	-	-	2	-	-
	Injection site bruising	1	1	-	-	1	-	-
	Vaccination site bruising	1	1	-	-	1	-	-
Injury, poisoning and procedural complications	Exposure via inhalation	1	-	1	-	1	-	-
Metabolism and nutrition disorders	Decreased appetite	1	-	1	-	-	1	-
Nervous system disorders	Any PT	2	2	-	-	2	-	-
	Headache	1	1	-	-	1	-	-
	Sciatica	1	1	-	-	1	-	-
Psychiatric disorders	Insomnia	1	1	-	-	-	1	-
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1	1	-	-	1	-	-
Vascular disorders	Diastolic hypertension	1	1	-	-	1	-	-

**TABLE 4E(ii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	7	3	3	1	6	1	-
Ear and labyrinth disorders	Vertigo	1	1	-	-	-	1	-
Infections and infestations	Paronychia	1	-	1	-	1	-	-
Metabolism and nutrition disorders	Hypoglycaemia	1	-	-	1	1	-	-
Respiratory, thoracic and mediastinal disorders	Any PT	2	1	1	-	2	-	-
	Nasal congestion	1	-	1	-	1	-	-
	Oropharyngeal pain	1	1	-	-	1	-	-
Skin and subcutaneous tissue disorders	Rash maculo-papular	1	-	1	-	1	-	-
Vascular disorders	Systolic hypertension	1	1	-	-	1	-	-

**TABLE 4E(iii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 56-70 years (N=20)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	16	10	5	1	13	3	-
Ear and labyrinth disorders	Vertigo	1	1	-	-	-	1	-
General disorders and administration site conditions	Any PT	2	2	-	-	2	-	-
	Injection site bruising	1	1	-	-	1	-	-
	Vaccination site bruising	1	1	-	-	1	-	-
Infections and infestations	Paronychia	1	-	1	-	1	-	-
Injury, poisoning and procedural complications	Exposure via inhalation	1	-	1	-	1	-	-
Metabolism and nutrition disorders	Any PT	2	-	1	1	1	1	-
	Decreased appetite	1	-	1	-	-	1	-
	Hypoglycaemia	1	-	-	1	1	-	-
Nervous system disorders	Any PT	2	2	-	-	2	-	-
	Headache	1	1	-	-	1	-	-
	Sciatica	1	1	-	-	1	-	-
Psychiatric disorders	Insomnia	1	1	-	-	-	1	-
Respiratory, thoracic and mediastinal disorders	Any PT	3	2	1	-	3	-	-
	Nasal congestion	1	-	1	-	1	-	-
	Oropharyngeal pain	2	2	-	-	2	-	-
Skin and subcutaneous tissue disorders	Rash maculo-papular	1	-	1	-	1	-	-
Vascular disorders	Any PT	2	2	-	-	2	-	-

**TABLE 4E(iii):
 Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and
 Preferred Term, Severity, Relationship, and
 Vaccination Group – 56-70 years (N=20) (continued)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
	Diastolic hypertension	1	1	-	-	1	-	-
	Systolic hypertension	1	1	-	-	1	-	-

**TABLE 4F(i):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	12	11	1	-	7	5	-
General disorders and administration site conditions	Any PT	2	2	-	-	1	1	-
	Energy increased	1	1	-	-	-	1	-
	Injection site bruising	1	1	-	-	1	-	-
Injury, poisoning and procedural complications	Any PT	4	4	-	-	4	-	-
	Arthropod bite	1	1	-	-	1	-	-
	Skin abrasion	2	2	-	-	2	-	-
	Sunburn	1	1	-	-	1	-	-
	Any PT	2	1	1	-	2	-	-
Musculoskeletal and connective tissue disorders	Joint swelling	1	1	-	-	1	-	-
	Musculoskeletal chest pain	1	-	1	-	1	-	-
Nervous system disorders	Dizziness	1	1	-	-	-	1	-
Psychiatric disorders	Anxiety	1	1	-	-	-	1	-
	Any PT	2	2	-	-	-	2	-
Skin and subcutaneous tissue disorders	Night sweats	1	1	-	-	-	1	-
	Pruritus	1	1	-	-	-	1	-

**TABLE 4F(ii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity				Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)	
Any SOC	Any PT	4	4	-	-	4	-	-	
General disorders and administration site conditions	Any PT	3	3	-	-	3	-	-	
	Injection site bruising	1	1	-	-	1	-	-	
	Vessel puncture site bruise	2	2	-	-	2	-	-	
Skin and subcutaneous tissue disorders	Dermatitis	1	1	-	-	1	-	-	

**TABLE 4F(iii):
Summary of All Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – ≥71 years (N=20)**

System Organ Class (SOC)	Preferred Term (PT)	Total Events (n)	Severity			Relationship to Study Vaccination		
			Mild (n)	Moderate (n)	Severe (n)	Not Related (n)	Related (n)	Not Yet Determined (n)
Any SOC	Any PT	16	15	1	-	11	5	-
General disorders and administration site conditions	Any PT	5	5	-	-	4	1	-
	Energy increased	1	1	-	-	-	1	-
	Injection site bruising	2	2	-	-	2	-	-
	Vessel puncture site bruise	2	2	-	-	2	-	-
Injury, poisoning and procedural complications	Any PT	4	4	-	-	4	-	-
	Arthropod bite	1	1	-	-	1	-	-
	Skin abrasion	2	2	-	-	2	-	-
	Sunburn	1	1	-	-	1	-	-
	Any PT	2	1	1	-	2	-	-
Musculoskeletal and connective tissue disorders	Joint swelling	1	1	-	-	1	-	-
	Musculoskeletal chest pain	1	-	1	-	1	-	-
Nervous system disorders	Dizziness	1	1	-	-	-	1	-
	Anxiety	1	1	-	-	-	1	-
Skin and subcutaneous tissue disorders	Any PT	3	3	-	-	1	2	-
	Dermatitis	1	1	-	-	1	-	-
	Night sweats	1	1	-	-	-	1	-
	Pruritus	1	1	-	-	-	1	-

**TABLE 4G(i):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 Years of Age (N=15)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence				Severity						Relationship to Study Vaccination			
		n		%		Mild		Moderate		Severe		Not Related		Related	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%
Gastrointestinal disorders	Any PT	11	73	2	13	-	-	-	-	-	-	10	67	4	27
	Any PT	4	27	2	13	-	-	-	-	-	-	3	20	1	7
	Flatulence	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Vomiting	3	20	1	7	2	13	-	-	-	-	2	13	1	7
General disorders and administration site conditions	Any PT	4	27	4	27	-	-	-	-	-	-	4	27	-	-
	Fatigue	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Injection site irritation	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Vessel puncture site bruise	2	13	2	13	-	-	-	-	-	-	2	13	-	-
	Any PT	4	27	4	27	-	-	-	-	-	-	4	27	-	-
Injury, poisoning and procedural complications	Contusion	2	13	2	13	-	-	-	-	-	-	2	13	-	-
	Muscle strain	2	13	2	13	-	-	-	-	-	-	2	13	-	-
	Skin abrasion	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Skin laceration	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Muscular weakness	1	7	1	7	-	-	-	-	-	-	-	-	1	7
Musculoskeletal and connective tissue disorders	Presyncope	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Any PT	2	13	2	13	-	-	-	-	-	-	2	13	1	7
Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Oropharyngeal pain	1	7	1	7	-	-	-	-	-	-	1	7	1	7
	Any PT	1	7	1	7	-	-	-	-	-	-	1	7	1	7

**TABLE 4G(i):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events by MedDRA® System Organ Class and Preferred Term,
Severity, Relationship, and Vaccination Group – 25 mcg mRNA-1273 18-55 Years of Age (N=15) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination			
		n		%		Mild		Moderate		Severe		Not Related		Related			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Skin and subcutaneous tissue disorders	Any PT	4	27	4	27	-	-	-	-	-	-	2	13	2	13		
	Dermatitis contact	1	7	1	7	-	-	-	-	-	-	1	7	-	-		
	Erythema	1	7	1	7	-	-	-	-	-	-	1	7	-	-		
	Petechiae	1	7	1	7	-	-	-	-	-	-	-	-	1	7		
	Urticaria	1	7	1	7	-	-	-	-	-	-	-	-	1	7		
Vascular disorders	Systolic hypertension	1	7	1	7	-	-	-	-	-	-	1	7	-	-		

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4G(ii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination					
		n		%		Mild		Moderate		Severe		Not Related		Related					
						n	%	n	%	n	%	n	%	n	%				
Any SOC	Any PT	10	67	9	60	3	20	-	-	8	53	3	20						
Cardiac disorders	Bradycardia	1	7	1	7	-	-	-	-	1	7	-	-						
Eye disorders	Eye irritation	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
Gastrointestinal disorders	Any PT	2	13	1	7	1	7	-	-	1	7	1	7	-	-				
	Abdominal discomfort	1	7	1	7	-	-	-	-	1	7	-	-						
	Abdominal pain	1	7	-	-	1	7	-	-	-	-	1	7	-	-				
	Faeces discoloured	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
General disorders and administration site conditions	Any PT	4	27	4	27	1	7	-	-	3	20	2	13						
	Feeling jittery	1	7	-	-	1	7	-	-	-	-	1	7	-	-				
	Injection site bruising	3	20	3	20	-	-	-	-	3	20	-	-						
	Injection site pruritus	2	13	2	13	-	-	-	-	-	-	2	13						
Injury, poisoning and procedural complications	Any PT	3	20	2	13	1	7	-	-	3	20	-	-						
	Muscle strain	2	13	1	7	1	7	-	-	2	13	-	-						
	Thermal burn	1	7	1	7	-	-	-	-	1	7	-	-						
Investigations	Heart rate increased	1	7	1	7	-	-	-	-	1	7	-	-						
Metabolism and nutrition disorders	Decreased appetite	1	7	1	7	-	-	-	-	-	-	1	7						
Musculoskeletal and connective tissue disorders	Neck pain	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
Nervous system disorders	Dizziness	1	7	1	7	-	-	-	-	-	-	1	7	-	-				

**TABLE 4G(ii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 100 mcg mRNA-1273 18-55 years (N=15) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination					
		n		%		Mild		Moderate		Severe		Not Related		Related					
		n	%	n	%	n	%	n	%	n	%	n	%	n	%				
Reproductive system and breast disorders	Breast pain	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
	Any PT	3	20	3	20	-	-	-	-	-	-	2	13	1	7				
Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm	1	7	1	7	-	-	-	-	-	-	-	-	1	7				
	Nasal congestion	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
	Oropharyngeal pain	1	7	1	7	-	-	-	-	-	-	1	7	-	-				
Vascular disorders	Vasodilatation	1	7	1	7	-	-	-	-	-	-	-	-	1	7				

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4G(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence				Severity						Relationship to Study Vaccination			
		n		%		Mild		Moderate		Severe		Not Related		Related	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any SOC	Any PT	11	73	7	47	7	47	7	47	1	7	8	53	7	47
Cardiac disorders	Bradycardia	1	7	1	7	-	-	-	-	-	-	1	7	-	-
Eye disorders	Scintillating scotoma	1	7	1	7	-	-	-	-	-	-	-	-	1	7
Gastrointestinal disorders	Any PT	3	20	3	20	-	-	-	-	-	-	1	7	2	13
	Abdominal pain upper	1	7	1	7	-	-	-	-	-	-	-	-	1	7
	Lip disorder	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Vomiting	1	7	1	7	-	-	-	-	-	-	-	-	1	7
General disorders and administration site conditions	Any PT	3	20	2	13	2	13	2	13	-	-	1	7	3	20
	Injection site erythema	2	13	1	7	1	7	1	7	-	-	-	-	2	13
	Injection site pruritus	1	7	1	7	-	-	-	-	-	-	-	-	1	7
	Malaise	1	7	-	-	-	-	1	7	-	-	-	-	1	7
	Vessel puncture site bruise	1	7	1	7	-	-	-	-	-	-	1	7	-	-
Metabolism and nutrition disorders	Any PT	4	27	1	7	3	20	3	20	-	-	1	7	3	20
	Decreased appetite	3	20	1	7	2	13	2	13	-	-	-	-	3	20
	Hypoglycaemia	1	7	-	-	-	-	1	7	-	-	1	7	-	-
Musculoskeletal and connective tissue disorders	Any PT	3	20	1	7	2	13	2	13	-	-	2	13	1	7
	Arthralgia	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Muscle spasms	1	7	-	-	-	-	1	7	-	-	-	-	1	7

TABLE 4G(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15) (continued)

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence		Severity						Relationship to Study Vaccination					
		n	%	Mild		Moderate		Severe		Not Related		Related			
				n	%	n	%	n	%	n	%	n	%		
Nervous system disorders	Muscle strain	1	7	-	-	1	7	-	-	-	-	1	7	-	-
	Any PT	3	20	1	7	1	7	1	7	1	7	2	13	1	7
	Dizziness	1	7	-	-	-	-	1	7	-	-	-	-	1	7
	Headache	2	13	1	7	1	7	-	-	-	-	2	13	-	-
	Syncope	1	7	-	-	-	-	1	7	-	-	-	-	1	7
Psychiatric disorders	Any PT	1	7	1	7	-	-	-	-	-	-	1	7	1	7
	Anxiety	1	7	1	7	-	-	-	-	-	-	-	-	1	7
	Insomnia	1	7	1	7	-	-	-	-	-	-	1	7	-	-
Reproductive system and breast disorders	Any PT	2	13	2	13	-	-	-	-	-	-	1	7	1	7
	Vaginal haemorrhage	1	7	1	7	-	-	-	-	-	-	-	-	1	7
	Vulvovaginal pruritus	1	7	1	7	-	-	-	-	-	-	1	7	-	-
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Any PT	2	13	-	-	2	13	-	-	-	-	-	-	2	13
Skin and subcutaneous tissue disorders	Hyperhidrosis	1	7	-	-	1	7	-	-	-	-	-	-	1	7
	Night sweats	1	7	-	-	1	7	-	-	-	-	-	-	1	7
	Any PT	2	13	2	13	-	-	-	-	-	-	2	13	-	-
Vascular disorders	Hypertension	1	7	1	7	-	-	-	-	-	-	1	7	-	-
	Hypotension	1	7	1	7	-	-	-	-	-	-	1	7	-	-

**TABLE 4G(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 250 mcg mRNA-1273 18-55 years (N=15) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Severity						Relationship to Study Vaccination				
		Any Incidence		Mild		Moderate		Severe		Not Related	Related	
		n	%	n	%	n	%	n	%	n	%	
Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.												

**TABLE 4G(iv):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 18-55 years (N=45)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence		Severity						Relationship to Study Vaccination			
		n	%	Mild		Moderate		Severe		Not Related		Related	
				n	%	n	%	n	%	n	%	n	%
Any SOC	Any PT	32	71	27	60	12	27	1	2	26	58	14	31
Cardiac disorders	Bradycardia	2	4	2	4	-	-	-	-	2	4	-	-
Eye disorders	Any PT	2	4	2	4	-	-	-	-	-	-	2	4
	Eye irritation	1	2	1	2	-	-	-	-	-	-	1	2
	Scintillating scotoma	1	2	1	2	-	-	-	-	-	-	1	2
Gastrointestinal disorders	Any PT	9	20	6	13	3	7	-	-	5	11	4	9
	Abdominal discomfort	1	2	1	2	-	-	-	-	1	2	-	-
	Abdominal pain	1	2	-	-	1	2	-	-	-	-	1	2
	Abdominal pain upper	1	2	1	2	-	-	-	-	-	-	1	2
	Faeces discoloured	1	2	1	2	-	-	-	-	1	2	-	-
	Flatulence	1	2	1	2	-	-	-	-	1	2	-	-
	Lip disorder	1	2	1	2	-	-	-	-	1	2	-	-
	Vomiting	4	9	2	4	2	4	-	-	2	4	2	4
General disorders and administration site conditions	Any PT	11	24	10	22	3	7	-	-	8	18	5	11
	Fatigue	1	2	1	2	-	-	-	-	1	2	-	-
	Feeling jittery	1	2	-	-	1	2	-	-	-	-	1	2
	Injection site bruising	3	7	3	7	-	-	-	-	3	7	-	-
	Injection site erythema	2	4	1	2	1	2	-	-	-	-	2	4
	Injection site irritation	1	2	1	2	-	-	-	-	1	2	-	-

**TABLE 4G(iv):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 18-55 years (N=45) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence				Severity				Relationship to Study Vaccination			
		Mild		Moderate		Severe		Not Related		Related			
		n	%	n	%	n	%	n	%	n	%		
	Injection site pruritus	3	7	3	7	-	-	-	-	-	-	3	7
	Malaise	1	2	-	-	1	2	-	-	-	-	1	2
	Vessel puncture site bruise	3	7	3	7	-	-	-	-	3	7	-	-
Injury, poisoning and procedural complications	Any PT	7	16	6	13	1	2	-	-	7	16	-	-
	Contusion	2	4	2	4	-	-	-	-	2	4	-	-
	Muscle strain	4	9	3	7	1	2	-	-	4	9	-	-
	Skin abrasion	1	2	1	2	-	-	-	-	1	2	-	-
	Skin laceration	1	2	1	2	-	-	-	-	1	2	-	-
	Thermal burn	1	2	1	2	-	-	-	-	1	2	-	-
	Heart rate increased	1	2	1	2	-	-	-	-	1	2	-	-
	Any PT	5	11	2	4	3	7	-	-	1	2	4	9
	Decreased appetite	4	9	2	4	2	4	-	-	-	-	4	9
	Hypoglycaemia	1	2	-	-	1	2	-	-	1	2	-	-
Musculoskeletal and connective tissue disorders	Any PT	5	11	3	7	2	4	-	-	3	7	2	4
	Arthralgia	1	2	1	2	-	-	-	-	1	2	-	-
	Muscle spasms	1	2	-	-	1	2	-	-	-	-	1	2
	Muscle strain	1	2	-	-	1	2	-	-	1	2	-	-
	Muscular weakness	1	2	1	2	-	-	-	-	-	-	1	2

**TABLE 4G(iv):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 18-55 years (N=45) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence				Severity				Relationship to Study Vaccination			
		Mild		Moderate		Severe		Not Related		Related			
		n	%	n	%	n	%	n	%	n	%		
Nervous system disorders	Neck pain	1	2	1	2	-	-	-	-	1	2	-	-
	Any PT	5	11	3	7	1	2	1	2	4	9	1	2
	Dizziness	2	4	1	2	-	-	1	2	1	2	1	2
	Headache	2	4	1	2	1	2	-	-	2	4	-	-
	Presyncope	1	2	1	2	-	-	-	-	1	2	-	-
	Syncope	1	2	-	-	-	-	1	2	-	-	1	2
	Any PT	1	2	1	2	-	-	-	-	1	2	1	2
Psychiatric disorders	Anxiety	1	2	1	2	-	-	-	-	-	-	1	2
	Insomnia	1	2	1	2	-	-	-	-	1	2	-	-
	Any PT	3	7	3	7	-	-	-	-	2	4	1	2
Reproductive system and breast disorders	Breast pain	1	2	1	2	-	-	-	-	1	2	-	-
	Vaginal haemorrhage	1	2	1	2	-	-	-	-	-	-	1	2
	Vulvovaginal pruritus	1	2	1	2	-	-	-	-	1	2	-	-
	Any PT	6	13	6	13	-	-	-	-	5	11	2	4
	Diaphragmatic spasm	1	2	1	2	-	-	-	-	-	-	1	2
Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional	1	2	1	2	-	-	-	-	1	2	-	-
	Nasal congestion	1	2	1	2	-	-	-	-	1	2	-	-
	Oropharyngeal pain	3	7	3	7	-	-	-	-	3	7	1	2
	Any PT	6	13	4	9	2	4	-	-	2	4	4	9

**TABLE 4G(iv):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 18-55 years (N=45) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence		Severity						Relationship to Study Vaccination					
		n	%	Mild		Moderate		Severe		Not Related		Related			
				n	%	n	%	n	%	n	%	n	%		
Skin and subcutaneous tissue disorders	Dermatitis contact	1	2	1	2	-	-	-	-	-	-	1	2	-	-
	Erythema	1	2	1	2	-	-	-	-	-	-	1	2	-	-
	Hyperhidrosis	1	2	-	-	1	2	-	-	-	-	-	-	1	2
	Night sweats	1	2	-	-	1	2	-	-	-	-	-	-	1	2
	Petechiae	1	2	1	2	-	-	-	-	-	-	-	-	1	2
	Urticaria	1	2	1	2	-	-	-	-	-	-	-	-	1	2
	Any PT	4	9	4	9	-	-	-	-	-	-	3	7	1	2
Vascular disorders	Hypertension	1	2	1	2	-	-	-	-	-	-	1	2	-	-
	Hypotension	1	2	1	2	-	-	-	-	-	-	1	2	-	-
	Systolic hypertension	1	2	1	2	-	-	-	-	-	-	1	2	-	-
	Vasodilatation	1	2	1	2	-	-	-	-	-	-	-	-	1	2

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4H(i):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 25 mcg mRNA-1273 56-70 years (N=10)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination			
		n		%		Mild		Moderate		Severe		Not Related		Related			
						n	%	n	%	n	%	n	%	n	%		
Any SOC	Any PT	8	80	7	70	2	20	-	-	-	-	6	60	2	20		
General disorders and administration site conditions	Any PT	2	20	2	20	-	-	-	-	-	-	2	20	-	-		
	Injection site bruising	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
	Vaccination site bruising	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
Injury, poisoning and procedural complications	Exposure via inhalation	1	10	-	-	1	10	-	-	-	-	1	10	-	-		
Metabolism and nutrition disorders	Decreased appetite	1	10	-	-	1	10	-	-	-	-	-	-	1	10		
Nervous system disorders	Any PT	2	20	2	20	-	-	-	-	-	-	2	20	-	-		
	Headache	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
	Sciatica	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
Psychiatric disorders	Insomnia	1	10	1	10	-	-	-	-	-	-	-	-	1	10		
Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
Vascular disorders	Diastolic hypertension	1	10	1	10	-	-	-	-	-	-	1	10	-	-		

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4H(ii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 100 mcg mRNA-1273 56-70 years (N=10)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence			Mild			Moderate			Severe			Relationship to Study Vaccination		
		n	%		n	%		n	%		n	%		n	%	
Any SOC	Any PT	6	60	3	30	2	20	1	10	5	50	1	10	1	10	
Ear and labyrinth disorders	Vertigo	1	10	1	10	-	-	-	-	-	-	-	-	1	10	
Infections and infestations	Paronychia	1	10	-	-	1	10	-	-	1	10	-	-	1	10	
Metabolism and nutrition disorders	Hypoglycaemia	1	10	-	-	-	-	1	10	-	-	-	-	1	10	
Respiratory, thoracic and mediastinal disorders	Any PT	2	20	1	10	1	10	-	-	2	20	-	-	-	-	
	Nasal congestion	1	10	-	-	1	10	-	-	1	10	-	-	1	10	
	Oropharyngeal pain	1	10	1	10	-	-	-	-	1	10	-	-	1	10	
Skin and subcutaneous tissue disorders	Rash maculo-papular	1	10	-	-	1	10	-	-	1	10	-	-	1	10	
Vascular disorders	Systolic hypertension	1	10	1	10	-	-	-	-	-	-	-	-	1	10	

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4H(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 56-70 years (N=20)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence		Severity						Relationship to Study Vaccination			
		n	%	Mild		Moderate		Severe		Not Related		Related	
				n	%	n	%	n	%	n	%	n	%
Any SOC	Any PT	14	70	10	50	4	20	1	5	11	55	3	15
Ear and labyrinth disorders	Vertigo	1	5	1	5	-	-	-	-	-	-	1	5
General disorders and administration site conditions	Any PT	2	10	2	10	-	-	-	-	2	10	-	-
	Injection site bruising	1	5	1	5	-	-	-	-	1	5	-	-
	Vaccination site bruising	1	5	1	5	-	-	-	-	1	5	-	-
Infections and infestations	Paronychia	1	5	-	-	1	5	-	-	1	5	-	-
Injury, poisoning and procedural complications	Exposure via inhalation	1	5	-	-	1	5	-	-	1	5	-	-
Metabolism and nutrition disorders	Any PT	2	10	-	-	1	5	1	5	1	5	1	5
	Decreased appetite	1	5	-	-	1	5	-	-	-	-	1	5
	Hypoglycaemia	1	5	-	-	-	-	1	5	1	5	-	-
Nervous system disorders	Any PT	2	10	2	10	-	-	-	-	2	10	-	-
	Headache	1	5	1	5	-	-	-	-	1	5	-	-
	Sciatica	1	5	1	5	-	-	-	-	1	5	-	-
Psychiatric disorders	Insomnia	1	5	1	5	-	-	-	-	-	-	1	5
Respiratory, thoracic and mediastinal disorders	Any PT	3	15	2	10	1	5	-	-	3	15	-	-
	Nasal congestion	1	5	-	-	1	5	-	-	1	5	-	-
	Oropharyngeal pain	2	10	2	10	-	-	-	-	2	10	-	-
Skin and subcutaneous tissue disorders	Rash maculo-papular	1	5	-	-	1	5	-	-	1	5	-	-

**TABLE 4H(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 56-70 years (N=20) (continued)**

MedDRA System Organ Class	MedDRA Preferred Term	Severity						Relationship to Study Vaccination					
		Any Incidence		Mild		Moderate		Severe		Not Related		Related	
		n	%	n	%	n	%	n	%	n	%	n	%
Vascular disorders	Any PT	2	10	2	10	-	-	-	-	-	-	-	-
	Diastolic hypertension	1	5	1	5	-	-	-	-	1	5	-	-
	Systolic hypertension	1	5	1	5	-	-	-	-	1	5	-	-

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4(i):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 25 mcg mRNA-1273 ≥71 years (N=10)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination					
		n		%		Mild		Moderate		Severe		Not Related		Related					
		n	%	n	%	n	%	n	%	n	%	n	%	n	%				
Any SOC	Any PT	7	70	7	70	1	10	-	-	-	-	4	40	3	30				
General disorders and administration site conditions	Any PT	2	20	2	20	-	-	-	-	-	-	1	10	1	10				
	Energy increased	1	10	1	10	-	-	-	-	-	-	-	-	1	10				
	Injection site bruising	1	10	1	10	-	-	-	-	-	-	1	10	-	-				
Injury, poisoning and procedural complications	Any PT	3	30	3	30	-	-	-	-	-	-	3	30	-	-				
	Arthropod bite	1	10	1	10	-	-	-	-	-	-	1	10	-	-				
	Skin abrasion	2	20	2	20	-	-	-	-	-	-	2	20	-	-				
	Sunburn	1	10	1	10	-	-	-	-	-	-	1	10	-	-				
Musculoskeletal and connective tissue disorders	Any PT	2	20	1	10	1	10	-	-	-	-	2	20	-	-				
	Joint swelling	1	10	1	10	-	-	-	-	-	-	1	10	-	-				
	Musculoskeletal chest pain	1	10	-	-	1	10	-	-	-	-	1	10	-	-				
Nervous system disorders	Dizziness	1	10	1	10	-	-	-	-	-	-	-	-	1	10				
Psychiatric disorders	Anxiety	1	10	1	10	-	-	-	-	-	-	-	-	1	10				
Skin and subcutaneous tissue disorders	Any PT	2	20	2	20	-	-	-	-	-	-	-	-	2	20				
	Night sweats	1	10	1	10	-	-	-	-	-	-	-	-	1	10				
	Pruritus	1	10	1	10	-	-	-	-	-	-	-	-	1	10				

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4I(ii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – 100 mcg mRNA-1273 ≥71 years (N=10)**

MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence						Severity						Relationship to Study Vaccination			
		n		%		Mild		Moderate		Severe		Not Related		Related			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any SOC	Any PT	3	30	3	30	-	-	-	-	-	-	3	30	-	-		
General disorders and administration site conditions	Any PT	2	20	2	20	-	-	-	-	-	-	2	20	-	-		
	Injection site bruising	1	10	1	10	-	-	-	-	-	-	1	10	-	-		
	Vessel puncture site bruise	2	20	2	20	-	-	-	-	-	-	2	20	-	-		
Skin and subcutaneous tissue disorders	Dermatitis	1	10	1	10	-	-	-	-	-	-	1	10	-	-		

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.

**TABLE 4I(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – ≥71 years (N=20)**


MedDRA System Organ Class	MedDRA Preferred Term	Any Incidence				Severity						Relationship to Study Vaccination			
		Mild		Moderate		Severe		Not Related		Related		Not Related		Related	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any SOC	Any PT	10	50	10	50	1	5	-	-	-	-	7	35	3	15
General disorders and administration site conditions	Any PT	4	20	4	20	-	-	-	-	-	-	3	15	1	5
	Energy increased	1	5	1	5	-	-	-	-	-	-	-	-	1	5
	Injection site bruising	2	10	2	10	-	-	-	-	-	-	2	10	-	-
	Vessel puncture site bruise	2	10	2	10	-	-	-	-	-	-	2	10	-	-
Injury, poisoning and procedural complications	Any PT	3	15	3	15	-	-	-	-	-	-	3	15	-	-
	Arthropod bite	1	5	1	5	-	-	-	-	-	-	1	5	-	-
	Skin abrasion	2	10	2	10	-	-	-	-	-	-	2	10	-	-
	Sunburn	1	5	1	5	-	-	-	-	-	-	1	5	-	-
Musculoskeletal and connective tissue disorders	Any PT	2	10	1	5	1	5	-	-	-	-	2	10	-	-
	Joint swelling	1	5	1	5	-	-	-	-	-	-	1	5	-	-
	Musculoskeletal chest pain	1	5	-	-	1	5	-	-	-	-	1	5	-	-
	Dizziness	1	5	1	5	-	-	-	-	-	-	-	-	1	5
Nervous system disorders	Anxiety	1	5	1	5	-	-	-	-	-	-	-	-	1	5
	Any PT	3	15	3	15	-	-	-	-	-	-	1	5	2	10
Skin and subcutaneous tissue disorders	Dermatitis	1	5	1	5	-	-	-	-	-	-	1	5	-	-
	Night sweats	1	5	1	5	-	-	-	-	-	-	-	-	1	5

**TABLE 4I(iii):
Number and Percentage of Subjects Experiencing Unsolicited Adverse Events
MedDRA® System Organ Class and Preferred Term, Severity, Relationship, and
Vaccination Group – ≥71 years (N=20) (continued)**


MedDRA System Organ Class	MedDRA Preferred Term	Severity						Relationship to Study Vaccination					
		Any Incidence		Mild		Moderate		Severe		Not Related		Related	
		n	%	n	%	n	%	n	%	n	%	n	%
	Pruritus	1	5	1	5	-	-	-	-	-	-	1	5

Note: This table presents number and percentage of subjects. A subject is only counted once per PT and is summarized according to their highest severity and closest relationship.


**FIGURE 2A(i):
 Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - 18-55 Years of Age**




**FIGURE 2A(ii):
Maximum Severity of Solicited Events by Symptom and Vaccination Group – Local - 18-55 Years of Age**




**Figure 2B(i):
 Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - 56-70 Years of Age**




**Figure 2B(ii):
 Maximum Severity of Solicited Events by Symptom and Vaccination Group - Local - 56-70 Years of Age**



**Figure 2C(i):
 Maximum Severity of Solicited Events by Symptom and Vaccination Group - Systemic - ≥ 71 Years of Age**



**Figure 2C(ii):
 Maximum Severity of Solicited Events by Symptom and Vaccination Group - Local - ≥71 Years of Age**



**TABLE 5A(i):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination
Group - Any Symptom - 18-55 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
Any Symptom	Dose 1	None	5	33.3	1	6.7	-	-	6	13.3
		Mild	8	53.3	10	66.7	9	60	27	60
		Moderate	2	13.3	3	20	5	33.3	10	22.2
		Severe	-	-	1	6.7	1	6.7	2	4.4
	Dose 2	None	3	23.1	-	-	-	-	3	7.1
		Mild	7	53.8	3	20	1	7.1	11	26.2
		Moderate	3	23.1	11	73.3	9	64.3	23	54.8
		Severe	-	-	1	6.7	4	28.6	5	11.9
	Any Dose	None	4	26.7	-	-	-	-	4	8.9
		Mild	6	40	3	20	1	6.7	10	22.2
		Moderate	5	33.3	11	73.3	10	66.7	26	57.8
		Severe	-	-	1	6.7	4	26.7	5	11.1

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

**TABLE 5A(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 18-55 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
Any Systemic Symptom	Dose 1	None	10	66.7	5	33.3	7	46.7	22	48.9
		Mild	3	20	8	53.3	4	26.7	15	33.3
		Moderate	2	13.3	2	13.3	4	26.7	8	17.8
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	6	46.2	-	-	-	-	6	14.3
		Mild	4	30.8	3	20	2	14.3	9	21.4
		Moderate	3	23.1	12	80	9	64.3	24	57.1
		Severe	-	-	-	-	3	21.4	3	7.1
	Any Dose	None	7	46.7	-	-	-	-	7	15.6
		Mild	3	20	3	20	3	20	9	20
		Moderate	5	33.3	12	80	9	60	26	57.8
		Severe	-	-	-	-	3	20	3	6.7
Arthralgia	Dose 1	None	15	100	13	86.7	14	93.3	42	93.3
		Mild	-	-	1	6.7	1	6.7	2	4.4
		Moderate	-	-	1	6.7	-	-	1	2.2
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	11	84.6	13	86.7	6	42.9	30	71.4
		Mild	-	-	1	6.7	5	35.7	6	14.3
		Moderate	2	15.4	1	6.7	3	21.4	6	14.3
		Severe	-	-	-	-	-	-	-	-
	Any Dose	None	13	86.7	13	86.7	7	46.7	33	73.3
		Mild	-	-	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-	-	-
		Severe	-	-	-	-	-	-	-	-

**TABLE 5A(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
Fatigue	Dose 1	Mild	-	-	-	-	5	33.3	5	11.1
		Moderate	2	13.3	2	13.3	3	20	7	15.6
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	11	73.3	11	73.3	10	66.7	32	71.1
		Mild	2	13.3	3	20	3	20	8	17.8
		Moderate	2	13.3	1	6.7	2	13.3	5	11.1
	Any Dose	Severe	-	-	-	-	-	-	-	-
		None	8	61.5	3	20	4	28.6	15	35.7
		Mild	4	30.8	6	40	2	14.3	12	28.6
	Fever ^a	Dose 1	Moderate	1	7.7	6	40	6	42.9	13
Severe			-	-	-	-	2	14.3	2	4.8
None			8	53.3	3	20	5	33.3	16	35.6
Dose 2		Mild	4	26.7	5	33.3	2	13.3	11	24.4
		Moderate	3	20	7	46.7	6	40	16	35.6
		Severe	-	-	-	-	2	13.3	2	4.4
Any Dose		None	15	100	15	100	15	100	45	100
		Mild	-	-	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-	-	-
Dose 1		Severe	-	-	-	-	-	-	-	-
	None	13	100	9	60	6	42.9	28	66.7	
	Mild	-	-	5	33.3	5	35.7	10	23.8	
Dose 2	Moderate	-	-	1	6.7	2	14.3	3	7.1	
	Severe	-	-	-	-	-	-	-	-	
	None	-	-	-	-	-	-	-	-	

**TABLE 5A(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
Feverishness	Any Dose	Severe	-	-	-	-	1	7.1	1	2.4
		None	15	100	9	60	7	46.7	31	68.9
		Mild	-	-	5	33.3	5	33.3	10	22.2
		Moderate	-	-	1	6.7	2	13.3	3	6.7
	Dose 1	Severe	-	-	-	-	1	6.7	1	2.2
		None	15	100	14	93.3	13	86.7	42	93.3
		Mild	-	-	1	6.7	2	13.3	3	6.7
		Moderate	-	-	-	-	-	-	-	-
		Severe	-	-	-	-	-	-	-	-
		None	12	92.3	3	20	2	14.3	17	40.5
Dose 2	Mild	1	7.7	8	53.3	4	28.6	13	31	
	Moderate	-	-	4	26.7	5	35.7	9	21.4	
	Severe	-	-	-	-	3	21.4	3	7.1	
	None	14	93.3	3	20	3	20	20	44.4	
Any Dose	Mild	1	6.7	8	53.3	4	26.7	13	28.9	
	Moderate	-	-	4	26.7	5	33.3	9	20	
	Severe	-	-	-	-	3	20	3	6.7	
	None	12	80	11	73.3	8	53.3	31	68.9	
Dose 1	Mild	3	20	4	26.7	4	26.7	11	24.4	
	Moderate	-	-	-	-	3	20	3	6.7	
	Severe	-	-	-	-	-	-	-	-	
	None	10	76.9	6	40	-	-	16	38.1	

**TABLE 5A(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)			100 mcg mRNA -1273 (N=15)			250 mcg mRNA -1273 (N=15)			All Subjects (N=45)		
			n	%		n	%		n	%		n	%	
Myalgia	Any Dose	Mild	2	15.4		5	33.3		9	64.3		16	38.1	
		Moderate	1	7.7		4	26.7		4	28.6		9	21.4	
		Severe	-	-		-	-		1	7.1		1	2.4	
	Dose 1	None	11	73.3		5	33.3		-	-		16	35.6	
		Mild	3	20		6	40		9	60		18	40	
		Moderate	1	6.7		4	26.7		5	33.3		10	22.2	
		Severe	-	-		-	-		1	6.7		1	2.2	
		None	14	93.3		14	93.3		11	73.3		39	86.7	
		Mild	1	6.7		1	6.7		4	26.7		6	13.3	
		Moderate	-	-		-	-		-	-		-	-	
Dose 2	None	10	76.9		7	46.7		1	7.1		18	42.9		
	Mild	2	15.4		2	13.3		5	35.7		9	21.4		
	Moderate	1	7.7		6	40		7	50		14	33.3		
Any Dose	Severe	-	-		-	-		1	7.1		1	2.4		
	None	11	73.3		7	46.7		2	13.3		20	44.4		
	Mild	3	20		2	13.3		5	33.3		10	22.2		
Dose 1	Moderate	1	6.7		6	40		7	46.7		14	31.1		
	Severe	-	-		-	-		1	6.7		1	2.2		
	None	14	93.3		15	100		14	93.3		43	95.6		
Nausea	Mild	-	-		-	-		1	6.7		1	2.2		
	Moderate	1	6.7		-	-		-	-		1	2.2		

**TABLE 5A(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	13	100	8	53.3	10	71.4	31	73.8
		Mild	-	-	6	40	1	7.1	7	16.7
	Any Dose	Moderate	-	-	1	6.7	2	14.3	3	7.1
		Severe	-	-	-	-	1	7.1	1	2.4
	Any Dose	None	14	93.3	8	53.3	11	73.3	33	73.3
		Mild	-	-	6	40	1	6.7	7	15.6
	Any Dose	Moderate	1	6.7	1	6.7	2	13.3	4	8.9
		Severe	-	-	-	-	1	6.7	1	2.2

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.

N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

^aFever percentages reflect the number of subjects with at least one measurement available in the data system as the denominator. This denominator may differ from other systemic symptoms, which are solicited in-clinic at the post-dose assessment.

**TABLE 5A(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms – 18-55 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)		
			n	%	n	%	n	%	n	%	
Any Local Symptom	Dose 1	None	5	33.3	1	6.7	-	-	6	13.3	
		Mild	10	66.7	11	73.3	9	60	30	66.7	
	Dose 2	Moderate	-	-	2	13.3	5	33.3	7	15.6	
		Severe	-	-	1	6.7	1	6.7	2	4.4	
	Any Dose	None	3	23.1	-	-	-	-	3	7.1	
		Mild	9	69.2	10	66.7	7	50	26	61.9	
	Any Dose	Moderate	1	7.7	4	26.7	6	42.9	11	26.2	
		Severe	-	-	1	6.7	1	7.1	2	4.8	
	Erythema/Redness	Dose 1	None	4	26.7	-	-	-	-	4	8.9
			Mild	10	66.7	9	60	6	40	25	55.6
Dose 2		Moderate	1	6.7	5	33.3	8	53.3	14	31.1	
		Severe	-	-	1	6.7	1	6.7	2	4.4	
Any Dose		None	15	100	13	86.7	13	86.7	41	91.1	
		Mild	-	-	2	13.3	2	13.3	4	8.9	
Any Dose		Moderate	-	-	-	-	-	-	-	-	
		Severe	-	-	-	-	-	-	-	-	
Any Dose		None	12	92.3	13	86.7	11	78.6	36	85.7	
		Mild	1	7.7	2	13.3	3	21.4	6	14.3	
Any Dose	Moderate	-	-	-	-	-	-	-	-		
	Severe	-	-	-	-	-	-	-	-		
Any Dose	None	14	93.3	13	86.7	11	73.3	38	84.4		

**TABLE 5A(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
		Mild	1	6.7	2	13.3	4	26.7	7	15.6
		Moderate	-	-	-	-	-	-	-	-
		Severe	-	-	-	-	-	-	-	-
		None	15	100	13	86.7	14	93.3	42	93.3
Erythema/Redness Measurement (mm)	Dose 1	Mild	-	-	-	-	-	-	-	-
		Moderate	-	-	1	6.7	-	-	1	2.2
		Severe	-	-	1	6.7	1	6.7	2	4.4
		None	13	100	13	86.7	11	78.6	37	88.1
	Dose 2	Mild	-	-	1	6.7	-	-	1	2.4
		Moderate	-	-	-	-	2	14.3	2	4.8
		Severe	-	-	1	6.7	1	7.1	2	4.8
		None	15	100	13	86.7	12	80	40	88.9
Any Dose		Mild	-	-	-	-	-	-	-	-
		Moderate	-	-	1	6.7	2	13.3	3	6.7
		Severe	-	-	1	6.7	1	6.7	2	4.4
		None	15	100	12	80	11	73.3	38	84.4
Induration/Swelling	Dose 1	Mild	-	-	3	20	3	20	6	13.3
		Moderate	-	-	-	-	1	6.7	1	2.2
		Severe	-	-	-	-	-	-	-	-
		None	13	100	14	93.3	11	78.6	38	90.5
Dose 2		Mild	-	-	1	6.7	2	14.3	3	7.1
		None	-	-	-	-	-	-	-	-

**TABLE 5A(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
Induration/Swelling (mm)	Any Dose	Moderate	-	-	-	-	1	7.1	1	2.4
		Severe	-	-	-	-	-	-	-	-
		None	15	100	12	80	11	73.3	38	84.4
	Dose 1	Mild	-	-	3	20	3	20	6	13.3
		Moderate	-	-	-	-	1	6.7	1	2.2
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	15	100	13	86.7	12	80	40	88.9
		Mild	-	-	2	13.3	1	6.7	3	6.7
		Moderate	-	-	-	-	1	6.7	1	2.2
	Pain	Any Dose	Severe	-	-	-	-	1	6.7	1
None			13	100	14	93.3	11	78.6	38	90.5
Mild			-	-	-	-	1	7.1	1	2.4
Dose 1		Moderate	-	-	1	6.7	2	14.3	3	7.1
		Severe	-	-	-	-	-	-	-	-
		None	15	100	13	86.7	11	73.3	39	86.7
Dose 2		Mild	-	-	1	6.7	2	13.3	3	6.7
		Moderate	-	-	1	6.7	1	6.7	2	4.4
		Severe	-	-	-	-	1	6.7	1	2.2
Any Dose		None	5	33.3	1	6.7	-	-	6	13.3
	Mild	10	66.7	12	80	9	60	31	68.9	
	Moderate	-	-	2	13.3	6	40	8	17.8	

**TABLE 5A(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - 18-55 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
			n	%	n	%	n	%	n	%
		Severe	-	-	-	-	-	-	-	-
	Dose 2	None	3	23.1	-	-	-	-	3	7.1
		Mild	9	69.2	11	73.3	10	71.4	30	71.4
		Moderate	1	7.7	4	26.7	4	28.6	9	21.4
		Severe	-	-	-	-	-	-	-	-
	Any Dose	None	4	26.7	-	-	-	-	4	8.9
		Mild	10	66.7	10	66.7	8	53.3	28	62.2
		Moderate	1	6.7	5	33.3	7	46.7	13	28.9
		Severe	-	-	-	-	-	-	-	-

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

**TABLE 5B(i):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Any Symptom – 56-70 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Symptom	Dose 1	None	3	30	1	10	4	20
		Mild	5	50	9	90	14	70
		Moderate	2	20	-	-	2	10
		Severe	-	-	-	-	-	-
	Dose 2	None	1	10	3	33.3	4	21.1
		Mild	6	60	3	33.3	9	47.4
		Moderate	2	20	3	33.3	5	26.3
		Severe	1	10	-	-	1	5.3
	Any Dose	None	-	-	1	10	1	5
		Mild	5	50	6	60	11	55
		Moderate	4	40	3	30	7	35
		Severe	1	10	-	-	1	5

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

**TABLE 5B(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 56-70 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Systemic Symptom	Dose 1	None	5	50	7	70	12	60
		Mild	3	30	3	30	6	30
		Moderate	2	20	-	-	2	10
		Severe	-	-	-	-	-	-
	Dose 2	None	4	40	3	33.3	7	36.8
		Mild	4	40	3	33.3	7	36.8
		Moderate	1	10	3	33.3	4	21.1
	Any Dose	Severe	1	10	-	-	1	5.3
		None	2	20	3	30	5	25
		Mild	4	40	4	40	8	40
Arthralgia	Dose 1	Moderate	3	30	3	30	6	30
		Severe	1	10	-	-	1	5
		None	7	70	10	100	17	85
		Mild	1	10	-	-	1	5
	Dose 2	Moderate	2	20	-	-	2	10
		Severe	-	-	-	-	-	-
		None	9	90	7	77.8	16	84.2
	Any Dose	Mild	-	-	1	11.1	1	5.3
		Moderate	1	10	1	11.1	2	10.5
		Severe	-	-	-	-	-	-
Any Dose	None	6	60	8	80	14	70	

**TABLE 5B(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 56-70 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Fatigue		Mild	1	10	1	10	2	10
		Moderate	3	30	1	10	4	20
		Severe	-	-	-	-	-	-
	Dose 1	None	8	80	7	70	15	75
		Mild	2	20	3	30	5	25
		Moderate	-	-	-	-	-	-
	Dose 2	Severe	-	-	-	-	-	-
		None	7	70	4	44.4	11	57.9
		Mild	1	10	2	22.2	3	15.8
Any Dose	Moderate	2	20	3	33.3	5	26.3	
	Severe	-	-	-	-	-	-	
	None	6	60	4	40	10	50	
Fever ^a		Mild	2	20	3	30	5	25
		Moderate	2	20	3	30	5	25
		Severe	-	-	-	-	-	-
	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
	Dose 2	Severe	-	-	-	-	-	-
		None	9	90	6	85.7	15	88.2
		Mild	-	-	1	14.3	1	5.9

**TABLE 5B(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 56-70 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Feverishness	Any Dose	Moderate	-	-	-	-	-	-
		Severe	1	10	-	-	1	5.9
		None	9	90	9	90	18	90
		Mild	-	-	1	10	1	5
	Moderate	-	-	-	-	-	-	
	Severe	1	10	-	-	1	5	
	None	10	100	10	100	20	100	
	Mild	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	
Headache	Dose 1	None	9	90	5	55.6	14	73.7
		Mild	-	-	2	22.2	2	10.5
		Moderate	1	10	2	22.2	3	15.8
		Severe	-	-	-	-	-	-
	Any Dose	None	9	90	6	60	15	75
		Mild	-	-	2	20	2	10
		Moderate	1	10	2	20	3	15
		Severe	-	-	-	-	-	-
		None	8	80	10	100	18	90
		Mild	2	20	-	-	2	10
Moderate	-	-	-	-	-	-		

**TABLE 5B(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 56-70 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Myalgia	Dose 2	Severe	-	-	-	-	-	-
		None	7	70	5	55.6	12	63.2
		Mild	2	20	3	33.3	5	26.3
		Moderate	1	10	1	11.1	2	10.5
	Any Dose	Severe	-	-	-	-	-	-
		None	6	60	6	60	12	60
		Mild	3	30	3	30	6	30
		Moderate	1	10	1	10	2	10
	Dose 1	Severe	-	-	-	-	-	-
		None	8	80	9	90	17	85
		Mild	2	20	1	10	3	15
		Moderate	-	-	-	-	-	-
Dose 2	Severe	-	-	-	-	-	-	
	None	5	50	5	55.6	10	52.6	
	Mild	4	40	2	22.2	6	31.6	
	Moderate	1	10	2	22.2	3	15.8	
Any Dose	Severe	-	-	-	-	-	-	
	None	4	40	6	60	10	50	
	Mild	5	50	2	20	7	35	
	Moderate	1	10	2	20	3	15	
Severe	Severe	-	-	-	-	-	-	
	None	-	-	-	-	-	-	
	Mild	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	

**TABLE 5B(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - 56-70 Years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Nausea	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
	Dose 2	None	8	80	8	88.9	16	84.2
		Mild	2	20	-	-	2	10.5
		Moderate	-	-	1	11.1	1	5.3
		Severe	-	-	-	-	-	-
	Any Dose	None	8	80	9	90	17	85
		Mild	2	20	-	-	2	10
		Moderate	-	-	1	10	1	5
		Severe	-	-	-	-	-	-

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.

N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

^aFever percentages reflect the number of subjects with at least one measurement available in the data system as the denominator. This denominator may differ from other systemic symptoms, which are solicited in-clinic at the post-dose assessment.

**TABLE 5B(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and Vaccination Group – Local Symptoms – 56-70 Years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Local Symptom	Dose 1	None	5	50	2	20	7	35
		Mild	5	50	8	80	13	65
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
	Dose 2	None	4	40	3	33.3	7	36.8
		Mild	5	50	5	55.6	10	52.6
		Moderate	1	10	1	11.1	2	10.5
	Any Dose	Severe	-	-	-	-	-	-
		None	2	20	1	10	3	15
		Mild	7	70	8	80	15	75
Erythema/Redness	Dose 1	Moderate	1	10	1	10	2	10
		Severe	-	-	-	-	-	-
		None	9	90	9	90	18	90
		Mild	1	10	1	10	2	10
	Dose 2	Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
		None	9	90	7	77.8	16	84.2
	Any Dose	Mild	1	10	2	22.2	3	15.8
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Any Dose	None	9	90	7	70	16	80	
	Mild	1	10	2	20	3	15	
	Moderate	-	-	-	-	-	-	

**TABLE 5B(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - 56-70 Years of Age (continued)**

		1	10	3	30	4	20
Erythema/Redness Measurement (mm)	Mild	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Dose 1	10	100	10	100	20	100
	Mild	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Dose 2	10	100	9	100	19	100
	Mild	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Any Dose	10	100	10	100	20	100
Induration/Swelling	Mild	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Dose 1	8	80	9	90	17	85
	Mild	2	20	1	10	3	15
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Dose 2	8	80	7	77.8	15	78.9
	Mild	2	20	2	22.2	4	21.1
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-
	Any Dose	6	60	8	80	14	70

**TABLE 5B(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - 56-70 Years of Age (continued)**

			4	40	2	20	6	30
Induration/Swelling (mm)	Mild		-	-	-	-	-	-
	Moderate		-	-	-	-	-	-
	Severe		-	-	-	-	-	-
	None	Dose 1	9	90	10	100	19	95
	Mild		1	10	-	-	1	5
	Moderate		-	-	-	-	-	-
	Severe		-	-	-	-	-	-
	None	Dose 2	9	90	8	88.9	17	89.5
	Mild		-	-	-	-	-	-
	Moderate		1	10	1	11.1	2	10.5
Pain	Severe		-	-	-	-	-	-
	None	Any Dose	8	80	9	90	17	85
	Mild		1	10	-	-	1	5
	Moderate		1	10	1	10	2	10
	Severe		-	-	-	-	-	-
	None	Dose 1	7	70	2	20	9	45
	Mild		3	30	8	80	11	55
	Moderate		-	-	-	-	-	-
	Severe		-	-	-	-	-	-
	None	Dose 2	5	50	3	33.3	8	42.1
Mild		5	50	5	55.6	10	52.6	
Moderate		-	-	1	11.1	1	5.3	
Severe		-	-	-	-	-	-	
None	Any Dose	4	40	1	10	5	25	

**TABLE 5B(iii):
 Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
 Vaccination Group – Local Symptoms - 56-70 Years of Age (continued)**

	6	60	8	80	14	70
Mild	-	-	1	10	1	5
Moderate	-	-	-	-	-	-
Severe	-	-	-	-	-	-

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
 N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

**TABLE 5C(i):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Any Symptom – ≥ 71 years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Symptom	Dose 1	None	1	10	2	20	3	15
		Mild	9	90	8	80	17	85
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.

**TABLE 5C(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - ≥71 years of Age**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Systemic Symptom	Dose 1	None	5	50	7	70	12	60
		Mild	5	50	3	30	8	40
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Arthralgia	Dose 1	None	9	90	10	100	19	95
		Mild	1	10	-	-	1	5
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Fatigue	Dose 1	None	8	80	7	70	15	75
		Mild	2	20	3	30	5	25
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Fever ^a	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Feverishness	Dose 1	None	10	100	9	90	19	95
		Mild	-	-	1	10	1	5
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Headache	Dose 1	None	7	70	10	100	17	85
		Severe	-	-	-	-	-	-

**TABLE 5C(ii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Systemic Symptoms - ≥71 years of Age (continued)**

Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
		Mild	3	30	-	-	3	15
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Myalgia	Dose 1	None	7	70	8	80	15	75
		Mild	3	30	2	20	5	25
		Moderate	-	-	-	-	-	-
Nausea	Dose 1	Severe	-	-	-	-	-	-
		None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	
		Severe	-	-	-	-	-	

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.
*Fever percentages reflect the number of subjects with at least one measurement available in the data system as the denominator. This denominator may differ from other systemic symptoms, which are solicited in-clinic at the post-dose assessment.

**TABLE 5C(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms – ≥ 71 years of Age**


Symptom	Dose	Severity	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
			n	%	n	%	n	%
Any Local Symptom	Dose 1	None	4	40	2	20	6	30
		Mild	6	60	8	80	14	70
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Erythema/Redness	Dose 1	None	9	90	10	100	19	95
		Mild	1	10	-	-	1	5
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Induration/Swelling	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Induration/Swelling (mm)	Dose 1	None	10	100	10	100	20	100
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-
Pain	Dose 1	None	4	40	2	20	6	30
		Mild	-	-	-	-	-	-
		Moderate	-	-	-	-	-	-
		Severe	-	-	-	-	-	-

**TABLE 5C(iii):
Number and Percentage of Subjects Experiencing Solicited Events by Symptom, Maximum Severity, Dose, and
Vaccination Group – Local Symptoms - ≥ 71 years of Age (continued)**


Symptom	Dose	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		n	%	n	%	n	%
	Mild	6	60	8	80	14	70
	Moderate	-	-	-	-	-	-
	Severe	-	-	-	-	-	-

Severity is the maximum severity reported over all solicited symptoms post dosing for each subject.
N=All subjects receiving Dose 1 with any solicited event data recorded in the database.


**FIGURE 3A(i):
Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group - 18-55 Years of Age**



**FIGURE 3A(ii):
 Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group – 56-70 Years of Age**



**FIGURE 3A(iii):
 Maximum Severity of Solicited Systemic Symptoms by Days Post Vaccination and Vaccination Group - ≥ 71 Years of Age**



**TABLE 6A(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	15	100	15	100	13	87	13	87	14	93	14	93	15	100	15	100	15	100	14	93	15	100	15	100
	Mild	-	-	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	-	1	7	-	-	4	27
	Moderate	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	15	100	13	87	13	87	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
Fever	Moderate	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	NA	NA	NA	NA	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 6A(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	15	100	14	93	14	93	14	93	14	93	14	93	15	100	15	100	14	93	15	100
Headache	Mild	-	-	-	-	1	7	1	7	1	7	1	7	1	7	-	-	-	-	1	7	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	15	100	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

TABLE 6A(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Nausea	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	-	-
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6A(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=13)		Post-Dose (N=13)		Day 1 (N=13)		Day 2 (N=13)		Day 3 (N=13)		Day 4 (N=13)		Day 5 (N=13)		Day 6 (N=13)		Day 7 (N=13)		Day 8+ (N=13)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	13	100	13	100	10	77	8	62	13	100	13	100	13	100	13	100	12	92	13	100	13	100		
	Mild	-	-	-	-	3	23	2	15	-	-	-	-	-	-	-	-	-	1	8	-	-	4	31	
	Moderate	-	-	-	-	-	-	3	23	-	-	-	-	-	-	-	-	-	-	-	-	-	3	23	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Arthralgia	None	13	100	13	100	13	100	11	85	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	2	15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	15
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA
Fatigue	None	13	100	13	100	12	92	8	62	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100
	Mild	-	-	-	-	1	8	4	31	-	-	-	-	-	-	-	-	-	-	-	-	-	4	31	
	Moderate	-	-	-	-	-	-	1	8	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA
Fever	None	NA	NA	NA	NA	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	12	92	13	100
	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 6A(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

	Severe	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
Feverishness	None Reported	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	None	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Headache	None Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	13	100	13	100	12	92	13	100	13	100	13	100	13	100	13	100	13	100	12	92	13	100	13	100	
	Mild	-	-	-	-	1	8	-	-	-	-	-	-	-	-	-	-	-	1	8	-	-	-	2	15	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Myalgia	None Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	13	100	13	100	12	92	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	
	Mild	-	-	-	-	1	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	15
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	8
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nausea	None Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 6A(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6A(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	15	100	15	100	12	80	9	60	14	93	14	93	15	100	15	100	14	93	15	100	15	100	
	Mild	-	-	-	-	2	13	2	13	1	7	1	7	-	-	-	-	-	1	7	-	-	4	27
	Moderate	-	-	-	-	1	7	4	27	-	-	-	-	-	-	-	-	-	-	-	-	-	5	33
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Arthralgia	None	15	100	15	100	15	100	13	87	15	100	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Fatigue	None	15	100	15	100	13	87	9	60	15	100	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	-	-	-	-	1	7	4	27	-	-	-	-	-	-	-	-	-	-	-	-	-	4	27
	Moderate	-	-	-	-	1	7	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	3	20
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Fever	None	NA	NA	NA	NA	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 6A(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Feverishness	None	15	100	15	100	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	15	100	15	100	14	93	13	87	14	93	14	93	15	100	15	100	15	100	14	93	15	100	15	100
Headache	Mild	-	-	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	-	1	7	-	-	3	20
	Moderate	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Myalgia	None	15	100	15	100	13	87	12	80	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	20
	Moderate	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	15	100	13	87	12	80	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
Myalgia	Mild	-	-	-	-	2	13	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	20
	Moderate	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

**TABLE 6A(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

TABLE 6B(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	15	100	12	80	11	73	12	80	13	87	15	100	15	100	15	100	14	93	15	100	15	100	15	100
	Mild	-	-	3	20	3	20	3	20	2	13	-	-	-	-	-	-	-	-	-	-	-	9	60	
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	1	7	-	-	2	13	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Arthralgia	None	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	14	93	15	100	15	100	15	100
	Mild	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	-	-	1	7	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Fatigue	None	15	100	14	93	12	80	13	87	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	1	7	2	13	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	4	27	
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Fever	None	NA	NA	NA	NA	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

TABLE 6B(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	15	100	15	100	14	93	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Headache	None	15	100	14	93	14	93	14	93	13	87	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	1	7	1	7	1	7	2	13	-	-	-	-	-	-	-	-	-	-	4	27
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	15	100	15	100	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA

TABLE 6B(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6B(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	15	100	15	100	4	27	-	-	11	73	14	93	15	100	15	100	14	93	15	100	15	100	
	Mild	-	-	6	40	7	47	3	20	1	7	-	-	-	-	-	-	-	-	1	7	11	73	
	Moderate	-	-	5	33	8	53	1	7	-	-	-	-	-	-	-	-	-	-	-	-	12	80	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Arthralgia	None	15	100	15	100	14	93	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Moderate	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Fatigue	None	15	100	15	100	9	60	3	20	14	93	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	-	-	-	-	5	33	7	47	1	7	-	-	-	-	-	-	-	-	-	-	9	60	
	Moderate	-	-	1	7	5	33	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	40	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Fever	None	NA	NA	NA	NA	14	93	9	60	15	100	15	100	15	100	15	100	15	100	15	100	15	100	
	Mild	NA	NA	NA	NA	1	7	5	33	-	-	-	-	-	-	-	-	-	-	-	-	5	33	
	Moderate	NA	NA	NA	NA	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	

**TABLE 6B(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	15	100	15	100	10	67	5	33	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	9	60	-	-	-	-	-	-	-	-	-	-	-	-	10	67
	Moderate	-	-	-	-	3	20	1	7	-	-	-	-	-	-	-	-	-	-	-	-	4	27
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Headache	None	15	100	15	100	11	73	8	53	14	93	14	93	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	4	27	4	27	-	-	1	7	-	-	-	-	-	-	-	-	6	40
	Moderate	-	-	-	-	-	-	3	20	1	7	-	-	-	-	-	-	-	-	-	-	4	27
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	15	100	15	100	10	67	7	47	13	87	15	100	15	100	15	100	15	100	14	93	15	100
	Mild	-	-	-	-	1	7	6	40	2	13	-	-	-	-	-	-	-	-	1	7	6	40
	Moderate	-	-	-	-	4	27	2	13	-	-	-	-	-	-	-	-	-	-	-	-	6	40
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

TABLE 6B(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	11	73	10	67	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	3	20	5	33	-	-	-	-	-	-	-	-	-	-	-	-	6	40
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6B(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	15	100	12	80	4	27	-	-	9	60	14	93	15	100	15	100	14	93	14	93	15	100
	Mild	-	-	3	20	5	33	7	47	5	33	1	7	-	-	-	-	-	-	1	7	10	67
	Moderate	-	-	-	-	6	40	8	53	1	7	-	-	-	-	-	-	-	1	7	-	12	80
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Arthralgia	None	15	100	14	93	14	93	14	93	15	100	15	100	15	100	15	100	14	93	15	100	15	100
	Mild	-	-	1	7	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	1	7	-	2	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Fatigue	None	15	100	14	93	9	60	3	20	14	93	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	1	7	4	27	7	47	1	7	-	-	-	-	-	-	-	-	-	-	10	67
	Moderate	-	-	-	-	2	13	5	33	-	-	-	-	-	-	-	-	-	-	-	-	7	47
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Fever	None	NA	NA	NA	NA	14	93	9	60	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	NA	NA	NA	NA	1	7	5	33	-	-	-	-	-	-	-	-	-	-	-	-	5	33
	Moderate	NA	NA	NA	NA	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7

**TABLE 6B(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Feverishness	None	15	100	15	100	9	60	5	33	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	3	20	9	60	-	-	-	-	-	-	-	-	-	-	-	-	-	10	67	
	Moderate	-	-	-	-	3	20	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	4	27	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	15	100	14	93	10	67	8	53	12	80	14	93	15	100	15	100	15	100	15	100	15	100	15	100
Headache	Mild	-	-	1	7	5	33	4	27	2	13	1	7	-	-	-	-	-	-	-	-	-	7	47	
	Moderate	-	-	-	-	-	-	3	20	1	7	-	-	-	-	-	-	-	-	-	-	-	4	27	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Myalgia	None	15	100	15	100	10	67	7	47	13	87	15	100	15	100	15	100	15	100	14	93	15	100	15	100
	Mild	-	-	-	-	1	7	6	40	2	13	-	-	-	-	-	-	-	-	1	7	6	40	6	40
	Moderate	-	-	-	-	4	27	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	6	40	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 6B(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	11	73	10	67	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	3	20	5	33	-	-	-	-	-	-	-	-	-	-	-	-	6	40
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6C(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	14	93	13	87	9	60	8	53	10	67	13	87	13	87	13	87	13	87	14	93	15	100
	Mild	1	7	2	13	3	20	6	40	5	33	2	13	1	7	2	13	2	13	1	7	8	53
	Moderate	-	-	-	-	3	20	1	7	-	-	-	-	-	-	-	-	-	-	-	-	4	27
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Arthralgia	None	14	93	15	100	15	100	15	100	14	93	14	93	14	93	14	93	14	93	15	100	14	93
	Mild	1	7	-	-	-	-	-	-	1	7	1	7	1	7	1	7	1	7	-	-	1	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Fatigue	None	15	100	13	87	11	73	11	73	12	80	13	87	13	87	14	93	14	93	15	100	15	100
	Mild	-	-	2	13	2	13	4	27	3	20	2	13	2	13	1	7	1	7	-	-	-	5
	Moderate	-	-	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
Fever	None	NA	NA	NA	NA	15	100	15	100	15	100	14	93	15	100	15	100	15	100	15	100	15	100
	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 6C(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	15	100	15	100	13	87	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Headache	None	15	100	15	100	12	80	11	73	11	73	14	93	14	93	15	100	15	100	13	87	15	100
	Mild	-	-	-	-	2	13	3	20	4	27	1	7	-	-	-	-	-	2	13	-	7	47
	Moderate	-	-	-	-	1	7	1	7	-	-	-	-	1	7	-	-	-	-	-	-	3	20
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	15	100	15	100	13	87	12	80	13	87	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	3	20	2	13	-	-	-	-	-	-	-	-	-	-	4	27
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

TABLE 6C(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	14	93	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6C(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 ^a (N=15)		Day 8 ^{a,ab} (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	14	100	14	100	3	21	-	-	4	29	10	71	12	86	10	71	11	79	10	71	14	100
	Mild	-	-	-	-	3	21	4	29	10	71	4	29	1	7	4	29	1	7	1	7	13	93
	Moderate	-	-	-	-	7	50	7	50	-	-	-	-	1	7	-	-	-	-	-	-	9	64
	Severe	-	-	-	-	1	7	3	21	-	-	-	-	-	-	-	-	-	-	-	-	3	21
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Arthralgia	None	14	100	14	100	12	86	7	50	12	86	14	100	14	100	14	100	12	86	11	79	14	100
	Mild	-	-	-	-	1	7	5	36	2	14	-	-	-	-	-	-	-	-	-	-	6	43
	Moderate	-	-	-	-	1	7	2	14	-	-	-	-	-	-	-	-	-	-	-	-	3	21
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Fatigue	None	14	100	14	100	8	57	4	29	7	50	12	86	12	86	12	86	12	86	10	71	14	100
	Mild	-	-	-	-	2	14	2	14	7	50	2	14	1	7	2	14	-	-	1	7	9	64
	Moderate	-	-	-	-	4	29	6	43	-	-	-	-	1	7	-	-	-	-	-	-	6	43
	Severe	-	-	-	-	-	-	2	14	-	-	-	-	-	-	-	-	-	-	-	-	2	14
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Fever	None	NA	NA	NA	NA	11	79	7	50	14	100	14	100	14	100	14	100	12	86	11	79	14	100
	Mild	NA	NA	NA	NA	3	21	4	29	-	-	-	-	-	-	-	-	-	-	-	-	5	36
	Moderate	NA	NA	NA	NA	-	-	2	14	-	-	-	-	-	-	-	-	-	-	-	-	2	14

**TABLE 6C(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 ^a (N=15)		Day 8 ^{a,ab} (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	NA	NA	NA	NA	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Feverishness	None	14	100	14	100	7	50	2	14	14	100	14	100	14	100	14	100	12	86	11	79	14	100	
	Mild	-	-	-	-	1	7	5	36	-	-	-	-	-	-	-	-	-	-	-	-	5	36	
	Moderate	-	-	-	-	5	36	4	29	-	-	-	-	-	-	-	-	-	-	-	-	5	36	
	Severe	-	-	-	-	1	7	3	21	-	-	-	-	-	-	-	-	-	-	-	-	3	21	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Headache	None	14	100	14	100	9	64	2	14	8	57	13	93	14	100	12	86	11	79	11	79	14	100	
	Mild	-	-	-	-	3	21	8	57	6	43	1	7	-	-	2	14	1	7	-	-	13	93	
	Moderate	-	-	-	-	2	14	3	21	-	-	-	-	-	-	-	-	-	-	-	-	4	29	
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA
Myalgia	None	14	100	14	100	6	43	2	14	11	79	13	93	14	100	14	100	12	86	11	79	14	100	
	Mild	-	-	-	-	5	36	5	36	3	21	1	7	-	-	-	-	-	-	-	-	9	64	
	Moderate	-	-	-	-	3	21	6	43	-	-	-	-	-	-	-	-	-	-	-	-	7	50	
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA

**TABLE 6C(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 ^a (N=15)		Day 8 ^{a,b} (N=15)		Any Post-Dose [*]	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	14	100	14	100	13	93	11	79	14	100	14	100	14	100	14	100	12	86	11	79	14	100
	Mild	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Moderate	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	2	14
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

^a The data for Day 7 and Day 8 following the second vaccination for 2 subjects in Cohort 3 was entered after the time of data cutoff; there were no graded events entered for these 2 subjects for this day.

^b Data for Day 8 following the second vaccination for 1 subject in Cohort 3 was confirmed as not available by the site.

**TABLE 6C(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	14	93	13	87	4	27	-	-	5	33	10	67	12	80	10	67	13	87	13	87	15	100
	Mild	1	7	2	13	1	7	5	33	10	67	5	33	2	13	5	33	2	13	2	13	14	93
	Moderate	-	-	-	-	9	60	7	47	-	-	-	-	1	7	-	-	-	-	-	-	10	67
	Severe	-	-	-	-	1	7	3	20	-	-	-	-	-	-	-	-	-	-	-	-	3	20
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	14	93	15	100	13	87	8	53	13	87	14	93	14	93	14	93	15	100	14	93	15	100
	Mild	1	7	-	-	1	7	5	33	2	13	1	7	1	7	1	7	-	-	1	7	6	40
	Moderate	-	-	-	-	1	7	2	13	-	-	-	-	-	-	-	-	-	-	-	-	3	20
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	13	87	8	53	5	33	8	53	11	73	12	80	12	80	15	100	14	93	15	100
	Mild	-	-	2	13	2	13	2	13	7	47	4	27	2	13	3	20	-	-	1	7	9	60
Fever	Moderate	-	-	-	-	5	33	6	40	-	-	-	-	1	7	-	-	-	-	-	-	6	40
	Severe	-	-	-	-	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	2	13	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	NA	NA	NA	NA	12	80	8	53	15	100	15	100	15	100	15	100	15	100	15	100	15	100
Moderate	Mild	NA	NA	NA	NA	3	20	4	27	-	-	-	-	-	-	-	-	-	-	-	-	5	33
	Severe	NA	NA	NA	NA	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	None	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13

**TABLE 6C(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	15	100	15	100	7	47	3	20	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	5	33	-	-	-	-	-	-	-	-	-	-	-	-	6	40
	Moderate	-	-	-	-	5	33	4	27	-	-	-	-	-	-	-	-	-	-	-	-	5	33
	Severe	-	-	-	-	1	7	3	20	-	-	-	-	-	-	-	-	-	-	-	-	3	20
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	15	100	15	100	8	53	1	7	7	47	13	87	14	93	13	87	13	87	15	100	15	100
Headache	Mild	-	-	-	-	4	27	9	60	8	53	2	13	-	-	2	13	2	13	-	-	14	93
	Moderate	-	-	-	-	3	20	4	27	-	-	-	-	-	1	7	-	-	-	-	-	5	33
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	15	100	15	100	7	47	3	20	11	73	14	93	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	5	33	5	33	4	27	1	7	-	-	-	-	-	-	-	-	10	67
	Moderate	-	-	-	-	3	20	6	40	-	-	-	-	-	-	-	-	-	-	-	-	7	47
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

**TABLE 6C(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Pre-Dose (N=15)		Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	15	100	15	100	14	93	11	73	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	2	13	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Moderate	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6D(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	9	90	9	90	7	70	8	80	10	100	9	90	9	90	9	90	9	90	9	90	10	100		
	Mild	1	10	1	10	3	30	1	10	-	-	1	10	-	-	1	10	1	10	1	10	-	-		
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	2	20
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	10	100	9	90	10	100	9	90	10	100	10	100	9	90	9	90	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	1	10	-	-	-	-	1	10	1	10	-	-	2	20
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	2	20
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	9	90	9	90	10	100	10	100	10	100	10	100	9	90	10	100	10	100	10	100
	Mild	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	1	10	-	-	-	-	2	20	
Fever	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	NA	NA	NA	NA	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 6D(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (56-70 years (continued))**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	9	90	9	90	8	80	10	100	10	100	10	100	9	90	10	100	10	100	10	100	10	100
Headache	Mild	1	10	1	10	2	20	-	-	-	-	1	10	-	-	-	-	-	-	-	-	2	20
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	10	100	10	100	10	100	9	90	10	100	10	100	10	100	9	90	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	1	10	-	-	-	-	-	-	1	10	-	-	1	10	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA

**TABLE 6D(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (56-70 years (continued))**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
Nausea	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	-	-	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6D(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	10	100	10	100	9	90	5	50	3	30	2	20	2	20	2	20	2	20	2	20	10	100	
	Mild	-	-	-	-	1	10	3	30	-	-	-	-	-	-	-	-	-	-	-	-	4	40	
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Severe	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA
	None	10	100	10	100	9	90	9	90	3	30	2	20	2	20	2	20	2	20	2	20	2	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA
	None	10	100	10	100	10	100	7	70	3	30	2	20	2	20	2	20	2	20	2	20	2	20	100
	Mild	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
Fever	Moderate	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA
	None	NA	NA	10	100	8	80	8	80	2	20	2	20	2	20	2	20	2	20	2	20	2	20	100
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 6D(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	NA	NA	NA	NA	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10		
	Not Reported	NA	NA	NA	NA	-	-	1	10	8	80	8	80	8	80	8	80	8	80	8	80	NA	NA		
Feverishness	None	10	100	10	100	10	100	9	90	3	30	2	20	2	20	2	20	2	20	2	20	10	100		
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA	NA
	None	10	100	10	100	10	100	7	70	3	30	2	20	2	20	2	20	2	20	2	20	10	100		
Headache	Mild	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	2	20		
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA	NA
Myalgia	None	10	100	10	100	9	90	6	60	3	30	2	20	2	20	2	20	2	20	2	20	10	100		
	Mild	-	-	-	-	1	10	3	30	-	-	-	-	-	-	-	-	-	-	-	-	4	40		
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	None	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	8	80	NA	NA

**TABLE 6D(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	10	100	10	100	10	100	8	80	3	30	2	20	2	20	2	20	2	20	2	20	10	100
	Mild	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	7	70	8	80	8	80	8	80	8	80	8	80	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6D(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	9	90	9	90	6	60	5	50	10	100	9	90	9	90	9	90	9	90	9	90	10	100	
	Mild	1	10	1	10	4	40	2	20	-	-	1	10	-	-	1	10	1	10	-	-	6	60	
	Moderate	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	1	10	3	30
	Severe	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	10	100	8	80	10	100	9	90	10	100	9	90	9	90	9	90	10	100	
	Mild	-	-	-	-	-	-	-	-	-	-	1	10	-	-	1	10	1	10	-	-	2	20	
	Moderate	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	1	10	3	30
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	9	90	7	70	10	100	10	100	10	100	9	90	9	90	10	100	10	100	
	Mild	-	-	-	-	1	10	1	10	-	-	-	-	-	-	1	10	1	10	-	-	2	20	
Fever	Moderate	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	2	20	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	NA	NA	NA	NA	10	100	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 6D(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	10	100	10	100	100	100	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	9	90	9	90	8	80	7	70	10	100	9	90	10	100	10	100	10	100	10	100	10	100
Headache	Mild	1	10	1	10	2	20	2	20	-	-	1	10	-	-	-	-	-	-	-	-	4	40
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	10	100	10	100	9	90	6	60	10	100	10	100	9	90	9	90	10	100	10	100	10	100
	Mild	-	-	-	-	1	10	3	30	-	-	-	-	-	-	1	10	-	-	-	-	5	50
	Moderate	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

**TABLE 6D(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Nausea	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

TABLE 6E(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	10	100	10	100	7	70	9	90	9	90	9	90	9	90	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	3	30	1	10	1	10	1	10	1	10	-	-	-	-	-	-	-	3	30	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA
Arthralgia	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA
Fatigue	None	10	100	10	100	7	70	10	100	9	90	9	90	9	90	9	90	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	3	30	-	-	1	10	1	10	1	10	-	-	-	-	-	-	-	3	30	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA
Fever	None	NA	NA	NA	NA	10	100	10	100	10	100	9	90	10	100	10	100	9	90	10	100	10	100	10	100
	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 6E(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	10	-	-	-	1	10	-	-	-	NA	NA	
Feverishness	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
Headache	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Myalgia	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

TABLE 6E(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Nausea	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	-	-
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6E(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Pre-Dose (N=9)		Post-Dose (N=9)		Day 1 (N=9)		Day 2 (N=9)		Day 3 (N=9)		Day 4 (N=9)		Day 5 (N=9)		Day 6 (N=9)		Day 7 (N=9)		Day 8+ (N=9)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	9	100	9	100	3	33	3	33	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	3	33	1	11	-	-	-	-	-	-	-	-	-	-	-	-	4	44
	Moderate	-	-	-	-	1	11	3	33	-	-	-	-	-	-	-	-	-	-	-	-	3	33
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100
Arthralgia	None	9	100	9	100	6	67	5	56	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	-	-	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Moderate	-	-	-	-	1	11	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100
Fatigue	None	9	100	9	100	4	44	3	33	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	3	33	1	11	-	-	-	-	-	-	-	-	-	-	-	-	4	44
	Moderate	-	-	-	-	-	-	3	33	-	-	-	-	-	-	-	-	-	-	-	-	3	33
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100
Fever	None	NA	NA	NA	NA	7	78	6	67	-	-	-	-	-	-	-	-	-	-	-	-	7	78
	Mild	NA	NA	NA	NA	-	-	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100

**TABLE 6E(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=9)		Post-Dose (N=9)		Day 1 (N=9)		Day 2 (N=9)		Day 3 (N=9)		Day 4 (N=9)		Day 5 (N=9)		Day 6 (N=9)		Day 7 (N=9)		Day 8+ (N=9)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	7	78	7	78	7	78	7	78	7	78	7	78	NA	NA
Feverishness	None	9	100	9	100	6	67	3	33	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	-	-	2	22	-	-	-	-	-	-	-	-	-	-	-	-	2	22
	Moderate	-	-	-	-	1	11	2	22	-	-	-	-	-	-	-	-	-	-	-	-	2	22
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100
Headache	None	9	100	9	100	4	44	5	56	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	2	22	1	11	-	-	-	-	-	-	-	-	-	-	-	-	3	33
	Moderate	-	-	-	-	1	11	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100
Myalgia	None	9	100	9	100	4	44	4	44	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	2	22	1	11	-	-	-	-	-	-	-	-	-	-	-	-	3	33
	Moderate	-	-	-	-	1	11	2	22	-	-	-	-	-	-	-	-	-	-	-	-	2	22
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100

**TABLE 6E(ii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=9)		Post-Dose (N=9)		Day 1 (N=9)		Day 2 (N=9)		Day 3 (N=9)		Day 4 (N=9)		Day 5 (N=9)		Day 6 (N=9)		Day 7 (N=9)		Day 8+ (N=9)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Nausea	None	9	100	9	100	6	67	6	67	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	1	11	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6E(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Systemic Symptom	None	10	100	10	100	4	40	6	60	9	90	9	90	9	90	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	5	50	1	10	1	10	1	10	1	10	-	-	-	-	-	-	-	5	50	
	Moderate	-	-	-	-	1	10	3	30	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	9	90	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Moderate	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	5	50	6	60	9	90	9	90	9	90	9	90	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	5	50	1	10	1	10	1	10	1	10	1	10	-	-	-	-	-	5	50	
Fever	Moderate	-	-	-	-	-	-	3	30	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	NA	NA	NA	NA	10	100	9	90	10	100	10	100	9	90	10	100	9	90	10	100	10	100	10	100
Moderate	Mild	NA	NA	NA	NA	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 6E(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	10	-	-	-	1	10	-	-	-	-	NA	NA	
Feverishness	None	10	100	10	100	9	90	6	60	10	100	10	100	10	100	10	100	10	100	10	100	10	100		
	Mild	-	-	-	-	-	-	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20	
	Moderate	-	-	-	-	1	10	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	10	100	10	100	7	70	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
Headache	Mild	-	-	-	-	2	20	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	
	Moderate	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Myalgia	None	10	100	10	100	7	70	7	70	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	2	20	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	
	Moderate	-	-	-	-	1	10	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

**TABLE 6E(iii):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
Nausea	None	10	100	10	100	9	90	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	-	-	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

TABLE 6F(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (≥71 years)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	10	100	10	100	7	70	10	100	9	90	8	80	7	70	7	70	9	90	9	90	10	100
	Mild	-	-	-	-	3	30	-	-	1	10	2	20	3	30	3	30	1	10	1	10	5	50
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
	None	10	100	10	100	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
	None	10	100	10	100	8	80	10	100	10	100	9	90	9	90	9	90	10	100	10	100	10	100
	Mild	-	-	-	-	2	20	-	-	-	-	1	10	1	10	1	10	1	10	-	-	-	2
Fever	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA
	None	NA	NA	NA	NA	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 6F(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (≥71 years) (continued)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Feverishness	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	10	100	10	100	8	80	10	100	10	100	10	100	10	100	9	90	10	100	10	100	10	100
Headache	Mild	-	-	-	-	2	20	-	-	-	-	-	-	-	-	1	10	-	-	-	-	3	30
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Myalgia	None	10	100	10	100	9	90	10	100	9	90	9	90	8	80	9	90	9	90	9	90	10	100
	Mild	-	-	-	-	1	10	-	-	1	10	1	10	2	20	1	10	1	10	1	10	3	30
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

TABLE 6F(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (≥71 years) (continued)

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Nausea	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	-	-
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6G(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (≥71 years)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	10	100	10	100	8	80	7	70	9	90	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	2	20	3	30	1	10	-	-	-	-	-	-	-	-	-	-	3	30
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
	None	10	100	10	100	8	80	7	70	9	90	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	2	20	3	30	1	10	-	-	-	-	-	-	-	-	-	-	3	30
Fever	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
	None	NA	NA	NA	NA	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100
Moderate	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 6G(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (≥71 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
Feverishness	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100	
	Mild	-	-	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
Headache	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA
Myalgia	None	10	100	10	100	9	90	9	90	10	100	10	100	10	100	10	100	10	100	9	90	10	100	
	Mild	-	-	-	-	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA

**TABLE 6G(i):
Summary of Systemic Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (≥71 years) (continued)**

Symptom	Severity	Pre-Dose (N=10)		Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Nausea	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100	-	-
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	NA	NA	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6H(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 1**

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	44	98	40	89	33	73	33	73	37	82	42	93	43	96	43	96	41	91	44	98	45	100
	Mild	1	2	5	11	7	16	10	22	8	18	3	7	1	2	2	4	3	7	1	2	21	47
	Moderate	-	-	-	-	5	11	2	4	-	-	-	-	1	2	-	-	1	2	-	-	8	18
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	44	98	44	98	45	100	45	100	44	98	44	98	44	98	44	98	44	98	44	98	45	100
	Mild	1	2	1	2	-	-	-	-	1	2	1	2	1	2	1	2	-	-	1	2	2	4
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	1	2
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	42	93	36	80	37	82	42	93	43	96	43	96	44	98	45	100	45	100	45	100
	Mild	-	-	3	7	5	11	7	16	3	7	2	4	2	4	1	2	-	-	-	-	11	24
Fever	Moderate	-	-	-	-	4	9	1	2	-	-	-	-	-	-	-	-	-	-	-	-	5	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	NA	NA	NA	NA	45	100	45	100	45	100	44	98	45	100	45	100	45	100	45	100	45	100
Fever	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	NA	NA	NA	NA	45	100	45	100	45	100	44	98	45	100	45	100	45	100	45	100	45	100

TABLE 6H(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 1 (continued)

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	45	100	42	93	44	98	45	100	45	100	45	100	45	100	45	100	45	100	45	100
	Mild	-	-	-	-	3	7	1	2	-	-	-	-	-	-	-	-	-	-	-	-	3	7
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Headache	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	44	98	40	89	39	87	38	84	43	96	44	98	45	100	45	100	42	93	45	100
	Mild	-	-	1	2	4	9	5	11	7	16	2	4	-	-	-	-	-	-	3	7	-	14
Myalgia	Moderate	-	-	-	-	1	2	1	2	-	-	-	-	1	2	-	-	-	-	-	-	-	3
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	45	100	42	93	41	91	43	96	45	100	45	100	45	100	45	100	45	100	45	100
Nausea	Mild	-	-	-	-	3	7	4	9	2	4	-	-	-	-	-	-	-	-	-	-	6	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Nausea	None	45	100	45	100	44	98	43	96	45	100	45	100	45	100	45	100	45	100	45	100	45	100
	Mild	-	-	-	-	1	2	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2

TABLE 6H(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 1 (continued)

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6H(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 2**

Symptom	Severity	Pre-Dose (N=42)		Post-Dose (N=42)		Day 1 (N=42)		Day 2 (N=42)		Day 3 (N=42)		Day 4 (N=42)		Day 5 (N=42)		Day 6 (N=42)		Day 7 ^a (N=42)		Day 8 ^{+ab} (N=42)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	42	100	42	100	17	40	8	19	28	67	37	88	40	95	38	90	37	88	42	100		
	Mild	-	-	-	-	12	29	13	31	13	31	5	12	1	2	4	10	2	5	2	5	28	67
	Moderate	-	-	-	-	12	29	18	43	1	2	-	-	1	2	-	-	-	-	-	-	24	57
	Severe	-	-	-	-	1	2	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7
Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
Arthralgia	None	42	100	42	100	39	93	32	76	40	95	42	100	42	100	42	100	42	95	39	93	42	100
	Mild	-	-	-	-	1	2	6	14	2	5	-	-	-	-	-	-	-	-	-	-	7	17
	Moderate	-	-	-	-	2	5	4	10	-	-	-	-	-	-	-	-	-	-	-	-	6	14
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA
Fatigue	None	42	100	42	100	29	69	15	36	34	81	40	95	40	95	40	95	40	95	38	90	42	100
	Mild	-	-	-	-	8	19	13	31	8	19	2	5	1	2	2	5	-	-	1	2	22	52
	Moderate	-	-	-	-	5	12	12	29	-	-	-	-	1	2	-	-	-	-	-	-	13	31
	Severe	-	-	-	-	-	-	2	5	-	-	-	-	-	-	-	-	-	-	-	-	2	5
Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
Fever	None	NA	NA	NA	NA	38	90	29	69	42	100	42	100	42	100	42	100	42	95	38	90	42	100
	Mild	NA	NA	NA	NA	4	10	9	21	-	-	-	-	-	-	-	-	-	-	-	-	10	24
	Moderate	NA	NA	NA	NA	-	-	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7
	Severe	NA	NA	NA	NA	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2

**TABLE 6H(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 2 (continued)**

Symptom	Severity	Pre-Dose (N=42)		Post-Dose (N=42)		Day 1 (N=42)		Day 2 (N=42)		Day 3 (N=42)		Day 4 (N=42)		Day 5 (N=42)		Day 6 (N=42)		Day 7 ^a (N=42)		Day 8 ^{+ab} (N=42)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	4	10	NA	NA
	None	42	100	42	100	30	71	19	45	42	100	42	100	42	100	42	100	40	95	39	93	42	100	
	Mild	-	-	-	-	3	7	15	36	-	-	-	-	-	-	-	-	-	-	-	-	16	38	
	Moderate	-	-	-	-	8	19	5	12	-	-	-	-	-	-	-	-	-	-	-	-	9	21	
	Severe	-	-	-	-	1	2	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7	
Headache	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	42	100	32	76	22	52	35	83	40	95	42	100	40	95	38	90	39	93	42	100	
	Mild	-	-	-	-	8	19	12	29	6	14	2	5	-	-	2	5	-	-	-	-	21	50	
	Moderate	-	-	-	-	2	5	7	17	1	2	-	-	-	-	-	-	-	-	-	-	9	21	
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	
Myalgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	42	100	28	67	19	45	37	88	41	98	42	100	42	100	40	95	38	90	42	100	
	Mild	-	-	-	-	7	17	13	31	5	12	1	2	-	-	-	-	-	-	-	1	2	17	40
	Moderate	-	-	-	-	7	17	9	21	-	-	-	-	-	-	-	-	-	-	-	-	14	33	
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	
Nausea	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	42	100	37	88	34	81	42	100	42	100	42	100	42	100	40	95	39	93	42	100	
	Mild	-	-	-	-	3	7	6	14	-	-	-	-	-	-	-	-	-	-	-	-	7	17	

**TABLE 6H(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 2 (continued)**

Symptom	Severity	Pre-Dose (N=42)		Post-Dose (N=42)		Day 1 (N=42)		Day 2 (N=42)		Day 3 (N=42)		Day 4 (N=42)		Day 5 (N=42)		Day 6 (N=42)		Day 7 ^a (N=42)		Day 8 ^{+ab} (N=42)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	2	5	1	2	-	-	-	-	-	-	-	-	-	-	-	-	3	7
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

^a The data for Day 7 and Day 8 following the second vaccination for 2 subjects in Cohort 3 was entered after the time of data cutoff; there were no graded events entered for these 2 subjects for these days.

^b Data for Day 8 following the second vaccination for 1 subject in Cohort 3 was confirmed as not available by the site.

**TABLE 6H(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Any Dose**

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	44	98	40	89	20	44	9	20	28	62	38	84	42	93	40	89	41	91	42	93	45	100	
	Mild	1	2	5	11	8	18	14	31	16	36	7	16	2	4	5	11	3	7	3	7	28	62	
	Moderate	-	-	-	-	16	36	19	42	1	2	-	-	1	2	-	-	1	2	-	-	27	60	
	Severe	-	-	-	-	1	2	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Arthralgia	None	44	98	44	98	42	93	35	78	43	96	44	98	44	98	44	98	44	98	44	98	45	100	
	Mild	1	2	1	2	1	2	6	13	2	4	1	2	1	2	1	2	-	-	-	1	2	8	18
	Moderate	-	-	-	-	2	4	4	9	-	-	-	-	-	-	-	-	-	1	2	-	-	7	16
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Fatigue	None	45	100	42	93	30	67	17	38	37	82	41	91	42	93	42	93	45	100	44	98	45	100	
	Mild	-	-	3	7	7	16	13	29	8	18	4	9	2	4	3	7	-	-	1	2	23	51	
	Moderate	-	-	-	-	8	18	13	29	-	-	-	-	1	2	-	-	-	-	-	-	16	36	
	Severe	-	-	-	-	-	-	2	4	-	-	-	-	-	-	-	-	-	-	-	-	2	4	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Fever	None	NA	NA	NA	NA	41	91	32	71	45	100	45	100	45	100	45	100	45	100	45	100	45	100	
	Mild	NA	NA	NA	NA	4	9	9	20	-	-	-	-	-	-	-	-	-	-	-	-	10	22	
	Moderate	NA	NA	NA	NA	-	-	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7	
	Severe	NA	NA	NA	NA	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	

**TABLE 6H(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Any Dose (continued)**

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	45	100	31	69	22	49	45	100	45	100	45	100	45	100	45	100	45	100	45	100	
	Mild	-	-	-	-	5	11	15	33	-	-	-	-	-	-	-	-	-	-	-	-	17	38	
	Moderate	-	-	-	-	8	18	5	11	-	-	-	-	-	-	-	-	-	-	-	-	9	20	
	Severe	-	-	-	-	1	2	3	7	-	-	-	-	-	-	-	-	-	-	-	-	3	7	
Headache	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	44	98	32	71	22	49	33	73	41	91	44	98	43	96	42	93	45	100	45	100	
	Mild	-	-	1	2	10	22	14	31	11	24	4	9	-	-	2	4	3	7	-	-	24	53	
	Moderate	-	-	-	-	3	7	8	18	1	2	-	-	1	2	-	-	-	-	-	-	10	22	
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	
Myalgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	45	100	30	67	22	49	39	87	44	98	45	100	45	100	45	100	44	98	45	100	
	Mild	-	-	-	-	8	18	13	29	6	13	1	2	-	-	-	-	-	-	-	1	2	19	42
	Moderate	-	-	-	-	7	16	9	20	-	-	-	-	-	-	-	-	-	-	-	-	14	31	
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	
Nausea	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	45	100	40	89	35	78	45	100	45	100	45	100	45	100	45	100	45	100	45	100	
	Mild	-	-	-	-	3	7	7	16	-	-	-	-	-	-	-	-	-	-	-	-	8	18	

TABLE 6H(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Any Dose (continued)

Symptom	Severity	Pre-Dose (N=45)		Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	2	4	2	4	-	-	-	-	-	-	-	-	-	-	-	-	4	9
	Severe	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6I(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 1**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	19	95	19	95	14	70	17	85	19	95	18	90	19	95	19	95	19	95	19	95	20	100	
	Mild	1	5	1	5	6	30	2	10	1	5	2	10	1	5	1	5	1	5	1	5	7	35	
	Moderate	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	1	5	2	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	20	100	20	100	20	100	19	95	20	100	19	95	20	100	19	95	19	95	19	95	20	100	
	Mild	-	-	-	-	-	-	-	-	-	-	1	5	-	-	1	5	-	-	1	5	2	10	
	Moderate	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	1	5	2	10
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	20	100	20	100	16	80	19	95	19	95	19	95	19	95	19	95	20	100	20	100	20	100	
	Mild	-	-	-	-	4	20	1	5	1	5	1	5	1	5	1	5	1	5	-	-	5	25	
Fever	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	NA	NA	NA	NA	20	100	20	100	20	100	19	95	20	100	20	100	19	95	20	100	20	100	
Fever	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	NA	NA	NA	NA	20	100	20	100	20	100	19	95	20	100	20	100	19	95	20	100	20	100	

TABLE 6I(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 1 (continued)

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	5	-	-	1	5	-	-	-	-	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Headache	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	19	95	19	95	18	90	20	100	20	100	19	95	20	100	20	100	20	100	20	100	20	100
	Mild	1	5	1	5	2	10	-	-	-	-	1	5	-	-	-	-	-	-	-	-	2	10
Myalgia	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	20	100	20	100	20	100	18	90	20	100	20	100	20	100	19	95	19	95	19	95	20	100
Nausea	Mild	-	-	-	-	-	-	2	10	-	-	-	-	-	-	1	5	1	5	1	5	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Nausea	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 6I(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 1 (continued)

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6I(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 2**

Symptom	Severity	Pre-Dose (N=19)		Post-Dose (N=19)		Day 1 (N=19)		Day 2 (N=19)		Day 3 (N=19)		Day 4 (N=19)		Day 5 (N=19)		Day 6 (N=19)		Day 7 (N=19)		Day 8+ (N=19)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Systemic Symptom	None	19	100	19	100	12	63	8	42	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	4	21	4	21	-	-	-	-	-	-	-	-	-	-	-	-	8	42
	Moderate	-	-	-	-	1	5	4	21	-	-	-	-	-	-	-	-	-	-	-	-	4	21
	Severe	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
Arthralgia	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	16	84	14	74	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Moderate	-	-	-	-	1	5	2	11	-	-	-	-	-	-	-	-	-	-	-	-	2	11
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	14	74	10	53	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	3	16	2	11	-	-	-	-	-	-	-	-	-	-	-	-	5	26
Fever	Moderate	-	-	-	-	-	-	5	26	-	-	-	-	-	-	-	-	-	-	-	-	5	26
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	NA	NA	NA	NA	17	89	14	74	2	11	2	11	2	11	2	11	2	11	2	11	17	89
Fever	Mild	NA	NA	NA	NA	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	NA	NA	NA	NA	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5

TABLE 6I(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 2 (continued)

Symptom	Severity	Pre-Dose (N=19)		Post-Dose (N=19)		Day 1 (N=19)		Day 2 (N=19)		Day 3 (N=19)		Day 4 (N=19)		Day 5 (N=19)		Day 6 (N=19)		Day 7 (N=19)		Day 8+ (N=19)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Feverishness	Not Reported	NA	NA	2	11			17	89	17	89	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	16	84	12	63	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	-	-	2	11	-	-	-	-	-	-	-	-	-	-	-	-	2	11
	Moderate	-	-	-	-	1	5	3	16	-	-	-	-	-	-	-	-	-	-	-	-	3	16
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Headache	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	14	74	12	63	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	2	11	3	16	-	-	-	-	-	-	-	-	-	-	-	-	5	26
	Moderate	-	-	-	-	1	5	2	11	-	-	-	-	-	-	-	-	-	-	-	-	2	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Myalgia	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	13	68	10	53	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	3	16	4	21	-	-	-	-	-	-	-	-	-	-	-	-	7	37
	Moderate	-	-	-	-	1	5	3	16	-	-	-	-	-	-	-	-	-	-	-	-	3	16
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nausea	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	19	100	16	84	14	74	4	21	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	-	-	2	11	-	-	-	-	-	-	-	-	-	-	-	-	2	11

TABLE 6I(ii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 2 (continued)

Symptom	Severity	Pre-Dose (N=19)		Post-Dose (N=19)		Day 1 (N=19)		Day 2 (N=19)		Day 3 (N=19)		Day 4 (N=19)		Day 5 (N=19)		Day 6 (N=19)		Day 7 (N=19)		Day 8+ (N=19)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	2	11	2	11	15	79	17	89	17	89	17	89	17	89	17	89	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6I(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Any Dose**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	19	95	19	95	10	50	11	55	19	95	18	90	19	95	19	95	19	95	19	95	20	100	
	Mild	1	5	1	5	9	45	3	15	1	5	2	10	1	5	1	5	1	5	-	-	11	55	
	Moderate	-	-	-	-	1	5	5	25	-	-	-	-	-	-	-	-	-	-	-	1	5	6	30
	Severe	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	20	100	20	100	19	95	16	80	20	100	19	95	20	100	19	95	19	95	19	95	20	100	
	Mild	-	-	-	-	-	-	1	5	-	-	1	5	-	-	1	5	-	-	1	5	-	-	
	Moderate	-	-	-	-	1	5	3	15	-	-	-	-	-	-	-	-	-	-	-	1	5	4	20
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	20	100	20	100	14	70	13	65	19	95	19	95	19	95	19	95	19	95	20	100	20	100	
	Mild	-	-	-	-	6	30	2	10	1	5	1	5	1	5	1	5	1	5	-	-	7	35	
Fever	Moderate	-	-	-	-	-	-	5	25	-	-	-	-	-	-	-	-	-	-	-	-	5	25	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	NA	NA	20	100	18	90	20	100	19	95	19	95	20	100	19	95	19	95	20	100	20	100	
Fever	Mild	NA	NA	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
	Moderate	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	NA	NA	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
	None	NA	NA	20	100	18	90	20	100	19	95	19	95	20	100	19	95	19	95	20	100	20	100	

**TABLE 6I(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Any Dose (continued)**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	1	5	-	-	1	5	-	-	-	-	NA	NA
	None	20	100	20	100	19	95	15	75	15	75	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	2	10	-	-	-	-	-	-	-	-	-	-	-	-	2	10
	Moderate	-	-	-	-	1	5	3	15	-	-	-	-	-	-	-	-	-	-	-	-	3	15
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Headache	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	19	95	19	95	15	75	15	75	20	100	19	95	20	100	20	100	20	100	20	100	20	100
	Mild	1	5	1	5	4	20	3	15	-	-	1	5	-	-	-	-	-	-	-	-	7	35
	Moderate	-	-	-	-	1	5	2	10	-	-	-	-	-	-	-	-	-	-	-	-	2	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Myalgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	20	100	20	100	16	80	13	65	20	100	20	100	20	100	19	95	19	95	20	100	20	100
	Mild	-	-	-	-	3	15	4	20	-	-	-	-	-	-	1	5	1	5	-	-	8	40
	Moderate	-	-	-	-	1	5	3	15	-	-	-	-	-	-	-	-	-	-	-	-	3	15
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Nausea	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	20	100	20	100	19	95	17	85	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	2	10	-	-	-	-	-	-	-	-	-	-	-	-	2	10

**TABLE 6I(iii):
Summary of Systemic Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Any Dose (continued)**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
	Moderate	-	-	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**TABLE 6J(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day ≥71 years of Age:
Dose Number = Dose 1**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Systemic Symptom	None	20	100	20	100	15	75	17	85	18	90	18	90	17	85	17	85	19	95	18	90	20	100	
	Mild	-	-	-	-	5	25	3	15	2	10	2	10	3	15	3	15	1	5	1	5	8	40	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Arthralgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA	
	None	20	100	20	100	19	95	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20	100	
	Mild	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Fatigue	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	
	None	20	100	20	100	16	80	17	85	19	95	19	95	19	95	19	95	20	100	19	95	20	100	
	Mild	-	-	-	-	4	20	3	15	1	5	1	5	1	5	1	5	-	-	-	-	5	25	
Fever	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	
	None	NA	NA	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20
Fever	Mild	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	NA	NA	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20

**TABLE 6J(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day ≥71 years of Age:
Dose Number = Dose 1 (continued)**

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
Feverishness	Not Reported	NA	NA	NA	NA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA		
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	
	Mild	-	-	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Headache	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA	
	None	20	100	20	100	18	90	20	100	20	100	20	100	20	100	20	100	19	95	20	100	19	95	20	100	
	Mild	-	-	-	-	2	10	-	-	-	-	-	-	-	-	-	1	5	-	-	-	-	-	3	15	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Myalgia	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA	
	None	20	100	20	100	18	90	19	95	19	95	19	95	18	90	19	95	19	95	19	95	18	90	20	100	
	Mild	-	-	-	-	2	10	1	5	1	5	1	5	2	10	1	5	1	5	1	5	1	5	1	5	25
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Nausea	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

TABLE 6J(i):
Summary of Systemic Solicited Events for All Vaccination Groups by Day \geq 71 years of Age:
Dose Number = Dose 1 (continued)

Symptom	Severity	Pre-Dose (N=20)		Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

FIGURE 4A:
Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group 18-55 Years of Age




FIGURE 4B:
Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group 56-70 Years of Age





FIGURE 4C:
Maximum Severity of Solicited Local Symptoms by Days Post Vaccination and Vaccination Group ≥ 71 Years of Age



**TABLE 7A(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	15	100	7	47	7	47	14	93	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	8	53	8	53	1	7	-	-	-	-	-	-	-	-	-	-	10	67
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7A(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration /Swelling (mm)	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	15	100	7	47	7	47	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	8	53	8	53	1	7	-	-	-	-	-	-	-	-	-	-	-	10	67	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7A(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=13)		Day 1 (N=13)		Day 2 (N=13)		Day 3 (N=13)		Day 4 (N=13)		Day 5 (N=13)		Day 6 (N=13)		Day 7 (N=13)		Day 8+ (N=13)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	13	100	5	38	4	31	4	69	13	100	12	92	13	100	13	100	13	100	13	100
	Mild	-	-	8	62	8	62	4	31	-	-	1	8	-	-	-	-	-	-	10	77
	Moderate	-	-	-	-	1	8	-	-	-	-	-	-	-	-	-	-	-	-	1	8
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	13	100	12	92	12	92	13	100	13	100	13	100	13	100	13	100	13	100	13	100
	Mild	-	-	1	8	1	8	-	-	-	-	-	-	-	-	-	-	-	-	1	8
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Moderate	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7A(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=13)		Day 1 (N=13)		Day 2 (N=13)		Day 3 (N=13)		Day 4 (N=13)		Day 5 (N=13)		Day 6 (N=13)		Day 7 (N=13)		Day 8+ (N=13)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling (mm)	None	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	13	100	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	13	100	5	38	4	31	9	69	13	100	12	92	13	100	13	100	13	100	13	100	100
	Mild	-	-	8	62	8	62	4	31	-	-	1	8	-	-	-	-	-	-	10	77	77
	Moderate	-	-	-	-	1	8	-	-	-	-	-	-	-	-	-	-	-	-	1	8	8
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7A(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	15	100	5	33	5	33	11	73	15	100	14	93	15	100	15	100	15	100	15	100
	Mild	-	-	10	67	9	60	4	27	-	-	1	7	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	None	15	100	14	93	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7A(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling (mm)	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	15	100	5	33	5	33	11	73	15	100	14	93	15	100	15	100	15	100	15	100	100
	Mild	-	-	10	67	9	60	4	27	-	-	1	7	-	-	-	-	-	-	11	73	73
	Moderate	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7B(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Local Symptom	None	12	80	5	33	1	7	14	93	14	93	14	93	15	100	14	93	15	100	15	100		
	Mild	3	20	9	60	13	87	-	-	1	7	1	7	-	-	-	-	-	-	14	93		
	Moderate	-	-	1	7	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	2	13	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	1	7
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	15	100	15	100	14	93	14	93	14	93	15	100	15	100	15	100	14	93	14	93	15	100
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	1	7	2	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	15	100	15	100	15	100	14	93	14	93	15	100	15	100	15	100	14	93	14	93	15	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	14	93	14	93	14	93	14	93	15	100	15	100	15	100	15	100	14	93	14	93	15	100
	Mild	1	7	1	7	1	7	1	7	-	-	-	-	-	-	-	-	-	-	1	7	3	20
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7B(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling (mm)	None	15	100	15	100	14	93	14	93	15	100	15	100	15	100	14	93	15	100	15	100	100
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	1	7	2	13	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	13	87	5	33	1	7	15	100	14	93	14	93	15	100	15	100	15	100	15	100	100
	Mild	2	13	9	60	13	87	-	-	1	7	1	7	-	-	-	-	-	-	14	93	93
	Moderate	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	2	13	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7B(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Local Symptom	None	14	93	2	13	-	-	6	40	13	87	14	93	14	93	15	100	15	100	15	100		
	Mild	1	7	9	60	11	73	8	53	1	7	-	-	-	-	-	-	-	-	-	14	93	
	Moderate	-	-	4	27	4	27	-	-	1	7	1	7	1	7	-	-	-	-	-	-	5	33
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	1	7
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	15	100	13	87	14	93	14	93	14	93	14	93	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	2	13	1	7	1	7	1	7	1	7	-	-	-	-	-	-	2	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	15	100	13	87	14	93	14	93	14	93	14	93	15	100	15	100	15	100	15	100
	Mild	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
Induration/Swelling	Moderate	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	14	93	14	93	14	93	14	93	15	100	15	100	15	100	15	100	15	100	15	100
	Mild	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	-	-	-	-	-	1	7
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7B(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration/Swelling (mm)	None	15	100	14	93	14	93	14	93	14	93	14	93	15	100	15	100	15	100	15	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	1	7	1	7	1	7	1	7	1	7	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	14	93	2	13	-	-	6	40	13	87	14	93	14	100	15	100	15	100	15	100	
	Mild	1	7	10	67	12	80	9	60	2	13	1	7	-	-	-	-	-	-	-	15	100
	Moderate	-	-	3	20	3	20	-	-	-	-	-	-	-	-	-	-	-	-	-	4	27
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7B(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Local Symptom	None	11	73	2	13	-	-	6	40	12	80	13	87	14	93	15	100	14	93	15	100	
	Mild	4	27	9	60	10	67	7	47	2	13	1	7	-	-	-	-	-	-	14	93	
	Moderate	-	-	4	27	5	33	1	7	1	7	1	7	1	7	-	-	-	-	-	6	40
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	1	7	1	7
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	15	100	13	87	13	87	14	93	14	93	14	93	15	100	14	93	15	100	
	Mild	-	-	-	-	2	13	2	13	1	7	1	7	1	7	-	-	1	7	-	2	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	15	100	13	87	13	87	14	93	14	93	14	93	15	100	14	93	15	100	
	Mild	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
Induration/Swelling	Moderate	-	-	-	-	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	1	7	1	7	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	14	93	13	87	13	87	13	87	14	93	15	100	15	100	15	100	14	93	15	100	
Moderate	Mild	1	7	2	13	2	13	2	13	1	7	-	-	-	-	-	-	1	7	3	20	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7B(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Induration /Swelling (mm)	None	15	100	14	93	13	87	13	87	14	93	15	100	15	100	15	100	14	93	15	100	15	100	
	Mild	-	-	-	-	1	7	1	7	-	-	-	-	-	-	-	-	1	7	2	13	2	13	
	Moderate	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	-	-	-	-	1	7	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	12	80	2	13	-	-	6	40	12	80	13	87	15	100	15	100	15	100	15	100	15	100	
	Mild	3	20	10	67	11	73	9	60	3	20	2	13	-	-	-	-	-	-	-	15	100	15	100
	Moderate	-	-	3	20	4	27	-	-	-	-	-	-	-	-	-	-	-	-	-	5	33	5	33
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7C(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Local Symptom	None	11	73	1	7	-	-	3	20	12	80	14	93	15	100	14	93	14	93	15	100	
	Mild	4	27	10	67	10	67	12	80	3	20	1	7	-	-	-	-	-	-	-	-	
	Moderate	-	-	4	27	5	33	-	-	-	-	-	-	-	-	-	-	-	-	-	6	40
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	1	7
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	15	100	14	93	15	100	15	100	15	100	15	100	15	100	15	100	14	93	15	100	
	Mild	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	2	13
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	15	100	15	100	15	100	15	100	15	100	15	100	15	100	15	100	14	93	15	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration /Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	15	100	13	87	11	73	14	93	14	93	15	100	15	100	15	100	15	100	15	100	
	Mild	-	-	1	7	3	20	1	7	1	7	-	-	-	-	-	-	-	-	-	4	27
Moderate	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	

TABLE 7C(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration/Swelling (mm)	None	15	100	14	93	14	93	14	93	14	93	14	93	15	100	15	100	14	93	15	100	15	100
	Mild	-	-	-	-	1	7	1	7	1	7	1	7	-	-	-	-	-	-	-	-	2	13
	Moderate	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	1	7	1
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	11	73	1	7	-	-	4	27	13	87	14	93	15	100	15	100	15	100	15	100	15	100
	Mild	4	27	10	67	11	73	11	73	2	13	1	7	-	-	1	7	-	-	-	15	100	
	Moderate	-	-	4	27	4	27	-	-	-	-	-	-	-	-	-	-	-	-	-	6	40	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7C(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 ^a (N=15)		Day 8 ^{a,b} (N=15)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Local Symptom	None	13	93	3	21	-	-	3	21	9	64	14	100	14	100	12	86	11	79	14	100	
	Mild	1	7	6	43	9	64	8	57	4	29	-	-	-	-	-	-	-	-	-	13	93
	Moderate	-	-	5	36	5	36	2	14	1	7	-	-	-	-	-	-	-	-	-	7	50
	Severe	-	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	2	14
Erythema/Redness	None	14	100	13	93	11	79	11	79	11	79	14	100	14	100	12	86	11	79	14	100	
	Mild	-	-	1	7	3	21	3	21	3	21	-	-	-	-	-	-	-	-	-	3	21
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	2	14
Erythema/Redness Measurement (mm)	None	14	100	14	100	11	79	11	79	11	79	14	100	14	100	12	86	11	79	14	100	
	Mild	-	-	-	-	1	7	-	-	2	14	-	-	-	-	-	-	-	-	-	2	14
	Moderate	-	-	-	-	2	14	2	14	1	7	-	-	-	-	-	-	-	-	-	3	21
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	-	-	-
Induration/Swelling	None	14	100	11	79	11	79	13	93	14	100	14	100	14	100	12	86	11	79	14	100	
	Mild	-	-	2	14	2	14	1	7	-	-	-	-	-	-	-	-	-	-	-	2	14
	Moderate	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7

**TABLE 7C(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 ^a (N=15)		Day 8 ^{a,b} (N=15)		Any Post-Dose*					
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%				
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	2	14			
Induration/Swelling (mm)	None	14	100	11	79	12	86	13	93	14	100	14	100	14	100	12	86	11	79	14	100	14	100		
	Mild	-	-	1	7	-	-	1	7	-	-	-	-	-	-	-	-	-	-	-	2	14	2	14	
	Moderate	-	-	2	14	2	14	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	2	14
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	-	-	-	-	
Pain	None	13	93	3	21	1	7	3	21	10	71	14	100	14	100	12	86	11	79	14	100	14	100		
	Mild	1	7	7	50	10	71	11	79	4	29	-	-	-	-	-	-	-	-	-	14	100	14	100	
	Moderate	-	-	4	29	3	21	-	-	-	-	-	-	-	-	-	-	-	-	-	4	29	4	29	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	14	3	21	2	14	2	14	2	14

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

^a The data for Day 7 and Day 8 following the second vaccination for 2 subjects in Cohort 3 was entered after the time of data cutoff; there were no graded events entered for these 2 subjects for this day.

^b Data for Day 8 following the second vaccination for 1 subject in Cohort 3 was confirmed as not available by the site.

**TABLE 7C(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 250 mcg mRNA-1273 (18-55 years)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
Any Local Symptom	None	11	73	1	7	-	-	2	13	8	53	14	93	15	100	14	93	14	93	15	100			
	Mild	4	27	9	60	7	47	10	67	6	40	1	7	-	-	1	7	-	-	14	93			
	Moderate	-	-	5	33	8	53	2	13	1	7	-	-	-	-	-	-	-	-	-	9	60		
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	1	7	1	7		
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	None	15	100	13	87	12	80	12	80	12	80	15	100	15	100	15	100	14	93	15	100	15	100	
	Mild	-	-	2	13	3	20	3	20	3	20	-	-	-	-	-	-	-	1	7	4	27	4	27
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	15	100	12	80	12	80	12	80	15	100	15	100	15	100	14	93	15	100	15	100	
	Mild	-	-	-	-	1	7	-	-	2	13	-	-	-	-	-	-	-	-	-	2	13	2	13
Induration/Swelling	Moderate	-	-	-	-	2	13	2	13	1	7	-	-	-	-	-	-	-	-	-	3	20	3	20
	Severe	-	-	-	-	-	-	1	7	-	-	-	-	-	-	-	-	-	1	7	1	7	1	7
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	15	100	12	80	11	73	13	87	14	93	15	100	15	100	15	100	15	100	15	100	15	100	15
Induration/Swelling	Mild	-	-	2	13	3	20	2	13	1	7	-	-	-	-	-	-	-	-	-	4	27	4	27
	Moderate	-	-	1	7	1	7	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	1	7

**TABLE 7C(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 250 mcg mRNA-1273 (18-55 years) (continued)**

Symptom	Severity	Post-Dose (N=15)		Day 1 (N=15)		Day 2 (N=15)		Day 3 (N=15)		Day 4 (N=15)		Day 5 (N=15)		Day 6 (N=15)		Day 7 (N=15)		Day 8+ (N=15)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration/Swelling (mm)	None	15	100	12	80	12	80	13	87	14	93	15	100	15	100	15	100	14	93	15	100	15	100
	Mild	-	-	1	7	1	7	2	13	1	7	-	-	-	-	-	-	-	-	-	-	4	27
	Moderate	-	-	2	13	2	13	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	13
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	7	1	7	1
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	11	73	1	7	-	-	2	13	10	67	14	93	15	100	14	93	15	100	15	100	15	100
	Mild	4	27	9	60	9	60	13	87	5	33	1	7	-	-	1	7	-	-	-	15	100	
	Moderate	-	-	5	33	6	40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	47
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7D(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	9	90	7	70	7	70	9	90	9	90	9	90	9	90	9	90	9	90	10	100
	Mild	1	10	3	30	3	30	1	10	1	10	1	10	1	10	1	10	1	10	5	50
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	10	100	9	90	9	90	9	90	9	90	9	90	9	90	9	90	9	90	10	100
	Mild	-	-	1	10	1	10	1	10	1	10	1	10	1	10	1	10	1	10	1	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	9	90	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7D(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Induration/Swelling (mm)	None	10	100	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	10	100	8	80	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	2	20	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7D(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	9	90	7	70	7	70	4	40	2	20	2	20	2	20	2	20	2	20	10	100
	Mild	1	10	2	20	3	30	-	-	-	-	-	-	-	-	-	-	-	-	5	50
	Moderate	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	-	-
	None	10	100	10	100	9	90	4	40	2	20	2	20	2	20	2	20	2	20	10	100
	Mild	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	-	-
	None	10	100	10	100	10	100	4	40	2	20	2	20	2	20	2	20	2	20	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	-	-
	None	9	90	9	90	10	100	4	40	2	20	2	20	2	20	2	20	2	20	10	100
	Mild	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7D(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	-	-	-	
Induration /Swelling (mm)	None	10	100	9	90	10	100	4	40	2	20	2	20	2	20	2	20	2	20	10	100	-	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	-	-	-	-
	None	10	100	7	70	7	70	4	40	2	20	2	20	2	20	2	20	2	20	10	100	-	
	Mild	-	-	3	30	3	30	-	-	-	-	-	-	-	-	-	-	-	-	5	50	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	6	60	8	80	8	80	8	80	8	80	8	80	8	80	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7D(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	8	80	6	60	5	50	9	90	9	90	9	90	9	90	9	90	9	90	10	100
	Mild	2	20	3	30	5	50	1	10	1	10	1	10	1	10	1	10	1	10	7	70
	Moderate	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	10	100	9	90	9	90	9	90	9	90	9	90	9	90	9	90	9	90	10	100
	Mild	-	-	1	10	1	10	1	10	1	10	1	10	1	10	1	10	1	10	1	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	8	80	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	2	20	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	40
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7D(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 25 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Induration/Swelling (mm)	None	10	100	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	1	10
	Moderate	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	10	100	7	70	5	50	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	3	30	5	50	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	60	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7E(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Local Symptom	None	9	90	8	80	2	20	8	80	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	1	10	2	20	8	80	2	20	-	-	-	-	-	-	-	-	-	-	8	80	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration/Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

TABLE 7E(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Induration /Swelling (mm)	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pain	None	9	90	8	80	2	20	8	80	2	20	8	80	2	20	8	80	2	20	8	80	2	20	
	Mild	1	10	2	20	8	80	8	80	2	20	8	80	2	20	8	80	2	20	8	80	2	20	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7E(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=9)		Day 1 (N=9)		Day 2 (N=9)		Day 3 (N=9)		Day 4 (N=9)		Day 5 (N=9)		Day 6 (N=9)		Day 7 (N=9)		Day 8+ (N=9)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	8	89	2	22	2	22	1	11	-	-	-	-	-	-	-	-	-	-	8	89
	Mild	1	11	5	56	4	44	-	-	-	-	-	-	-	-	-	-	-	-	5	56
	Moderate	-	-	-	-	1	11	-	-	-	-	-	-	-	-	-	-	-	-	1	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	-	-
	None	8	89	6	67	5	56	1	11	-	-	-	-	-	-	-	-	-	-	8	89
	Mild	1	11	1	11	2	22	-	-	-	-	-	-	-	-	-	-	-	-	2	22
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	-	-
	None	9	100	7	78	7	78	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	-	-
	None	9	100	6	67	5	56	1	11	-	-	-	-	-	-	-	-	-	-	9	100
	Mild	-	-	1	11	2	22	-	-	-	-	-	-	-	-	-	-	-	-	2	22
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7E(ii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 2
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Post-Dose (N=9)		Day 1 (N=9)		Day 2 (N=9)		Day 3 (N=9)		Day 4 (N=9)		Day 5 (N=9)		Day 6 (N=9)		Day 7 (N=9)		Day 8+ (N=9)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	-	-	-	
Induration /Swelling (mm)	None	9	100	7	78	6	67	1	11	-	-	-	-	-	-	-	-	-	-	9	100	-	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	1	11	-	-	-	-	-	-	-	-	-	-	-	-	-	1	11	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	-	-	-	-
Pain	None	9	100	3	33	2	22	1	11	-	-	-	-	-	-	-	-	-	-	-	9	100	-
	Mild	-	-	4	44	4	44	-	-	-	-	-	-	-	-	-	-	-	-	-	5	56	-
	Moderate	-	-	-	-	1	11	-	-	-	-	-	-	-	-	-	-	-	-	-	1	11	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	22	2	22	8	89	9	100	9	100	9	100	9	100	9	100	9	100	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7E(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (56-70 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Local Symptom	None	8	80	3	30	1	10	8	80	10	100	10	100	10	100	10	100	10	100	10	100		
	Mild	2	20	7	70	8	80	2	20	-	-	-	-	-	-	-	-	-	-	9	90		
	Moderate	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	8	80	9	90	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	2	20	1	10	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	3	30	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	9	90	9	90	8	80	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	1	10	1	10	2	20	-	-	-	-	-	-	-	-	-	-	-	-	-	2	20	
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

**TABLE 7E(iii):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Any Dose
Vaccination Group – 100 mcg mRNA-1273 (56-70 years) (continued)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
Induration /Swelling (mm)	None	10	100	10	100	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100		
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Moderate	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Pain	None	9	90	4	40	1	10	8	80	10	100	10	100	10	100	10	100	10	100	10	100		
	Mild	1	10	6	60	8	80	2	20	-	-	-	-	-	-	-	-	-	-	-	9	90	
	Moderate	-	-	-	-	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7F(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (≥71 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*					
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%				
Any Local Symptom	None	10	100	6	60	5	50	10	100	10	100	10	100	10	100	10	100	10	100	10	100				
	Mild	-	-	4	40	5	50	-	-	-	-	-	-	-	-	-	-	-	-	6	60				
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
	None	10	100	9	90	9	90	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100		
	Mild	-	-	1	10	1	10	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

TABLE 7F(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 25 mcg mRNA-1273 (≥71 years) (continued)

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration /Swelling (mm)	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	None	10	100	6	60	5	50	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100
	Mild	-	-	4	40	5	50	-	-	-	-	-	-	-	-	-	-	-	-	-	6	60	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7G(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (≥71 years)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	10	100	5	50	2	20	8	80	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	5	50	8	80	2	20	-	-	-	-	-	-	-	-	-	-	8	80
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-
	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7G(i):
Summary of Local Solicited Events by Days Post Treatment and Vaccination Group
Dose Number = Dose 1
Vaccination Group – 100 mcg mRNA-1273 (≥71 years) (continued)**

Symptom	Severity	Post-Dose (N=10)		Day 1 (N=10)		Day 2 (N=10)		Day 3 (N=10)		Day 4 (N=10)		Day 5 (N=10)		Day 6 (N=10)		Day 7 (N=10)		Day 8+ (N=10)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-	
Induration/Swelling (mm)	None	10	100	10	100	10	100	10	100	10	100	10	100	10	100	10	100	9	90	10	100	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-	-
Pain	None	10	100	5	50	2	20	8	80	10	100	10	100	10	100	10	100	9	90	10	100	100	
	Mild	-	-	5	50	8	80	2	20	-	-	-	-	-	-	-	-	-	-	-	8	80	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	10	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7H(i):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 1**

Symptom	Severity	Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Any Local Symptom	None	38	84	13	29	8	18	31	69	41	91	43	96	45	100	44	98	43	96	45	100	
	Mild	7	16	27	60	31	69	13	29	4	9	2	4	-	-	1	2	-	-	39	87	
	Moderate	-	-	5	11	6	13	1	2	-	-	-	-	-	-	-	-	-	-	-	8	18
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	4	2	4
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	44	98	44	98	44	98	45	100	45	100	45	100	45	100	43	96	45	100	
	Mild	-	-	1	2	1	2	1	2	-	-	-	-	-	-	-	-	2	4	4	9	
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	45	100	45	100	45	100	44	98	45	100	45	100	45	100	45	100	43	96	45	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Induration/Swelling	Moderate	-	-	-	-	-	-	1	2	-	-	-	-	-	-	-	-	-	-	1	2	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	4	2	4	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
	None	44	98	42	93	40	89	43	96	44	98	45	100	45	100	45	100	44	98	45	100	
Moderate	Mild	1	2	2	4	4	9	2	4	1	2	-	-	-	-	-	-	1	2	7	16	
	Moderate	-	-	1	2	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2	

**TABLE 7H(i):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 1 (continued)**

Symptom	Severity	Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Induration /Swelling (mm)	None	45	100	44	98	42	93	43	96	44	98	45	100	45	100	45	100	43	96	45	100	45	
	Mild	-	-	-	-	2	4	2	4	1	2	-	-	-	-	-	-	1	2	4	9	9	
	Moderate	-	-	1	2	1	2	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	1	2	2	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Pain	None	39	87	13	29	8	18	33	73	42	93	43	96	45	100	44	98	45	100	45	100	45	
	Mild	6	13	27	60	32	71	12	27	3	7	2	4	-	-	1	2	-	-	-	39	87	
	Moderate	-	-	5	11	5	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	18
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7H(ii):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 2**

Symptom	Severity	Post-Dose (N=42)		Day 1 (N=42)		Day 2 (N=42)		Day 3 (N=42)		Day 4 (N=42)		Day 5 (N=42)		Day 6 (N=42)		Day 7 ^a (N=42)		Day 8 ^{a,ab} (N=42)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	40	95	10	24	4	10	18	43	35	83	40	95	41	98	40	95	39	93	42	100
	Mild	2	5	23	55	28	67	20	48	5	12	1	2	-	-	-	-	-	-	37	88
	Moderate	-	-	9	21	10	24	2	5	2	5	1	2	1	2	-	-	-	-	13	31
	Severe	-	-	-	-	-	-	-	2	5	-	-	-	-	-	-	-	-	-	2	5
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	40	95	36	86	38	90	38	90	41	98	41	98	40	95	39	93	42	100
	Mild	-	-	2	5	6	14	4	10	4	10	1	2	1	2	-	-	-	-	6	14
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	42	100	37	88	38	90	38	90	41	98	41	98	40	95	39	93	42	100
	Mild	-	-	-	-	2	5	-	-	2	5	-	-	-	-	-	-	-	-	3	7
Induration/Swelling	Moderate	-	-	-	-	3	7	2	5	2	5	1	2	1	2	-	-	-	-	4	10
	Severe	-	-	-	-	-	-	2	5	-	-	-	-	-	-	-	-	-	-	2	5
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA
	None	42	100	38	90	38	90	40	95	41	98	42	100	42	100	40	95	39	93	42	100
Moderate	Mild	-	-	3	7	3	7	2	5	1	2	-	-	-	-	-	-	-	-	3	7
	Moderate	-	-	1	2	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2

**TABLE 7H(ii):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Dose 2 (continued)**

Symptom	Severity	Post-Dose (N=42)		Day 1 (N=42)		Day 2 (N=42)		Day 3 (N=42)		Day 4 (N=42)		Day 5 (N=42)		Day 6 (N=42)		Day 7 ^a (N=42)		Day 8 ^{a,b} (N=42)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA	NA
Induration /Swelling (mm)	None	42	100	38	90	39	93	41	98	42	100	42	100	42	100	40	95	39	93	42	100	
	Mild	-	-	1	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5
	Moderate	-	-	3	7	3	7	1	2	1	2	-	-	-	-	-	-	-	-	-	3	7
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	3	7	NA	NA	NA
Pain	None	40	95	10	24	5	12	36	86	40	95	42	100	40	95	40	95	39	93	42	100	
	Mild	2	5	25	60	30	71	6	14	2	5	-	-	-	-	-	-	-	-	39	93	
	Moderate	-	-	7	17	7	17	-	-	-	-	-	-	-	-	-	-	-	-	-	9	21
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	2	5	2	5	3	7	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

^a The data for Day 7 and Day 8 following the second vaccination for 2 subjects in Cohort 3 was entered after the time of data cutoff; there were no graded events entered for these 2 subjects for these days.

^b Data for Day 8 following the second vaccination for 1 subject in Cohort 3 was confirmed as not available by the site.

**TABLE 7H(iii):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Any Dose**

Symptom	Severity	Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	37	82	8	18	5	11	19	42	35	78	41	91	44	98	44	98	43	96	45	100
	Mild	8	18	28	62	26	58	21	47	8	18	3	7	-	-	1	2	-	-	39	87
	Moderate	-	-	9	20	14	31	3	7	2	4	1	2	1	2	-	-	-	-	16	36
	Severe	-	-	-	-	-	-	2	4	-	-	-	-	-	-	-	-	2	4	2	4
Erythema/Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	42	93	39	87	40	89	41	91	44	98	44	98	45	100	43	96	45	100
	Mild	-	-	3	7	6	13	5	11	4	9	1	2	1	2	-	-	2	4	7	16
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	45	100	45	100	40	89	40	89	41	91	44	98	44	98	45	100	43	96	45	100
	Mild	-	-	-	-	2	4	-	-	2	4	-	-	-	-	-	-	-	-	3	7
Induration/Swelling	Moderate	-	-	-	-	3	7	3	7	2	4	1	2	1	2	-	-	-	-	5	11
	Severe	-	-	-	-	-	-	2	4	-	-	-	-	-	-	-	-	2	4	2	4
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	44	98	40	89	39	87	41	91	43	96	45	100	45	100	45	100	44	98	45	100
Moderate	Mild	1	2	4	9	5	11	4	9	2	4	-	-	-	-	-	-	1	2	7	16
	Moderate	-	-	1	2	1	2	-	-	-	-	-	-	-	-	-	-	-	-	1	2

**TABLE 7H(iii):
Summary of Local Solicited Events for All Vaccination Groups by Day 18-55 Years of Age:
Dose Number = Any Dose (continued)**

Symptom	Severity	Post-Dose (N=45)		Day 1 (N=45)		Day 2 (N=45)		Day 3 (N=45)		Day 4 (N=45)		Day 5 (N=45)		Day 6 (N=45)		Day 7 (N=45)		Day 8+ (N=45)		Any Post-Dose*					
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%				
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA			
Induration /Swelling (mm)	None	45	100	41	91	40	89	41	91	43	96	45	100	45	100	45	100	43	96	45	100	45	100		
	Mild	-	-	1	2	2	4	3	7	1	2	-	-	-	-	-	-	1	2	6	13	6	13		
	Moderate	-	-	3	7	3	7	1	2	1	2	-	-	-	-	-	-	-	-	-	3	7	3	7	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	1	2	1	2	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA	NA	
Pain	None	38	84	8	18	5	11	19	42	37	82	41	91	45	100	44	98	45	100	45	100	45	100		
	Mild	7	16	29	64	29	64	26	58	8	18	4	9	-	-	1	2	-	-	-	41	91	41	91	
	Moderate	-	-	8	18	11	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13	29	13	29
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7I(i):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 1**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Local Symptom	None	18	90	15	75	9	45	17	85	19	95	19	95	19	95	19	95	19	95	19	95	20	100
	Mild	2	10	5	25	11	55	3	15	1	5	1	5	1	5	1	5	1	5	1	5	13	65
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	19	95	19	95	19	95	19	95	19	95	19	95	19	95	19	95	19	95	19	95	20	100
	Mild	1	5	1	5	1	5	1	5	1	5	1	5	1	5	1	5	1	5	1	5	2	10
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
	None	18	90	19	95	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
Moderate	Mild	2	10	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	15
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7I(i):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 1 (continued)**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*				
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%			
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA		
Induration /Swelling (mm)	None	20	100	19	95	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	
	Mild	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Pain	None	19	95	16	80	10	50	18	90	20	100	20	100	20	100	20	100	20	100	20	100	20	100	
	Mild	1	5	4	20	10	50	2	10	-	-	-	-	-	-	-	-	-	-	-	11	55	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had "None", "Mild", "Moderate", "Severe", or "Not Reported" as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7I(ii):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 2**

Symptom	Severity	Post-Dose (N=19)		Day 1 (N=19)		Day 2 (N=19)		Day 3 (N=19)		Day 4 (N=19)		Day 5 (N=19)		Day 6 (N=19)		Day 7 (N=19)		Day 8+ (N=19)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	17	89	9	47	9	47	5	26	2	11	2	11	2	11	2	11	2	11	18	95
	Mild	2	11	7	37	7	37	-	-	-	-	-	-	-	-	-	-	-	-	10	53
	Moderate	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	2	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	18	95	16	84	14	74	5	26	2	11	2	11	2	11	2	11	2	11	18	95
	Mild	1	5	1	5	3	16	-	-	-	-	-	-	-	-	-	-	-	-	3	16
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema/Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	19	100	17	89	17	89	5	26	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration/Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	NA	NA
	None	18	95	15	79	15	79	5	26	2	11	2	11	2	11	2	11	2	11	19	100
Induration/Swelling	Mild	1	5	2	11	2	11	-	-	-	-	-	-	-	-	-	-	-	-	4	21
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7I(ii):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Dose 2 (continued)**

Symptom	Severity	Post-Dose (N=19)		Day 1 (N=19)		Day 2 (N=19)		Day 3 (N=19)		Day 4 (N=19)		Day 5 (N=19)		Day 6 (N=19)		Day 7 (N=19)		Day 8+ (N=19)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	17	89	NA	
Induration /Swelling (mm)	None	19	100	16	84	16	84	5	26	2	11	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	11
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	17	89	NA	NA
Pain	None	19	100	10	53	9	47	5	26	2	11	2	11	2	11	2	11	2	11	2	11	19	100
	Mild	-	-	7	37	7	37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10	53
	Moderate	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	2	11	2	11	14	74	17	89	17	89	17	89	17	89	17	89	17	89	NA	NA

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7I(iii):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Any Dose**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
Any Local Symptom	None	16	80	9	45	6	30	17	85	19	95	19	95	19	95	19	95	19	95	19	95	20	100
	Mild	4	20	10	50	13	65	3	15	1	5	1	5	1	5	1	5	1	5	1	5	16	80
	Moderate	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	10
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Erythema/Redness	None	18	90	18	90	17	85	19	95	19	95	19	95	19	95	19	95	19	95	19	95	20	100
	Mild	2	10	2	10	3	15	1	5	1	5	1	5	1	5	1	5	1	5	1	5	4	20
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Erythema/Redness Measurement (mm)	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA
Induration/Swelling	None	17	85	17	85	18	90	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	3	15	3	15	2	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	30
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7I(iii):
Summary of Local Solicited Events for All Vaccination Groups by Day 56-70 Years of Age:
Dose Number = Any Dose (continued)**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*			
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%		
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Induration /Swelling (mm)	None	20	100	18	90	19	95	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
	Moderate	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	2	10	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	
Pain	None	19	95	11	55	6	30	18	90	20	100	20	100	20	100	20	100	20	100	20	100	20	100
	Mild	1	5	9	45	13	65	2	10	-	-	-	-	-	-	-	-	-	-	-	15	75	
	Moderate	-	-	-	-	1	5	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	NA	NA	

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had "None", "Mild", "Moderate", "Severe", or "Not Reported" as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 7J(i):
Summary of Local Solicited Events for All Vaccination Groups by Day ≥71 years of Age:
Dose Number = Dose 1**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any Local Symptom	None	20	100	11	55	7	35	18	90	20	100	20	100	20	100	20	100	19	95	20	100
	Mild	-	-	9	45	13	65	2	10	-	-	-	-	-	-	-	-	-	-	14	70
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	19	95	19	95	20	100	20	100	20	100	20	100	20	100	19	95	20	100
	Mild	-	-	1	5	1	5	-	-	-	-	-	-	-	-	-	-	-	-	1	5
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Erythema /Redness Measurement (mm)	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20	100
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Induration /Swelling	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20	100
Induration /Swelling	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

**TABLE 7J(i):
Summary of Local Solicited Events for All Vaccination Groups by Day ≥71 years of Age:
Dose Number = Dose 1 (continued)**

Symptom	Severity	Post-Dose (N=20)		Day 1 (N=20)		Day 2 (N=20)		Day 3 (N=20)		Day 4 (N=20)		Day 5 (N=20)		Day 6 (N=20)		Day 7 (N=20)		Day 8+ (N=20)		Any Post-Dose*		
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Induration /Swelling (mm)	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	20	100	20	100	20	100	20	100	20	100	20	100	20	100	19	95	20	100	
	Mild	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pain	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
	None	20	100	11	55	7	35	18	90	20	100	20	100	20	100	20	100	19	95	20	100	
	Mild	-	-	9	45	13	65	2	10	-	-	-	-	-	-	-	-	-	-	-	14	70
	Moderate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Severe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Not Reported	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	5	NA	NA
		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Severity is the maximum severity reported post dosing for each subject for each day.

*Indicates how many subjects had “None”, “Mild”, “Moderate”, “Severe”, or “Not Reported” as their maximum severity for any day. A subject may be counted in more than one of these categories.

**TABLE 8A:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	10	9	90	1	10	-	-	-	-
Day 1, Baseline	100 mcg mRNA-1273 (≥71 years)	10	10	8	80	2	20	-	-	-	-
	All Subjects	85	85	77	91	8	9	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	10	67	5	33	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	11	73	4	27	-	-	-	-

TABLE 8A:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	6	60	3	30	1	10	-	-
	All Subjects	85	85	70	82	14	16	1	1	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	5	36	9	64	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	5	33	10	67	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	2	13	12	80	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	1	10	7	70	2	20	-	-

TABLE 8A:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	1	10	9	90	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	1	10	9	90	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	10	100	-	-	-	-
	All Subjects	85	84	15	18	66	79	3	4	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	3	20	12	80	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	6	40	9	60	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	4	29	10	71	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	1	10	7	70	1	10	1	10
	100 mcg mRNA-1273 (56-70 years)	10	10	1	10	9	90	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8A:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	15	23	47	73	1	2	1	2
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	6	40	9	60	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	4	27	11	73	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	2	13	11	73	2	13	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	1	50	1	50	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	13	28	32	68	2	4	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	2	13	13	87	-	-	-	-

TABLE 8A:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group - Any Hematology Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	3	20	12	80	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	1	7	11	73	3	20	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	7	70	2	20	1	10
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	10	100	-	-	-	-
	25 mcg mRNA-1273 (>=71 years)	10	10	1	10	9	90	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	10	100	-	-	-	-
	All Subjects	85	84	7	8	72	85	5	6	1	1

Note: The "Max Severity Post Baseline" rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.
N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA- 1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
		15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA- 1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
		15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
	250 mcg mRNA- 1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
		10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA- 1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
		10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
25 mcg mRNA- 1273 (≥71 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-	
	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-	
All Subjects		85	85	100	-	-	-	-	-	-	-	-	-	-	-	-	
Day 1, Baseline	25 mcg mRNA- 1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	
		15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	8	80	2	20	-	-	-	-	-	-	-	-	-	-
	All Subjects	85	85	79	93	6	7	-	-	-	-	-	-	-	-	-	-
Day 8 (Days 7 to 9)	25 mcg mRNA-1273 (18-55 years)	15	14	12	86	2	14	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-	-	-	-	-	-	-

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥ 71 years)	10	10	9	90	1	10	-	-	-	-	-	-	-	-	-	-
	All Subjects	85	84	79	94	5	6	-	-	-	-	-	-	-	-	-	-
Day 29 (Days 27 to 31)	25 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)		
				n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-	
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-	
	25 mcg mRNA-1273 (>=71 years)	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	100 mcg mRNA-1273 (>=71 years)	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	All Subjects	85	64	61	95	3	5	-	-	-	-	-	-	-	-	-	-	
	25 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	44	94	3	6	-	-	-	-	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	11	73	4	27	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-

TABLE 8B:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
White Blood Cells (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1 (Low)		Mild/ Grade 1 (High)		Moderate/ Grade 2 (Low)		Moderate/ Grade 2 (High)		Severe/ Grade 3 (Low)		Severe/ Grade 3 (High)	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
	25 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-	-	-	-	-	-	-
	All Subjects	85	84	77	91	8	9	-	-	-	-	-	-	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8C:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Hemoglobin**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	10	8	80	2	20	-	-	-	-
	All Subjects	85	85	81	95	4	5	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	12	80	3	20	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	12	80	3	20	-	-	-	-

TABLE 8C:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Hemoglobin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	8	80	2	20	-	-	-	-
	All Subjects	85	85	75	88	10	12	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	5	36	9	64	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	6	40	9	60	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	3	20	11	73	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	1	10	7	70	2	20	-	-

TABLE 8C:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Hemoglobin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	1	10	9	90	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	1	10	9	90	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	2	20	8	80	-	-	-	-
	All Subjects	85	84	19	23	62	74	3	4	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	3	20	12	80	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	6	40	9	60	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	4	29	10	71	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	1	10	7	70	1	10	1	10
	100 mcg mRNA-1273 (56-70 years)	10	10	1	10	9	90	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8C:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Hemoglobin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	15	23	47	73	1	2	1	2
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	7	47	8	53	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	4	27	11	73	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	2	13	11	73	2	13	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	1	50	1	50	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	14	30	31	66	2	4	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	2	13	13	87	-	-	-	-

TABLE 8C:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Hemoglobin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	3	20	12	80	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	2	13	10	67	3	20	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	7	70	2	20	1	10
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	10	100	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	1	10	9	90	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	2	20	8	80	-	-	-	-
	All Subjects	85	84	10	12	69	81	5	6	1	1

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8D:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Platelets**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3		
				n	%	n	%	n	%	n	%	
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-	
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-	
	100 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-	
	All Subjects	85	85	85	100	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-	-

TABLE 8D:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Platelets (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	-	-	1	10	-	-
	All Subjects	85	85	84	99	-	-	1	1	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8D:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Platelets (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	83	99	1	1	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8D:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Platelets (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	64	100	-	-	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	47	100	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	15	100	-	-	-	-	-	-

TABLE 8D:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Platelets (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	84	99	1	1	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8E:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Prothrombin Time**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
Day 1, Baseline	All Subjects	85	85	83	98	2	2	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-

TABLE 8E:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Prothrombin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	85	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-

TABLE 8E:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Prothrombin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	84	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8E:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Prothrombin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	-	-	-	-	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	-	-	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-

TABLE 8E:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Prothrombin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	84	-	-	-	-	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8F:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Partial Thromboplastin Time**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
Day 1, Baseline	All Subjects	85	85	83	98	2	2	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-

TABLE 8F:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Partial Thromboplastin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	85	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-

TABLE 8F:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Partial Thromboplastin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	84	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8F:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Partial Thromboplastin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	-	-	-	-	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	-	-	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	-	-	-	-	-	-	-	-

TABLE 8F:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Partial Thromboplastin Time (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	-	-	-	-	-	-	-	-
	All Subjects	85	84	-	-	-	-	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8G:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Any Chemistry Parameter**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
Day 1, Baseline	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8G:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Any Chemistry Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	85	81	95	4	5	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	12	86	2	14	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8G:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Any Chemistry Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	79	94	5	6	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	-	-	1	7	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	12	80	3	20	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	13	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8G:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Any Chemistry Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	58	91	5	8	1	2	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	-	-	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	43	91	3	6	1	2	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	12	80	2	13	1	7	-	-

TABLE 8G:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Any Chemistry Parameter (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	11	73	4	27	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	13	87	1	7	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	73	86	10	12	2	2	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8H:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Creatinine**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
Day 1, Baseline	100 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8H:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Creatinine (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8H:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Creatinine (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	84	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8H:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Creatinine (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	64	100	-	-	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	47	100	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	15	100	-	-	-	-	-	-

TABLE 8H:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Creatinine (continued)

Timepoint	Study Group	N		None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
		N	N*	n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	85	100	-	-	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.
N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alanine Aminotransferase

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alanine Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	83	98	2	2	-	-	-	-
Day 8 (Days 7 to 9)	25 mcg mRNA-1273 (18-55 years)	15	14	13	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alanine Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	82	98	2	2	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alanine Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	63	98	1	2	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	47	100	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	14	93	1	7	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alanine Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	13	87	2	13	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	82	96	3	4	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Aspartate Aminotransferase

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
Day 1, Baseline	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Aspartate Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Aspartate Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	84	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Aspartate Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	63	98	1	2	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	46	98	1	2	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	14	93	1	7	-	-	-	-

TABLE 8I:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Aspartate Aminotransferase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	83	98	2	2	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

TABLE 8J:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alkaline Phosphatase

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8J:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alkaline Phosphatase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8J:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alkaline Phosphatase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	84	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8J:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alkaline Phosphatase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	64	100	-	-	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	47	100	-	-	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	15	100	-	-	-	-	-	-

TABLE 8J:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Alkaline Phosphatase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	85	100	-	-	-	-	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8K:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Total Bilirubin**

Timepoint	Study Group	N		None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
		N	N*	n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	Day 1, Baseline	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8K:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Total Bilirubin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	85	84	99	1	1	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	13	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8K:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Total Bilirubin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	83	99	1	1	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	-	-	1	7	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	13	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8K:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Total Bilirubin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	61	95	2	3	1	2	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	46	98	1	2	-	-	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	14	93	-	-	1	7	-	-

TABLE 8K:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Total Bilirubin (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	84	82	96	2	2	1	1	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

**TABLE 8L:
Laboratory Results by Parameter, Severity, and Study Day
Serum Lipase**

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Screening (Day -42 to -1)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥ 71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	85	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-

TABLE 8L:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Lipase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 8 (Days 7 to 9)	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	10	100	-	-	-	-	-	-
	All Subjects	85	85	84	99	1	1	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-

TABLE 8L:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Lipase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
Day 29 (Days 27 to 31)	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	82	98	2	2	-	-	-	-
	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	14	14	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	-	-	-	-	-	-	-	-	-

TABLE 8L:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Lipase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	64	63	98	1	2	-	-	-	-
Day 36 (Days 35 to 37)	25 mcg mRNA-1273 (18-55 years)	15	15	15	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	-	-	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	2	2	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	-	-	-	-	-	-	-	-	-
	25 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	100 mcg mRNA-1273 (≥71 years)	10	-	-	-	-	-	-	-	-	-
	All Subjects	85	47	45	96	1	2	1	2	-	-
Max Severity Post Baseline	25 mcg mRNA-1273 (18-55 years)	15	14	15	100	-	-	-	-	-	-

TABLE 8L:
Laboratory Results by Parameter, Severity, Study Day, and Vaccination Group –
Serum Lipase (continued)

Timepoint	Study Group	N	N*	None		Mild/ Grade 1		Moderate/ Grade 2		Severe/ Grade 3	
				n	%	n	%	n	%	n	%
	100 mcg mRNA-1273 (18-55 years)	15	15	14	93	1	7	-	-	-	-
	250 mcg mRNA-1273 (18-55 years)	15	15	14	93	-	-	1	7	-	-
	25 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	100 mcg mRNA-1273 (56-70 years)	10	10	10	100	-	-	-	-	-	-
	25 mcg mRNA-1273 (<71 years)	10	10	9	90	1	10	-	-	-	-
	100 mcg mRNA-1273 (>=71 years)	10	10	9	90	1	10	-	-	-	-
	All Subjects	85	84	81	95	3	4	1	1	-	-

Note: The “Max Severity Post Baseline” rows indicate the maximum severity experienced by each subject at any time point post baseline, including unscheduled assessments.

N = Number of subjects enrolled and vaccinated; N* = Number of subjects that completed the visit.

FIGURE 5A:
Clinical Laboratory Results by Severity and Vaccination Group 18-55 Years of Age




FIGURE 5B:
Clinical Laboratory Results by Severity and Vaccination Group 56-70 Years of Age




FIGURE 5C:
Clinical Laboratory Results by Severity and Vaccination Group ≥ 71 Years of Age




TABLE 9A:
Distribution of Protocol Deviations by Category, Type, and Vaccination Group 18-55 Years of Age

Category	Deviation Type	25 mcg mRNA-1273 (N=15)		100 mcg mRNA -1273 (N=15)		250 mcg mRNA -1273 (N=15)		All Subjects (N=45)	
		#of Subj.	#of Dev.	#of Subj.	#of Dev.	#of Subj.	#of Dev.	#of Subj.	#of Dev.
Follow-up visit schedule	Missed visit/visit not conducted	-	-	-	-	-	-	-	-
	Out of window visit	-	-	1	1	-	-	1	1
Protocol procedure/assessment	Other: breach of confidentiality	-	-	1	1	-	-	1	1
	Other: non-required lab tests performed	1	1	-	-	-	-	1	1
	Other: v4 safety labs collected out of window	1	1	-	-	-	-	1	1
	Required procedure done incorrectly	1	1	2	3	1	1	4	5
	Required procedure not conducted	1	1	-	-	1	1	2	2
Treatment administration schedule	Too few aliquots obtained	-	-	6	9	2	2	8	11
	Required procedure done incorrectly	-	-	-	-	1	1	1	1

TABLE 9B:
Distribution of Protocol Deviations by Category, Type, and Vaccination Group 56-70 Years of Age

Category	Deviation Type	25 mcg mRNA-1273 (N=10)		100 mcg mRNA-1273 (N=10)		All Subjects (N=20)	
		#of Subj.	#of Dev.	#of Subj.	#of Dev.	#of Subj.	#of Dev.
Follow-up visit schedule	Missed visit/visit not conducted	-	-	1	1	1	1
	Out of window visit	-	-	-	-	-	-
Protocol procedure/assessment	Other: breach of confidentiality	-	-	-	-	-	-
	Other: non-required lab tests performed	-	-	-	-	-	-
	Other: v4 safety labs collected out of window	-	-	-	-	-	-
	Required procedure done incorrectly	-	-	-	-	-	-
	Required procedure not conducted	-	-	-	-	-	-
Treatment administration schedule	Too few aliquots obtained	1	1	-	-	1	1
	Required procedure done incorrectly	-	-	-	-	-	-

**TABLE 9C:
Distribution of Protocol Deviations by Category, Type, and Vaccination Group \geq 71 Years of Age**

No protocol deviations have been reported.

CLINICAL RESEARCH IN INFECTIOUS DISEASES

SAFETY SUMMARY REPORT

Prepared for the Safety Monitoring Committee

for

DMID Protocol 20-0003:

Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults

APPENDICES - REDACTED

02 JUNE 2020

Prepared and distributed by:
Statistical and Data Coordinating Center (SDCC)
Emmes
Rockville, Maryland

THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL

TABLE OF CONTENTS

APPENDIX A: Adverse Event Definitions	2
APPENDIX B: Listing of Non-Serious, Unsolicited, Moderate or Mild, or Severe Adverse Events	5
APPENDIX C1: Solicited Systemic Events.....	30
APPENDIX C2: Solicited Local Events	166
APPENDIX D: Attribution for Systemic Solicited Events that Contribute to Halting Criteria	301
APPENDIX E: Listing of Abnormal Clinical Laboratory Results.....	302
APPENDIX F: Vital Signs Listing	672
APPENDIX G1: Listing of Protocol Deviations.....	709
APPENDIX G2: Listing of Non-Subject Deviations	712
APPENDIX H: Listing of Pregnancies	713

APPENDIX A: Adverse Event Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

Definition of Adverse Event (AE)

AEs means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.

Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre-existing medical condition increases, it should be recorded as an AE.

AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for which the study team will specifically query the subject whether they occurred. Unsolicited AEs are those events that the subject report occurring without being queried about the specific event.

All AEs will be assessed for severity and relationship to study intervention (see section 8.3.3 of the protocol). Reporting of all AEs, solicited and unsolicited, will occur during the period from study product administration at Day 1 through 28 days after the last vaccination. After Day 57 through the end of study on Day 394, only SAEs, MAAEs, and NOCMCs will be recorded as AEs.

All AEs, solicited and unsolicited, will be captured on the appropriate DCF. Information to be collected for AEs includes event description, date of onset, assessment of severity, relationship to study product and alternate etiology (assessed only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator), date of resolution, seriousness, and outcome. AEs occurring during the study-collection and reporting period will be documented appropriately regardless of relationship.

AEs will be followed to resolution or stabilization.

Severity of Adverse Events: All AEs or SAEs will be assessed for severity, according to the toxicity grading scales in the FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”.

For AEs not included in the protocol-defined grading system, the following guidelines will be used to describe severity.

- **Mild (Grade 1)**: Events that are usually transient and may require only minimal or no treatment or therapeutic intervention and generally do not interfere with the subject’s usual activities of daily living.
- **Moderate (Grade 2)**: Events that are usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject.

Appendix A (continued)
Adverse Events Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

- **Severe (Grade 3):** Events interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.

AEs characterized as intermittent require documentation of onset and duration of each episode. The start and stop date of each reported AE will be recorded on the appropriate DCF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.

Relationship to Study Intervention: For each reported adverse reaction, the participating site PI or qualified designee must assess the relationship of the event to the study product using the following guidelines:

- **Related** – The AE is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.
- **Not Related** – There is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.

Definition of Serious Adverse Event (SAE)

An SAE is defined in 21 CFR 312.32 as follows: “An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in any of the following outcomes:

- Death,
- a life-threatening AE,
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions,
- or a congenital anomaly/birth defect.

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

Appendix A (continued)
Adverse Events Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

“Life-threatening” refers to an AE that at occurrence represents an immediate risk of death to a subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospital admission for an elective procedure is not considered an SAE.

All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.

All SAEs will be recorded on the appropriate SAE DCF.

All SAEs will be followed through resolution or stabilization by a study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator.

All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC (for periodic review unless related) and IRB/IEC.

**APPENDIX B:
 Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® Sytem Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	14 (8)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Petechiae
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	25 (17)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	4 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Flatulence
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	28 (8)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	14 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Erythema
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (3)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	15 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	8 (6)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	6 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	3 (9)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	2 (2)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (0)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	5 (1)	Mild	Related	REDACTED	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Urticaria
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscular weakness
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	0 (8)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003									
REDACTED	8 (3)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	5 (7)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	22 (1)	Moderate	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	20 (3)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	1 (8)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site irritation
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									
REDACTED	14 (Ongoing)	Mild	Not Related	REDACTED	Not Applicable	No		Injury, poisoning and procedural complications	Contusion
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005									
REDACTED	18 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Presyncope
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									
REDACTED	8 (7)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005									
REDACTED	11 (3)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006									
REDACTED	25 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Injury, poisoning and procedural complications	Contusion
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	13 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Investigations	Heart rate increased
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	4 (3)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	9 (6)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	6 (6)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	14 (27)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (13)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	3 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Vasodilatation
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	2 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (15)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (7)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003									
REDACTED	7 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	20 (4)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Breast pain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	14 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No	Recovering /resolving	Cardiac disorders	Bradycardia

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (1)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	2 (1)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Neck pain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	22 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Injury, poisoning and procedural complications	Muscle strain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (3)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Feeling jittery
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Eye disorders	Eye irritation
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 007									
REDACTED	4 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 008									
REDACTED	3 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 009									
REDACTED	4 (11)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Faeces discoloured
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	10 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	27 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	6 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No	Recovering /resolving	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	8 (12)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 004									
REDACTED	21 (7)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Lip disorder
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	12 (3)	Moderate	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	6 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	2 (0)	Mild	Not related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthralgia
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	24 (3)	Mild	Not related	REDACTED	WD- Drug withdrawn	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	10 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (1)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vaginal haemorrhage
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	7 (4)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	14 (14)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 005									
REDACTED	28 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Vascular disorders	Hypotension
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	11 (7)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle strain
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	7 (Ongoing)	Moderate	Not related	REDACTED	Not applicable	No	Recovering /resolving	Metabolism and nutrition disorders	Hypoglycaemia
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									
REDACTED	7 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain upper
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	1 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	1 (0)	Severe	Related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									
REDACTED	1 (0)	Severe	Related	REDACTED	Not applicable	No	Recovered /resolved	Nervous system disorders	Syncope
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005									
REDACTED	1 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		General disorders and administration site conditions	Vessel puncture site bruise

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 006									
REDACTED	13 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Eye disorders	Scintillating scotoma
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 002									
REDACTED	0 (2)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	0 (1)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Hyperhidrosis
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									
REDACTED	7 (Ongoing)	Mild	Not related	REDACTED	Not applicable	No		Psychiatric disorders	Insomnia
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 005									
REDACTED	1 (Ongoing)	Mild	Related	REDACTED	Not applicable	No		Psychiatric disorders	Anxiety
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 003									
REDACTED	1 (1)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Malaise
Comments: REDACTED									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: REDACTED, AE Number: 004									
REDACTED	2 (0)	Moderate	Related	REDACTED	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	27 (0)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	5 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Sciatica
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	12 (0)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Exposure via inhalation
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (11)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (4)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vaccination site bruising
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	28 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No	Recovering /resolving	Vascular disorders	Diastolic hypertension
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	1 (1)	Moderate	Related	REDACTED	Not Applicable	No	Recovered /Resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (1)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Psychiatric disorders	Insomnia
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	13 (2)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	21 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	2 (13)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Infections and infestations	Paronychia
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	9 (Ongoing)	Moderate	Not related	REDACTED	WD- Drug withdrawn	No	Recovering /resolving	Skin and subcutaneous tissue disorders	Rash maculo-papular
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	14 (15)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	8 (5)	Severe	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (0)	Mild	Related	REDACTED	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	4 (9)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Sunburn
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	2 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Joint swelling
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	2 (2)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003									
REDACTED	4 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (3)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments: REDACTED									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	1 (12)	Moderate	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									
REDACTED	1 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (0)	Mild	Related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Pruritus
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	2 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 003									
REDACTED	3 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		Injury, poisoning and procedural complications	Arthropod bite
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (10)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	0 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		General disorders and administration site conditions	Injection site bruising
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
REDACTED	0 (Ongoing)	Mild	Not related	REDACTED	Dose not changed	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: REDACTED, AE Number: 001									
REDACTED	3 (1)	Mild	Not related	REDACTED	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments: REDACTED									

**APPENDIX C1:
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	Moderate	Moderate	Moderate	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.4	None	None	None	None	None	Moderate
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Moderate	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Mild	Moderate	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.1 (Mild)	Moderate	Moderate	Moderate	None	Moderate	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.6	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	Moderate	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	None	None	Mild	Moderate	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Moderate	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	Mild	Mild	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	Mild	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	Mild	None	Mild	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 9	MA	N/A				Mild		
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.7	Mild	Moderate	Moderate	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	Mild	Mild	Mild	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.5	None	Moderate	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.5	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	Mild	None	None	None	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Moderate	Mild	Moderate
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Moderate	Moderate	Moderate	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Mild	Moderate	Moderate	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	39.2 (Severe)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	Moderate	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	Moderate	Mild	Moderate	Moderate	Moderate	Moderate
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.4	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	38.4 (Mild)	Mild	Mild	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	Moderate	Mild	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.9	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.4	None	Moderate	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	Moderate	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.8	Mild	Moderate	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Moderate	Moderate	Moderate	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	Mild	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	Mild	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 12	MA	N/A			Mild			
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37	Mild	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	Mild	None	None	None	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	Moderate	None	None	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	Moderate	Moderate	Mild	Mild	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	Mild	None	Moderate	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	Mild	Mild	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.4	None	None	None	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	N/A				Mild		
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	35.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	Mild	Mild	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	Mild	Mild	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.5	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Moderate	Moderate	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	Mild	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.2	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.2	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	35.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	35.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	35.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	35.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	Moderate	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Mild	Moderate	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	Mild	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Moderate	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Moderate	None	Mild	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	None	Mild	None	None	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	Mild	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	Mild	Moderate	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	Mild	None	None	Moderate	Mild
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	Mild	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	Mild	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	None	None	Moderate	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.5	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Moderate	None	None	Mild	Moderate
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	None	Mild	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	Moderate	Moderate	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38 (Mild)	Mild	None	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	Mild	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.5	None	Mild	Mild	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	Severe	Mild	Mild	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	39.6 (Severe)	Severe	Severe	Moderate	Mild	Severe	Moderate
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.4	Mild	Mild	None	None	Moderate	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.8	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.8 (Moderate)	Severe	Severe	Moderate	Moderate	Moderate	Mild
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.5	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Severe	None	Severe	None	None	Severe
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	Mild	Mild	None	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	Moderate	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	Mild	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Moderate	Mild	None	Moderate	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Mild	Moderate	Moderate	Moderate	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	Mild	Moderate	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.7	None	Mild	Mild	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	Mild	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	Mild	Mild	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	Mild	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	37.3	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.2	None	None	Mild	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 14	MA	N/A			Mild			
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.5	None	Mild	Mild	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None

**Appendix C1 (continued)
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	Mild	Mild	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**APPENDIX C2:
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	Mild	0	1
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Moderate	0	75 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Moderate	0	78 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	Mild	0	36 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	Mild	0	26 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Moderate	0	65 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Moderate	0	76 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	23
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	Mild	0	35 (Mild)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	20
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	15
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	Mild	None	1	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	Mild	None	1	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	Mild	None	3	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	Mild	None	3	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	Mild	None	3	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA	.	Mild	.	2	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	1	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	1

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	10
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	8
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	2
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	3	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	Mild	None	2	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	Mild	None	2	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	3	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	2	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	Mild	None	65 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	65 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	40 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	40 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	50 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	Mild	None	25 (Mild)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	Mild	0	15
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	20
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	5

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	Mild	0	1
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	Mild	Mild	Mild	2	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Moderate	None	Mild	0	50 (Moderate)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	3
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	Mild	Mild	5	30 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	Mild	Mild	60 (Moderate)	45 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	35 (Mild)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	.	Mild	Mild	110 (Severe)	40 (Mild)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	115 (Severe)	90 (Moderate)

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	Mild	None	60 (Moderate)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	Mild	None	60 (Moderate)	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	Not Done	Not Done	Not Done	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	7
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	30 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Mild	0	20
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	Mild	0	30 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Mild	0	1
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	1
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	None	50 (Moderate)	50 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	.	Mild	.	105 (Severe)	105 (Severe)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	Mild	Mild	10	60 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	Mild	75 (Moderate)	60 (Moderate)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	105 (Severe)	25 (Mild)

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	60 (Moderate)	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	Not Done	Not Done	Not Done	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	Mild	None	2	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
REDACTED	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	Mild	None	20	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	Mild	None	20	20
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

**Appendix C2 (continued)
 Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
REDACTED	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
 Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
 See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**APPENDIX D:
 Attribution for Systemic Solicited Events that Contribute to Halting Criteria**

Subject ID	Vaccination Group	Systemic Reaction	Dose Number	Post-Dose Day	Severity	Attributed to Alternate Etiology?
REDACTED	25 mcg mRNA-1273 (56-70 years)	Fever	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	1	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Headache	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fever	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Myalgia	02	2	SEVERE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	Nausea	02	2	SEVERE	No

**APPENDIX E:
 Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade I, due to phlebotomy procedure	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	PT (seconds)	11.8 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	182	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	197	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-22	WBC (10 ³ /uL)	3.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	334	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 ³ /uL)	358	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	343	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	238	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	WBC (10 ³ /uL)	7.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	Due to phlebotomy (study procedure)	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Platelets (10 ³ /uL)	162	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	1.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	1.4 (Mild)	NOT RELATED	Grade 1 Similar to baseline bilirubin	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	57	55	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	34	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	78.0 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	70.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	56	Serum Lipase (U/L)	77.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	3.2 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	2.8 (Mild)	NOT RELATED	Grade I - similar to Grade I that was present prior to receipt of vaccine	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	3.0 (Mild)	NOT RELATED	Grade I Similar to her baseline	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	56	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Due to study - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	15.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	175	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	168	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Grade I due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Grade I Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	29	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 ³ /uL)	291	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	275	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	64.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	59.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	112.0 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	7	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	PTT (seconds)	36 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Platelets (10 ³ /uL)	304	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Platelets (10 ³ /uL)	283	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	277	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-7	WBC (10 ³ /uL)	8.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	7	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	study procedures -phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	11.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Platelets (10 ³ /uL)	203	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	30	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	181	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	103	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	104	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	102	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	337	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	8.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	8.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	8.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	13.1 (Moderate)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	study procedures - phlebotomy	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	371	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	355	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	370	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (U/L)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	7.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	7.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	65.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedures -phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Platelets (10 ³ /uL)	361	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	395	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	388	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	350	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-3	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Platelets (10 ³ /uL)	350	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	346	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	358	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	42.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-7	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	52 (Mild)	NOT RELATED	Related to Alcohol	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	37	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	33	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	379	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	345	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	88 (Mild)	NOT RELATED	subject confirmed alcohol use	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Creatinine (mg/dL)	1.18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Platelets (10 ³ /uL)	359	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	328	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	348	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-4	WBC (10 ³ /uL)	8.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	7.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-3	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Normal variation	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	normal lab variation	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	11.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	373	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	420	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	415	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 ³ /uL)	407	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedures - phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	related to study procedure	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	13.6 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-15	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	7.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	36	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.2 (Moderate)	NOT RELATED	normal variation	NC-DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	285	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	238	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	7.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	related to study blood draws	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PT (seconds)	9.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	324	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	343	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	308	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	WBC (10 ³ /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure (phlebotomy)	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Platelets (10 ³ /uL)	173	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	67.0 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-2	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	36	36	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.4 (Mild)
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-6	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Normal variation or phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	279	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	8.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.8 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Severe)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	312	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	271	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	12.3 (Mild)
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	310	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	316	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-5	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.6 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-4	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	37	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	284	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	283	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	-1	-6	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	54 (Mild)	NOT RELATED	alcohol consumption	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	normal variation	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	-1	-5	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (56-70 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	16.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	225	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Platelets (10 ³ /uL)	183	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 ³ /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	30	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	38	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	study procedure	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	13.4 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	3.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	11.2 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 ³ /uL)	274	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Aspartate Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PT (seconds)	9.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	317	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	319	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-10	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	30	WBC (10 ³ /uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	38	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.61	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	235	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	10.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	10.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Platelets (10 ³ /uL)	307	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	254	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	297	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-8	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	3.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	3.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	3.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.06	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	12.9 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	272	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	66 (Mild)	NOT RELATED	increased alcohol night before	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	PTT (seconds)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	8.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-15	WBC (10 ³ /uL)	8.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	8.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Study procedure	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	11.5 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	57	58	Hemoglobin (g/dL)	11.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Platelets (10 ³ /uL)	289	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	246	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-7	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	7.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	7	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Platelets (10 ³ /uL)	280	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	255	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-14	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	2.9 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	3.2 (Mild)	RELATED	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	2.8 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	2.7 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Platelets (10 ³ /uL)	313	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	274	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alanine Aminotransferase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Alanine Aminotransferase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	285	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	311	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	309	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	310	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	16.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-12	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	45 (Mild)	NOT RELATED	Alcohol intake	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 ³ /uL)	286	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	3.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.52	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.59	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.7 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	13.2 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	293	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	224	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-11	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Hemoglobin (g/dL)	16.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.7 (Moderate)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	16.1 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	16.2 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Platelets (10 ³ /uL)	251	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	223	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	269	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PT (seconds)	10.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	172	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	148	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-11	WBC (10 ³ /uL)	7.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	study procedure	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	14.9 (Mild)	NOT RELATED	Study Procedure	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	PT (seconds)	10.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Platelets (10 ³ /uL)	327	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	312	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	324	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	302	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	335	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	1.6 (Mild)	NOT RELATED	suspected Gilberts	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	2.1 (Moderate)	NOT RELATED	suspected Gilberts	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	1.8 (Mild)	NOT RELATED	Other	NA- NOT APPLICABLE	No
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-8	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	31	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	11.6 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	13.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-22	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	28	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	16.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Hemoglobin (g/dL)	14.8 (Mild)
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	PTT (seconds)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	265	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Platelets (10 ³ /uL)	284	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	58.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Serum Lipase (U/L)	61.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	1.5 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-26	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	36	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.57	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	9.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 ³ /uL)	317	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Platelets (10 ³ /uL)	301	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 ³ /uL)	7.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	35	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	122	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Alkaline Phosphatase (U/L)	106	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Alkaline Phosphatase (U/L)	93	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	15.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	Study procedure	NC- DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Hemoglobin (g/dL)	16.2 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Hemoglobin (g/dL)	15.7 (Mild)	NOT RELATED	phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-20	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	28	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	35	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	36	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	248	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	261	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	36.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-25	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	3.4 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Study procedure	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Platelets (10 ³ /uL)	245	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	-1	-24	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	7.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	29	29	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	MALE	REDACTED	36	37	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Hemoglobin (g/dL)	13.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.4 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	PT (seconds)	10.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Platelets (10 ³ /uL)	298	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	243	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	255	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-24	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	Study procedure	NC-DOSE NOT CHANGED	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	Phlebotomy	NA- NOT APPLICABLE	No
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	193	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Serum Lipase (U/L)	11.0	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	-1	-21	WBC (10 ³ /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	29	29	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	250 mcg mRNA-1273 (18-55 years)	FEMALE	REDACTED	36	37	WBC (10 ³ /uL)	6.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	10.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	210	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	45.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	61	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.76	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC-DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	PTT (seconds)	27	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Platelets (10 ³ /uL)	260	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Serum Lipase (U/L)	51.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	47.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-17	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 ³ /uL)	203	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	230	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PT (seconds)	9.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Platelets (10 ³ /uL)	276	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-17	WBC (10 ³ /uL)	7.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.8	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	95	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	90	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 ³ /uL)	207	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	228	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	55.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	52.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	7.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Creatinine (mg/dL)	0.83	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	PT (seconds)	9.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	PTT (seconds)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Platelets (10 ³ /uL)	442	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	389	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	362	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	363	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-22	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	38	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	92	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	83	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.1 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 ³ /uL)	151	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	153	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	17.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	3.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PT (seconds)	11.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Platelets (10 ³ /uL)	201	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	165	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	176	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Serum Lipase (U/L)	37.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-14	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Hemoglobin (g/dL)	11.9 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	PT (seconds)	10.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	PTT (seconds)	31	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	191	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	200	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	67.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	3.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	3.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	40	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Creatinine (mg/dL)	0.98	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Hemoglobin (g/dL)	13.5 (Mild)	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	PT (seconds)	10.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	333	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-15	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.0 (Mild)
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	PT (seconds)	10.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-21	WBC (10 ³ /uL)	3.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-15	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	3.1 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	3.8	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Creatinine (mg/dL)	1.10	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Hemoglobin (g/dL)	13.0 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	196	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Platelets (10 ³ /uL)	208	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-13	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
REDACTED	25 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	9	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	63	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	13.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Hemoglobin (g/dL)	12.7 (Mild)
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	PT (seconds)	9.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	PTT (seconds)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Platelets (10 ³ /uL)	171	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	187	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Platelets (10 ³ /uL)	183	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-13	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	9	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alkaline Phosphatase (U/L)	84	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	12.3 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PT (seconds)	9.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Platelets (10 ³ /uL)	356	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	369	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	357	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	7.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	1.03	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.07	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	13.7 (Mild)	NOT RELATED	Phlebotomy	NC-DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	194	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.0 (Mild)
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	PT (seconds)	10.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	PTT (seconds)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Platelets (10 ³ /uL)	242	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	257	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	234	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Serum Lipase (U/L)	26.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-20	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	6.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Creatinine (mg/dL)	0.71	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PT (seconds)	9.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Platelets (10 ³ /uL)	281	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Platelets (10 ³ /uL)	318	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Platelets (10 ³ /uL)	303	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	Total Bilirubin (mg/dL)	1.4 (Mild)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	-1	-19	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	1	1	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	FEMALE	REDACTED	8	8	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	60	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Creatinine (mg/dL)	1.05	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PT (seconds)	10.2	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	PTT (seconds)	28	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	213	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	34.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-20	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Aspartate Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	PT (seconds)	9.8	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	PTT (seconds)	28	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Platelets (10 ³ /uL)	144	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Platelets (10 ³ /uL)	104 (Moderate)	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Platelets (10 ³ /uL)	125 (Mild)	RELATED	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Serum Lipase (U/L)	31.0	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	-1	-18	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
REDACTED	100 mcg mRNA-1273 (≥71 years)	MALE	REDACTED	8	8	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A

**APPENDIX F:
 Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-21	37.2	121	85	80	79.9	184.5
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	66	81	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.4	108	73	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.2	120	82	82	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.3	123	76	82	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.1	114	77	71	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	115	80	64	84.4	175.5
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	110	76	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.4	130	82	79	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	130	82	102 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	128	80	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.6	119	82	75	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.3	121	79	80	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	37.1	126	83	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.1	137	98 (Moderate)	78	68.8	169.4
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.4	138	90	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	37.2	138	80	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	137	90	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.9	133	87	92	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	136	89	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	37.1	133	84	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	37.1	129	84	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	130	83	63	93	181.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37	128	81	76	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.8	117	75	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	37.2	117	81	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.4	134	89	68	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	34	36.4	109	71	62	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	40	36.9	100	66	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.3	111	75	76	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	106	68	51 (Mild)	73.5	172
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	129	74	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.9	122	72	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37.1	120	74	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	118	78	58	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	36.8	117	69	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	108	76	53 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.2	113	70	57	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	37.3	116	77	53 (Mild)	69.7	160.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	114	78	53 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	37.1	101	67	56	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	37.1	109	67	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.3	106	76	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.6	107	66	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.9	110	74	96	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	36.9	108	74	66	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.9	137	81	63	76.1	170
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	111	71	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	105	65	59	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.7	111	73	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	118	69	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	37	119	66	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	77	74	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	57	36.3	114	69	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	37.3	115	73	76	55.7	157.5

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.2	120	78	66	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	37.3	107	74	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	37.4	111	76	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.8	104	77	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37	105	71	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-10	36.8	127	86	55	95.9	181.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.2	124	89	58	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	37.1	122	87	60	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	121	82	72	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	130	87	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.5	114	86	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.2	150 (Mild)	85	69	81.5	177
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	82	71	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	36.6	145 (Mild)	79	69	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.4	139	83	68	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	130	83	63	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	122	79	83	83.3	174.5
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.3	120	75	99	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	9	36.4	123	77	82	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.5	109	76	94	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	30	36.4	112	67	96	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	37.3	136	81	80	72.2	158.1
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37.2	113	77	82	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	37.2	128	71	80	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.2	132	71	78	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.6	119	73	79	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	138	78	56	64.7	166.5
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.3	109	66	66	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	111	69	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.3	92	53	63	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	102	60	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	138	84	81	52	149
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37	140	86	78	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	134	80	86	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	16	36.1	134	78	80	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	37	113	72	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	115	72	41 (Severe)	88.6	186
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37	143 (Mild)	79	74	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	122	74	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	102	55	61	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	30	36.3	116	69	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.7	110	72	78	56.4	164.5

**Appendix F (continued)
 Vital Signs Listing**

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	101	71	89	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	37.3	113	70	88	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	37.2	109	75	86	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	37.1	110	75	90	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.4	147 (Mild)	93 (Mild)	75	64.2	160.1
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.5	150 (Mild)	93 (Mild)	75	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.1	142 (Mild)	89	83	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.4	142 (Mild)	92 (Mild)	85	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	36.3	146 (Mild)	91 (Mild)	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	37.2	134	87	60	66.5	171
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.4	130	84	66	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	37	120	79	71	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	116	78	77	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	126	88	75	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-2	36.4	121	79	58	62	163.1
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	37.1	113	71	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	9	36.3	104	64	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	16	36.4	113	68	63	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	30	36.8	124	69	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-6	36.3	129	74	53 (Mild)	60.6	167.7
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.9	129	81	62	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	7	36.5	116	70	65	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.9	113	71	64	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	37.4	128	72	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	122	77	77	78.5	167.9
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	119	58	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.8	126	73	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	13	36.7	112	68	80	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	113	79	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37.2	118	67	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	41	36.9	117	68	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55	36.8	125	72	98	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.7	129	71	67	98.7	188
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	136	75	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	9	36.7	137	73	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	116	73	83	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.6	125	74	75	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	119	74	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	46					.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	55					.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-3	36.8	140	92 (Mild)	85	81.6	172.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.7	138	83	85	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	136	84	85	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	37	138	90	86	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.7	123	87	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	37.1	136	87	84	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.8	129	77	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	57	36.9	139	81	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-2	36.7	142 (Mild)	70	78	77.1	177.8
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	120	77	88	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	129	68	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	36.7	113	76	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	28	36.7	125	80	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	36.7	140	71	91	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	124	77	72	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	56	36.6	126	79	70	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-4	36.4	119	83	56	87	172.7
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	117	82	69	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	8	36.7	110	76	63	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	15	36.6	111	64	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.4	107	68	55	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	36	36.5	110	67	56	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.6	109	77	60	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.4	109	70	66	64.5	165.1
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.5	106	52	66	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	7	36.3	147 (Mild)	86	80	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	108	60	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.6	115	72	69	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.7	114	61	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-14	36.7	103	58	58	70.6	154.9

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.6	118	57	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	104	56	59	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.7	100	67	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	112	58	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	36.8	113	56	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-13	36.8	116	71	68	74.1	162.6
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.9	117	62	76	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	37.2	110	63	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	14	36.8	112	69	85	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	112	61	73	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	112	65	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.9	115	67	69	82.9	167.6
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.8	100	58	79	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	7	36.8	112	61	75	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (56-70 years)	.	9	36.7	119	71	77	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	14	36.9	114	69	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	111	68	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	36	35	36.8	115	56	62	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-1	36.8	142 (Mild)	72	66	67.8	167.6
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	118	64	75	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	37.1	138	70	65	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	37	123	61	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	118	59	70	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	36	36	36.7	129	65	70	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.6	124	78	59	71.1	167.6
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	120	84	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.6	140	78	76	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	139	80	60	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	37.1	132	79	57	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.8	140	80	85	89.8	180.3
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	150 (Mild)	76	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.8	140	78	88	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.7	110	75	68	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.8	141 (Mild)	87	97	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.6	150 (Mild)	92 (Mild)	68	68.7	175.3
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.6	146 (Mild)	92 (Mild)	64	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.5	148 (Mild)	80	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.6	140	85	72	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.7	130	92 (Mild)	68	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	134	90	60	50.5	152.4
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	140	92 (Mild)	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	37	139	68	79	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.8	153 (Moderate)	87	73	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	30	36.8	130	70	84	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	-1	-4	36.9	116	72	68	86	182.9
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	1	36.9	114	73	69	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	8	8	36.6	115	62	76	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	15	15	36.9	117	69	77	.	.
REDACTED	25 mcg mRNA-1273 (56-70 years)	29	29	36.9	127	77	72	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-5	36.7	101	58	58	64.7	171.5
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.8	96	60	64	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	8	36.9	91	63	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	15	36.6	103	57	69	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	29	36.8	105	70	61	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	-1	-4	36.5	141 (Mild)	70	74	95.2	195.6
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	1	36.6	129	74	75	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (56-70 years)	8	9	36.2	130	79	81	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	15	14	36.6	137	71	76	.	.
REDACTED	100 mcg mRNA-1273 (56-70 years)	29	28	36.8	128	84	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	144 (Mild)	88	75	92.7	185.7
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	132	88	77	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	37.3	122	80	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	16	36.9	130	76	88	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	36.8	142 (Mild)	80	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	36.9	128	82	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.6	130	84	64	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	120	80	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	106	74	65	56.2	158.7
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37.1	104	65	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	37.2	101	64	88	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.8	114	69	99	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	37.1	102	67	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	113	79	89	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.9	103	58	86	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	37	111	72	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	114	69	56	62.9	172.6
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37	120	63	56	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	36.7	111	65	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.7	112	63	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	37	106	56	58	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	37.2	118	61	57	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	36.7	108	53	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.6	114	64	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-9	36.6	105	65	80	57.8	164.6

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	128	61	87	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8	36.4	113	57	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	15	36.6	103	65	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	30	36.9	114	59	77	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	38	36.4	115	52	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	44	37.1	109	52	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	59	36.8	100	66	78	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.7	139	97 (Moderate)	73	83.4	162.6
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.1	137	80	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	37	122	79	64	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	131	83	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	133	76	82	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	35	37	127	79	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	42	36.8	125	71	64	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	59	36.6	122	84	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-7	36.8	103	55	73	54.2	163.1
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.8	103	55	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.9	105	52	67	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37	101	62	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	37.1	97	54	65	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	36.8	115	64	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	36.9	96	54	79	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	59	36.9	108	56	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.5	117	61	61	72.2	166.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.9	103	61	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	110	68	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.6	108	70	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.4	109	71	69	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.3	102	59	63	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	105	59	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	111	72	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-14	36.3	121	70	61	107.9	182
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	128	73	89	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.9	112	74	96	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	116	68	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	150 (Mild)	69	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	112	64	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.7	116	64	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	115	68	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.4	139	66	55	81.6	169.2
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	37.2	138	71	72	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	37.1	130	65	68	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37.1	118	60	69	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	120	61	70	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	37.1	117	56	68	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37.1	114	72	80	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	58	37.2	109	52	73	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	-1	-6	36.8	114	69	84	72.5	166.6
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	1	36.6	116	67	87	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	8	7	36.7	112	63	93	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	15	14	37	114	67	88	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	29	29	36.9	94	50	81	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	36	37	37.4	119	55	94	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	43	43	37	113	61	97	.	.
REDACTED	100 mcg mRNA-1273 (18-55 years)	57	58	37.3	96	52	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-13	36.5	110	70	63	76.6	173.7

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	37.2	101	62	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	37	105	65	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.8	110	72	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	107	64	68	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.5	106	62	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	37	115	68	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	58	36.8	102	61	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-12	36.5	115	70	64	88.3	182.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	114	65	57	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	8					.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	17	36.7	133	76	62	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	125	69	56	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.6	114	65	55	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.9	126	61	55	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	118	67	65	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	115	59	62	72.8	182.9
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	110	58	60	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	113	73	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	104	60	68	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.9	115	57	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.4	116	53	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.4	117	68	73	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	36.8	114	65	70	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.8	107	72	77	91.5	174.2
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	111	72	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	121	85	95	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	117	71	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	115	71	73	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	36	36.6	118	73	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	125	76	98	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	114	71	93	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-11	36.9	106	67	84	65.9	174.5
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	80	82	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.8	107	70	97	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37.6	110	67	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.7	104	64	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	37.1	111	71	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	100	58	91	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	37.1	111	71	93	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.3	129	79	75	71.5	177.4
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.7	131	79	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	123	76	77	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.7	115	72	74	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	108	62	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	106	59	81	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	117	72	83	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.8	113	68	76	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	37.2	105	64	72	69.2	167.4
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	104	55	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.7	110	65	85	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37.1	108	66	80	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.8	99	58	70	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.7	110	60	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.8	110	60	84	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	58	36.6	118	57	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	142 (Mild)	82	56	76.7	185.7

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	133	69	90	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.7	132	60	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	37	128	68	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.4	125	75	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.8	120	64	65	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.3	122	71	67	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-10	36.9	131	72	72	68.8	179.5
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.8	124	69	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	116	70	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	37	104	58	71	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	37.1	104	58	78	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	123	69	92	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.6	120	79	86	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	56	36.7	110	73	80	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (18-55 years)	-1	-7	36.6	132	74	98	92.3	194.1
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	1	36.4	129	73	69	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	8	9	36.6	122	67	71	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	15	14	36.9	109	64	66	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	29	29	36.6	116	62	75	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	36	37	36.8	119	55	79	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	43	45	36.5	114	68	72	.	.
REDACTED	25 mcg mRNA-1273 (18-55 years)	57	57	37.1	121	59	79	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-21	36.9	107	56	72	53	161
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	116	72	70	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	111	75	70	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	36.6	116	72	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	36.5	117	76	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	110	69	82	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.6	122	68	95	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-25	37.2	136	96 (Moderate)	87	81.1	173.2
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37	133	85	87	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	138	91 (Mild)	56	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	138	83	64	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	37.7	137	83	84	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	36	37.2	130	84	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	37	120	62	90	53.2	159.8
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	114	62	88	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	118	72	88	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	36.5	131	72	89	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28					.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	36.7	111	55	84	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	36.7	122	72	82	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-19	37	127	66	77	75.6	176.2
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37.4	120	69	99	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.8	131	75	90	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	16	37.1	116	67	86	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	28	37.1	130	65	83	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	35	37.1	129	67	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	43	43	37.1	123	75	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-24	36.9	142 (Mild)	85	53 (Mild)	80.1	167
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	37	124	68	75	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	131	75	74	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	109	71	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	37.1	126	73	62	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	137	81	65	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.7	136	82	71	83.9	179.3

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	139	86	72	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	37.1	139	82	69	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	131	74	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.9	118	66	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.3	124	76	71	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-23	36.4	102	61	65	52.1	152.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	98	54	63	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.9	94	52	67	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.4	98	53	52 (Mild)	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.7	85 (Mild)	49	55	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	36.5	85 (Mild)	49	61	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	-1	-20	36.9	114	55	71	55.1	157.7
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	1	36.7	107	63	68	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	8	8	36.6	114	65	66	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	250 mcg mRNA-1273 (18-55 years)	15	15	36.9	113	65	83	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	29	29	36.8	116	61	77	.	.
REDACTED	250 mcg mRNA-1273 (18-55 years)	36	37	37.1	105	59	75	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.7	109	69	76	87.6	173.2
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.7	110	68	81	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.7	112	78	72	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.5	120	78	65	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	36.9	131	60	58	47.4	153.9
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.3	145 (Mild)	70	57	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	149 (Mild)	68	53 (Mild)	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	140	70	58	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	122	77	71	84	179
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	128	77	74	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.8	112	72	73	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	113	68	71	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-16	37.1	143 (Mild)	66	75	62.5	171.7
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	141 (Mild)	76	68	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	129	68	70	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.7	140	76	67	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	37.1	112	73	74	83.5	174.9
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	136	79	72	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	37.1	130	84	80	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.9	134	75	78	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-21	36.4	121	69	55	83.7	169.1
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.8	109	57	62	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.6	115	55	62	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.9	126	84	77	78.3	171.1
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	148 (Mild)	92 (Mild)	62	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	128	87	89	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	136	85	94	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-13	36.8	124	65	86	73.8	180.1
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.9	135	81	82	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.5	124	66	75	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.7	120	74	71	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-14	36.9	112	56	78	67.4	152.5
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.4	122	58	66	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	103	54	65	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	109	67	71	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.1	117	68	71	53.3	163.6
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.6	120	69	68	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	128	73	69	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.4	122	68	65	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-14	37.2	125	68	74	78.3	164.6
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	37	139	63	79	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.9	117	62	63	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	16	36.8	114	59	77	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-20	36.9	143 (Mild)	78	73	60.7	156.9
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.3	145 (Mild)	75	72	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	37	148 (Mild)	75	73	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	-1	-12	36.7	146 (Mild)	70	53 (Mild)	80.8	178.2
REDACTED	25 mcg mRNA-1273 (≥71 years)	1	1	36.8	119	64	62	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	8	9	36.6	136	66	56	.	.
REDACTED	25 mcg mRNA-1273 (≥71 years)	15	15	36.9	129	71	58	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-12	36.8	122	67	68	68.4	162.8
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.5	117	58	72	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	9	36.5	128	69	65	.	.

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	15	16	36.9	129	62	61	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-18	36.7	114	56	74	78.7	162.8
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	118	56	74	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	137	60	83	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.6	133	74	63	91.2	181.7
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	136	67	59	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	37.2	134	78	73	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.9	118	53	63	57.9	169.6
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	116	54	64	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	139	60	63	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-18	37.1	118	58	57	62.4	171
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.7	113	75	65	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.7	127	60	54 (Mild)	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-19	36.8	134	65	69	71.2	173.9

Appendix F (continued)
Vital Signs Listing

Subject ID	Vaccination Group	Planned Study Day	Actual Study Day	Temperature (°C)	Systolic Blood Pressure (mmHg)	Diastolic Blood Pressure (mmHg)	Heart Rate (beats/min)	Weight (kg)	Height (cm)
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	36.6	119	58	60	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.8	132	70	57	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	-1	-17	37.2	144 (Mild)	83	78	80	165.4
REDACTED	100 mcg mRNA-1273 (≥71 years)	1	1	37.1	132	71	75	.	.
REDACTED	100 mcg mRNA-1273 (≥71 years)	8	8	36.9	142 (Mild)	74	78	.	.

**APPENDIX G1:
 Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?*	Deviation Resulted in Subject Termination?*	Deviation Affected Product Stability?*	Deviation Resolution	Comments
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Too few aliquots obtained	Protocol procedure/assessment	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	3	Too few aliquots obtained	Protocol procedure/assessment	34	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	55	REDACTED	No	No	No	REDACTED	REDACTED

**Appendix G1 (continued)
 Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (56-70 years)	1	Too few aliquots obtained	Protocol procedure/assessment	1	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (56-70 years)	1	Missed visit/visit not conducted	Follow-up visit schedule	2	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Out of window visit	Follow-up visit schedule	46	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	2	Required procedure done incorrectly	Protocol procedure/assessment	46	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	3	Required procedure done incorrectly	Protocol procedure/assessment	55	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	7	REDACTED	Yes, unsolicited AE	No	No	REDACTED	REDACTED

**Appendix G1 (continued)
 Listing of Protocol Deviations**

Subject ID	Vaccination Group	Deviation Number	Deviation	Deviation Category	Study Day	Reason for Deviation	Deviation Resulted in AE?	Deviation Resulted in Subject Termination?	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Other: non-required lab tests performed	Protocol procedure/assessment	1	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	-14	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	100 mcg mRNA-1273 (18-55 years)	1	Other: breach of confidentiality	Protocol procedure/assessment	-4	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	1	Required procedure not conducted	Protocol procedure/assessment	8	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	25 mcg mRNA-1273 (18-55 years)	2	Other: V4 safety labs collected out of window	Protocol procedure/assessment	17	REDACTED	No	No	N/A	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Treatment administration schedule	28	REDACTED	No	No	No	REDACTED	REDACTED
REDACTED	250 mcg mRNA-1273 (18-55 years)	1	Required procedure done incorrectly	Protocol procedure/assessment	1	REDACTED	No	No	N/A	REDACTED	REDACTED

**APPENDIX G2:
 Listing of Non-Subject Deviations**

Study Site	Deviation Number	Deviation	Deviation Category	Reason for Deviation	Deviation Affected Product Stability?	Deviation Resolution	Comments
REDACTED	1	REDACTED	Protocol procedure/assessment	REDACTED	Yes	REDACTED	REDACTED

**APPENDIX H:
Listing of Pregnancies**

Table 1 – Maternal Information

No maternal information has been reported

Table 2 – Gravida and Para

No gravida and para have been reported.

Table 3 – Live Birth Outcomes

No live birth outcomes have been reported

Table 4 – Still Birth Outcomes

No maternal information has been reported

Table 5 – Spontaneous, Elective, or Therapeutic Abortion Outcomes

No spontaneous, elective, or therapeutic abortion outcomes have been reported
